cytogenix: ist das die wende? - 500 Beiträge pro Seite

[crashpoet]

Wär ja schön...

[crashpoet]

Hm, die Aktie ist wohl zu langweilig.

[crashpoet]

Was ist das besondere an der Meldung unten?

Es handelt sich hier NICHT um ein Medikament, das noch im Laufe der klinischen Prüfung versagen kann, sondern um eine TECHNOLOGIE mit erheblichem Marktpotential, die m.W. kokurrenzlos ist.
Deshalb der Kurssprung bei riesigem Volumen.

CytoGenix Inc. Invents Revolutionary Large-Scale Manufacturing Process for High-Purity DNA

HOUSTON--(BUSINESS WIRE)--Dec. 14, 2004--CytoGenix Inc. (OTCBB:CYGX) announces the filing of a patent application with the US Patent and Trademark Office for an invention titled "Chemo-Enzymatic Synthesis of DNA and Uses Thereof." This new technology is a significant advance and a big step towards making DNA medicines a reality. The limited supply and high cost of FDA-approved DNA has stifled the development of powerful DNA vaccines and cancer immunotherapy drugs.

Currently, manufacturers use large fermentation vats of cloned E. coli bacteria to produce DNA by culturing, then rupturing the bacteria to extract the DNA. This process produces great quantities of toxic bacterial contaminants. Sophisticated and expensive purification methods are necessary to remove these toxins, driving the cost of FDA-approved DNA to as much as $250,000 a gram or $250,000,000 a kilogram.

CytoGenix` breakthrough synthesis technology does not use bacteria and therefore produces no bacterial toxins. Gram or greater quantities of very high purity DNA can now be produced in test tubes or flasks in laboratories at a fraction of the time and cost of DNA manufactured using traditional bioprocess methods.

Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "Once you eliminate the bacteria, the scale of production and related costs of DNA come way down. This technology transcends economic implications. More importantly, we have introduced a fundamental improvement to the science of making DNA. For example, DNA vaccines are made of DNA `rings` called plasmids. Scientists design these plasmids to contain instructions that `prompt` the immune system to identify and destroy a viral or bacterial pathogen, such as those that cause AIDS, SARS or influenza."

"Along with the therapeutic DNA, the traditional bacteria-based technology requires that the plasmid contain DNA `instructions` for its replication in E. coli as well. These extraneous bacterial genes are not entirely benign and can elicit serious side effects. By eliminating the need for this extra DNA, the plasmids are significantly smaller and safer, thus enabling greater drug concentrations if required. We believe that by eliminating these extra pieces in the DNA plasmid, scientists will now have much more freedom and control in designing better and safer DNA drugs."

"We will use this technology to reduce the costs of the DNA needed for the clinical trials of our herpes anti-viral and anti-inflammatory topical products as well as making the technology available to others through licensing or contract manufacturing," adds Dr. Skolnick.

CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.

CONTACT: CytoGenix Inc.Juan Ferreira, 407-774-9949

SOURCE: CytoGenix Inc.

[crashpoet]

Hier noch ein Link für Leute, die sich wirklich für Hintergründe interessieren

http://scholar.google.com/scholar?q=cytogenix&hl=en&lr=&star…

[waldy40]

Ich denke das war endgültig die Wende für CytoGenix, nachdem die Aktie monatelang m.M. nach unterbewertet zwischen 20 und 30 Cents herumgedümpelt ist.

Komisch nur, dass der Anstieg 2 Tage nach Bekanntgabe der Meldung stattgefunden hat...

[crashpoet]

Einen Tag später, wobei der über Anstieg am selben Tag auch schon nicht schlecht war.
Vermutlich musste die Meldung erstmal richtig eingeordnet werden, sind halt wenig Naturwissenschaftler an der Börse.

[crashpoet]

entscheidend ist natürlich der otcbb-kurs

[crashpoet]

#5
Um einen Eindruck zu bekommen, wie lange es dauert, bis Börsianer sowas kapieren, brauchst du dir ja nur die lahme Reaktion hier im Board zu vergegenwärtigen.
Wäre es einem Unternehmen gelungen, Gold in nie dagewesener Qualität zu konkurrenzlos günstigen Preisen synthetisch herzustellen - was dann hier wohl los wäre?

[crashpoet]

na gut, gold ist ein blödes beispiel. sagen wir diamenten!

[lassevegas]

ups, ich bin ganz überrascht, daß es hier schon einen thread gibt, das hatte ich nicht erwartet und wollte gerade einen eröffnen. halte cygx schon so lange, daß ich mittlerweile völlig schmerzfrei gegenüber allen kursbewegungen bin, obwohl sowas wie gestern natürlich mehr spaß macht......
früher war cyto eine wette: schaffen sie es ihre technologien zur marktreife zu bringen BEVOR ihnen das geld ausgeht, dann gibt es einiges zu verdienen, wenn nicht - alles futsch.
heute sieht es deutlich besser aus. solange die aktie an der otc gelistet ist sind die kurse leicht zu manipulieren, das kann an die nerven gehen ( über das stadium bin ich, wie gesagt, hinaus). ich gehe aber besonders mit der meldung von dienstag und den folgenden publikationen davon aus, daß cytogenix innerhalb der nächsten 12 monate einen kurs erreichen wird, mit dem sie problemlos an der amex oder im idealfall an der nasdaq gelistet werden. die nachricht war nichts weniger als bahnbrechend. aus meiner abolut subjekitven sicht würde ich meinen, daß man hier die chance hat bei einer großen story von anfang an dabei zu sein.

lassevegas

[crashpoet]

sag ich doch - so ähnlich zumindest :-)

[traderofthelord]

Weiterhin hohes VOL am US-Markt...

mit unvermindertem "UPWARD-TREND".

[traderofthelord]

Kaufen MARSCH, MARSCH!

[traderofthelord]

Und sie steigt immer weiter, wow!

[starbull]

Hallo,
auch heute wieder ein schöner Kursanstieg! Genau wie bei 164580. Beide haben ein Produkt,daß uns bei erfolgreicher Vermarktung viele, viele Euros in die Kasse spülen wird. Habe beide Firmen schon ca. ein halbes Jahr und nur wegen des Produktes erworben. Ich denke, daß wir erst am Anfang eines steilen Kursanstieges sind.

[wehr]

Was hält das Board von dieser Meldung? Wird es heute weiter aufwärts gehen?



CytoGenix Scientists Discover Unique Gene Knock-Down Sequence to Kill Resistant Staph Bacteria
CytoGenix Scientists Discover Unique Gene Knock-Down Sequence to Kill Resistant Staph Bacteria



BW5147 JAN 05,2005 6:02 PACIFIC 09:02 EASTERN



( BW)(TX-CYTOGENIX)(CYGX) CytoGenix Scientists Discover Unique GeneKnock-Down Sequence to Kill Resistant Staph Bacteria

Business Editors/Health/Medical Writers

HOUSTON--(BUSINESS WIRE)--Jan. 5, 2005--CytoGenix Inc.(OTCBB:CYGX) announces that its researchers have identified and testedan anti-sense oligonucleotide sequence that will kill Staphylococcusaureus bacteria including Vancomycin-resistant (VRSA) andMethicillin-resistant (MRSA) strains. This achievement is part ofCytoGenix´s ongoing research and development program for a newgeneration of antimicrobial compounds designed to defeat thebacteria´s natural defenses.
Infection by the new strains of resistant staph is a growingpublic health problem. The Centers for Disease Control and Preventionreports, "Staph bacteria are one of the most common causes of skininfection in the United States, and are a common cause of pneumoniaand bloodstream infections ... as many as 100,000 persons arehospitalized each year with MRSA infections, although only a smallproportion of these persons have disease onset occurring in thecommunity."
Johns Hopkins AIDS Service reports, "The emergence of CA-MRSAinfections is an additional threat to the growing global public healthcrisis of antimicrobial resistance. Efforts to control MRSA infectionscan no longer depend solely on surveillance, infection controlefforts, and judicious antibiotic prescribing practices within thehospital setting. Proactive patient education, aggressive diagnosticefforts, and effective treatment for CA-MRSA infections by outpatientclinicians, will not only improve patient care, but also protect ourcommunities and hospitals from an increasingly prevalent pathogen."
Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "Wecontinue to focus our scientific assets on addressing significantunmet medical needs such as multi-drug resistant bacterial infections.In 2005, we plan to accelerate the pace of drug discovery and productdevelopment of this and other antimicrobial compounds.
"We are at the point that by using our proprietary genomictechniques, we can screen for gene targets and develop effectivecompounds to inhibit disease-causing activity in a matter of monthsrather than the years required for traditional drug discovery. Forthis reason we have been able to readily isolate several lead drugcandidates against these resistant bacteria strains," adds Dr.Skolnick.
CytoGenix Inc. is a Houston-based biopharmaceutical company thatdevelops and markets innovative products and services based on itsproprietary ssDNA expression technology. CytoGenix currently has oneissued US patent and 37 international or US pending patentapplications claiming methods and materials in connection with thisplatform technology.
SAFE HARBOR: Except for statements of historical fact, thestatements in this press release are forward-looking. Such statementsare subject to a number of risks and uncertainties that could causeactual results to differ materially from the statements made. Thesefactors include, but are not limited to, general economic conditions,risks associated with the acceptance of new products, competition, andother factors more fully detailed in the company´s filings with theSecurities and Exchange Commission. Additional information aboutCytoGenix and its technology can be found on the Web site atwww.cytogenix.com.

--30--JV/ho* CONTACT: CytoGenix Inc. Juan Ferreira, 407-774-9949 KEYWORD: TEXAS INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY SOURCE: CytoGenix Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

[crashpoet]

das betrifft das kerngeschäft von cytogenix.
in anbetracht der dramatisch zunehmenden antibiotikaresistenzen ist das ein riesenmarkt, allerdings sind die entwicklungen noch in einer recht frühen phase und deshalb risikobelastet.
das gute an cytogenix ist aber, daß die company mit erfolgsmeldungen eher zurückhaltend ist, deshalb dürfte hier ein wirklicher fortschritt erzielt worden sein.
da die in #3 wiedergegebene meldung bedeutet, daß cytogenix wohl bald einen verlässlichen cashflow erzielen wird, ist das unternehmen gegenüber rückschlägen relativ gut abgesichert.
deshalb: strong buy!!!

[Niemoney]

[crashpoet]

gibts irgendwas fundamental neues?
die news vom 25. war doch eher positiv

[Niemoney]

nicht wirklich.............

Es hätte eine "heiße"Pase beginnen können,statt dessen wurde die Einführung des Medikaments herausgezögert......

[crashpoet]

naja, ich denke, da hatten einige wohl etwas überzogene erwartungen

[crashpoet]

die übertriebene abwärtsreaktion ist damit wohl korrigiert (scheiß otc...)

[crashpoet]

CytoGenix Announces Results of Simplivir CY301 Herpes Cream Pre-Clinical Animal Study



HOUSTON--(BUSINESS WIRE)--March 2, 2005--CytoGenix Inc. (OTCBB:CYGX) announced today that a pre-clinical animal study has demonstrated that Simplivir(TM) (CY301) reduced the size of herpes lesions compared to placebo. In this study, Simplivir(TM) was applied to herpes infected skin of guinea pigs twice daily for three days.

The treatment with 0.1% Simplivir(TM) resulted in a reduction in the total lesion area when compared to placebo. A trend toward a reduction in the amount of herpes virus was observed as well. Simplivir(TM) activity in this pilot study is encouraging and additional studies to optimize the dose and timing of therapy will follow.

Herpes is a public health problem of major significance in the United States and worldwide. The Centers for Disease Control and Prevention has reported that 45 million people ages twelve and over test positive for the type of herpes most often affecting the genital area. Active lesions from herpes infections can have catastrophic effects on newborn children and are a major risk factor for the transmission of other diseases such as AIDS.

Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "This is the first in a series of in-life proof-of-principle data we expected based on our earlier observations in cell culture where Simplivir(TM) reduced viral titer load up to 500-fold. These data extend the validation of CytoGenix` proprietary delivery method for topical administration of plasmid DNA-based therapeutics."

CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued U.S. patent and over 48 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.


CONTACT: CytoGenix Inc.Juan Ferreira, 407-774-9949

SOURCE: CytoGenix Inc.

[crashpoet]

hat irgendjemand ne ahnung, warum der kurs so abschmiert?

[Niemoney]

.........nur mit "Schripsen"und blauem Dunst werden die nie Umsätze generieren können.

[crashpoet]

tjaja, das ist das problem einer company, die an der schnittstelle zwischen wissenschaft und wirtschaft positioniert ist.
was in dem einen system als großer erfolg gilt (s. ad hoc vom 23.), gilt in dem anderen als blauer dunst.
nur: medizinische verfahren, die wirtschaftlich erfolgreich sein wollen, müssen halt auch wissenschaftlich fundiert sein

[Niemoney]

Der Kurs zeigt,dass Erfolge erhofft werden - bisher wurde nur Geld verbrannt u.die Firma konnte bis jetzt nicht nachweisen ob oder wie sie in absehbarer Zeit auch etwas auf den Weg bringen kann!!!
Mir ist die persönliche Interpretation egal:wichtig ist die Kursentwicklung - es spiegelt sich die Meinung ALLER Anleger
wieder!
Die Firma schaffte es bisher nicht zu überzeugen
Gern lege ich auch längerfristig an - es sollte aber ein Weg erkennbar sein - aber außer "blauen Dunst" erkenne ich
in absehbarer Zeit nichts am Horizont..........
sollte bis sagen wir mal Jahresende keinerlei Umsätze in Aussicht stehen,kann ich mit meinem Geld etwas besseres anfangen,als Wissenschaftlern die Möglichkeit zum spielen zu geben...........

[crashpoet]

Langsam, aber ziemlich sicher, geht es ans Geld verdienen...

CytoGenix Engages Premier Biopharmaceutical Engineering Firm to Design DNA Production Plant



HOUSTON--(BUSINESS WIRE)--April 20, 2005--CytoGenix, Inc. (OTCBB:CYGX) has engaged the global engineering firm of Alfa Laval Biokinetics, Inc., headquartered in Philadelphia, to conduct the conceptual engineering phase of the company`s DNA plant construction project. This production plant will house the Company`s revolutionary cell-free process that produces high purity DNA at much lower costs than traditional recombinant bacteria fermentation methods. Work will commence this week with a site survey by Alfa Laval engineers to the proposed Houston location.

Frank Vazquez, CytoGenix` Executive Vice President and COO, commented, "We decided to get into the DNA production business because the extremely high price of pharmaceutical quality DNA would make several of our drugs economically unfeasible. We know that other companies are in a similar situation, thus creating a significant latent demand for low cost pharmaceutical grade DNA. In the next few years, this technology will drive the overall DNA therapeutic market, especially for cost-sensitive products such as DNA vaccines and antimicrobials.

"This is the first step of a multi-phase project that will include architectural design, engineering, permitting, construction, equipment specification, installation, validation and certification. Constructing a state-of-the-art FDA compliant biopharmaceutical facility to achieve maximum benefit from this new technology requires a highly experienced and creative team of scientists and engineers."

"Alfa Laval is a leading firm in biopharmaceutical plant design and construction with a wide breadth of experience on projects for major pharmaceutical and biotechnology companies worldwide. Their engineers are recognized in the industry for their technical expertise. As a smaller company, we will greatly benefit from this wealth of experience and resources," added Mr. Vazquez.

Robert A. Bader, Sr. Vice President of Technology for Alfa Laval Biokinetics, commented, "The thing that impressed me most about CytoGenix is the simplicity of their process. They have developed a method of producing DNA that avoids the complication of conventional microbial fermentation and the complex purification processes associated with that technology. The purpose of the Conceptual Study is to demonstrate the significant cost savings associated with the CytoGenix technology."

About CytoGenix, Inc.: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 44 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CONTACT: CytoGenix, Inc., HoustonJuan Ferreira, 800-677-5707

SOURCE: CytoGenix, Inc.

[crashpoet]

ES wird!!! (langsam aber sicher gut!)

CytoGenix Launches Innovative Vaccine Program Using Proprietary Cell-Free DNA Production Process



HOUSTON--(BUSINESS WIRE)--May 17, 2005--CytoGenix, Inc. (OTCBB:CYGX) announced today that it has begun an accelerated program to develop DNA vaccines against several diseases including influenza. CytoGenix scientists are constructing a new generation of DNA vaccines employing the Company`s breakthrough cell-free synthetic DNA production process.

Unlike traditional vaccines that are made from dead or attenuated pathogens, DNA vaccines carry only the coding sequence for the antigen gene from the disease causing pathogen that is then expressed in human cells to elicit an immune response. Currently DNA vaccines are made by growing the plasmid DNA in recombinant bacteria. This process is lengthy, expensive and risky. The CytoGenix cell-free synthetic DNA production method is less expensive, faster and safer.

The world vaccine market, including pediatric and adult vaccines, is estimated at $7-$9 billion in 2005 with an annual growth rate of over 20%. Pediatric vaccines hold the largest share of the overall market, but sales of adult vaccines for influenza and hepatitis have grown significantly over the past few years and will continue to increase in value.

Dr. Malcolm Skolnick, CytoGenix CEO, commented, "This vaccine program is the culmination of our efforts to integrate our experience in developing anti-viral therapeutics with our newly developed synthetic DNA production technology. We expect equal or greater levels of immune response from our synthetic DNA vaccines than from the current generation of plasmid DNA constructs."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CONTACT: CytoGenix, Inc.Juan Ferreira, 407-774-9949

SOURCE: CytoGenix, Inc.

[Fortschritt]

CytoGenix Obtains HIV Vaccine License from NIH
Houston, TX (May 25, 2005) CytoGenix, Inc. (CYGX.OB) announced today that it has obtained a commercial evaluation license from the National Institutes of Health (NIH) for a DNA plasmid developed by scientists from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). This license gives CytoGenix the right to conduct experiments using this proprietary DNA vaccine.

CytoGenix scientists will conduct animal studies with a synthetic DNA vaccine derived from HIV gene sequences contained in the NIH plasmid.
Dr. Yin Chen, CytoGenix Chief Scientific Officer, commented, “We have seen strong evidence of protein expression activity from our cell-free DNA in recent in vitro and in vivo experiments. Now we are poised to test against animal disease models such as HIV and influenza. We expect to see equal or greater levels of host immune response produced by our synthetic DNA vaccines than from the first generation plasmid DNA constructs.”

Das wird schöööön...........

[crashpoet]

CytoGenix, Inc. Files US Patent Application for Family of DNA Antimicrobial Agents



HOUSTON--(BUSINESS WIRE)--July 28, 2005--CytoGenix, Inc. (OTCBB:CYGX) announces filing of a patent application with the US Patent and Trademark Office for an invention titled "Nucleotides for Prevention and Treatment of Microbial-Based Pathologies."

Over the past two years, CytoGenix scientists have conducted numerous studies showing that DNA compounds are effective against bacterial pathogens including E. coli and resistant strains of Staphylococcus aureus (MRSA). These studies have led to discoveries of unique compounds and DNA sequences that regulate crucial bacterial proteins.

Life-threatening infections by newly evolving strains of resistant Staph are becoming a significant public health problem. The Centers for Disease Control and Prevention reports, "Staph bacteria are one of the most common causes of skin infection in the United States, and are a common cause of pneumonia and bloodstream infections...as many as 100,000 persons are hospitalized each year with MRSA infections, although only a small proportion of these persons have disease onset occurring in the community."

The nation`s annual cost associated with sepsis care is approximately $16.7 billion, and the average length of hospital stay is 19.6 days per patient. The incidence of sepsis is likely to increase because of an aging population and the widespread use of broad-spectrum antibiotics that cause pathogens to mutate and become resistant.

Dr. Malcolm Skolnick, CytoGenix President and CEO, commented, "This patent application includes the results of many months of difficult scientific investigation and covers several discoveries that when combined produce powerful and safe DNA compounds against these very dangerous pathogens."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 42 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CONTACT: CytoGenix, Inc., HoustonJuan Ferreira, 800-677-5707

SOURCE: CytoGenix, Inc.

[crashpoet]

CytoGenix and Aldevron Collaborate on DNA Vaccine Technology



HOUSTON & FARGO, N.D.--(BUSINESS WIRE)--Aug. 2, 2005--CytoGenix, Inc. (OTCBB:CYGX) and Aldevron announced today a collaboration to conduct experiments with a DNA vaccine produced using CytoGenix proprietary DNA production process.

CytoGenix scientists will prepare the synthetic DNA vaccine designed to stimulate an immune response to a Hepatitis B Surface antigen. Aldevron will test the activity of this DNA vaccine in models established and validated by Aldevron scientists. Aldevron will conduct the experimental evaluation of the DNA vaccine with the company`s proprietary Genetic Immunization and Antibody (GIA(TM)) technology.

Dr. Malcolm Skolnick, President and CEO, commented, "This mutually beneficial corporate collaboration will provide important data key to the future of DNA vaccine research and development. We look forward to working with Aldevron on this seminal project."

Michael Chambers, President and CEO of Aldevron, stated, "CytoGenix has developed a technology capable of greatly reducing the cost of DNA vaccine production. We are excited to evaluate plasmid-DNA produced with this technology via our GIA(TM) platform. Furthermore, we expect these studies will show equal or greater levels of immune response from the CytoGenix synthetic DNA vaccines when compared to first generation plasmid DNA constructs."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued U.S. patent and 41 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.

About Aldevron: With facilities in the United States and Europe, Aldevron offers products and services to the DNA vaccine and gene therapy community. These include contract bio-manufacturing, genetic immunization and antibody production, and a complete line of gene therapy plasmids. More information can be found at http://www.aldevron.com.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CONTACT: CytoGenix, Inc., HoustonJuan Ferreira, 800-677-5707

SOURCE: CytoGenix, Inc.

[crashpoet]

CytoGenix Initiates Second Phase of $2 MM DNA Production Plant Construction Program



HOUSTON--(BUSINESS WIRE)--Aug. 16, 2005--CytoGenix Inc. (OTCBB:CYGX) announced today the signing of a contract with the engineering firm of Alfa Laval Biokinetics for the design and construction of a prototype production module for CytoGenix`s proprietary, high throughput DNA manufacturing technology. The production module will be a self-contained, closed-loop system that will produce gram quantities of high purity DNA in a single pass. Delivery is planned for fourth quarter 2005.

Traditionally, DNA for therapeutic compounds is made in fermentation vats using cloned E. coli bacteria. The bacteria are cultured and the DNA is extracted by rupturing the walls of the bacterial cells. This bioprocess produces large amounts of toxic contaminants. These toxins which can be fatal to humans must be removed by sophisticated and costly purification methods, thus driving the cost of therapeutic grade DNA to as much as $300,000 a gram.

CytoGenix`s breakthrough synthesis technology does not use bacteria and produces no bacterial toxins. Large quantities of high purity DNA can now be produced in small, highly automated suites at a fraction of the time and cost of traditional bioprocess methods.

Dr. Malcolm Skolnick, CytoGenix President and CEO, commented, "This is the next step in our march to make pharmaceutical grade DNA affordable. This is truly a breakthrough technology that changes the economics of cost-sensitive products such as DNA vaccines, antimicrobials and cancer immunotherapy. In the next few years, this technology will drive the development of DNA therapeutics for human and animal application by significantly reducing the costs of finished products."

About CytoGenix: CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued U.S. patent and 41 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CONTACT: CytoGenix Inc., HoustonJuan Ferreira, 800-677-5707

SOURCE: CytoGenix Inc.

[crashpoet]

Dutton Associates Announces Investment Opinion: CytoGenix Rating Maintained at Speculative Buy By Dutton Associates



EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Aug. 29, 2005--Dutton Associates updates its coverage of CytoGenix (OTCBB:CYGX) with its rating maintained at Speculative Buy and a price target of $.90. The 10-page report by Dutton senior analyst William Prather, RPh, MD, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Our due diligence surrounding CytoGenix`s development of their cell-free DNA plasmid manufacturing business suggests the Company is making progress toward having commercial product available within the next 24 months. We believe CytoGenix is focusing on the nearer-term revenue potential of this unique manufacturing business while, in our opinion, correctly placing the clinical development of their longer-term revenue in-house products such as Simplivir(TM) in a position of secondary importance. We believe CytoGenix intends to re-emphasize these clinical products when their DNA plasmid manufacturing business is cash-flow positive and able to provide capital for these R&D programs. Because of our belief that the Company has shown progress in developing their manufacturing process for DNA combined with our additional belief that, if successful, CytoGenix`s proprietary cell-free DNA represents enormous revenue potential, we are re-iterating our investment rating of Speculative Buy with a 12-month price target of $0.90.

About Dutton & Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 110 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid before commencement of our research activities. We received $47,000 from the Company for eight reports and requisite Research Notes commencing 7/17/2002, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst`s personal views about the subject securities or issuer. Neither the analyst`s compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.


CONTACT: Dutton Associates, LLC
John M. Dutton, 916-941-8119

SOURCE: CytoGenix

[crashpoet]

Es sieht so aus, als stünden gute News bzgl. der DNA-Fabrik an

[crashpoet]

Nur der Vollständigkeit halber das neueste SEC-Filing.
Das ist aber wohl nicht der Grund für die Performance der letzten Tage. Ich glaube, da kommt Wichtigeres...

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the quarterly period ended September 30, 2005

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

For the transition period from _____________to _____________

Commission file number: 0-26807

CYTOGENIX, INC.
(Exact name of small business issuer as specified in its charter)

NEVADA 76-0484097
------ ----------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)




3100 Wilcrest, Suite140, Houston, Texas 77042
--------------------------------------- -----
(Address of principal executive offices) (Zip Code)




Issuer`s telephone number, including area code: [phone]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

--------------------------------------------------------------------------------

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes No X

--------------------------------------------------------------------------------

The number of shares outstanding of each of the issuer`s classes of common equity, as of the latest practicable date:

As of September 30, 2005, 119,162,970 shares of the issuer`s common stock was outstanding.


--------------------------------------------------------------------------------

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

ITEM 1. - Financial Statements

Balance Sheets as of September 30, 2005 (Unaudited) and
December 31, 2004 3

Statements of Operations for the nine months ended
September 30, 2005 (Unaudited) and 2004 4

Statements of Cash Flows for the nine months ended
September 30, 2005 (Unaudited) and 2004 5

Notes to Financial Statements (unaudited) 6

ITEM 2. Management`s Discussion and Analysis of Financial
Condition and Results of Operations 7

ITEM 3. Quantitative and Qualitative disclosures About Market Risk 11

ITEM 4. Controls and Procedures 11

PART II OTHER INFORMATION 12

ITEM 1. Legal Proceedings 12

ITEM 2. Changes in Securities 12

ITEM 4. Submission of Matters to a Vote of Security Holders 12

ITEM 6. Exhibits 14

SIGNATURES 15




-2-

--------------------------------------------------------------------------------

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

CYTOGENIX, INC.
(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEET


September 30, December 31,
2005 2004
------------- -------------
(Unaudited)

ASSETS
------
CURRENT ASSETS:
Cash $ 685,449 $ 453,235
Prepaid expenses 8,046 --
------------- -------------
Total current assets 693,495 453,235
------------- -------------

Property and equipment:

Research Fixtures & Equipment 104,635 114,514
Office Furniture & Fixtures 57,759 56,461
Office Equipment 57,518 45,733
Leasehold Improvements 3,164 --
------------- -------------
223,076 216,708
Less - accumulated depreciation (162,761) (151,649)
------------- -------------
60,315 65,059
Deposits 6,399 6,399
Long-term Investment - Restricted 116,913 --
------------- -------------
Total assets $ 877,122 $ 524,693
============= =============


LIABILITIES AND STOCKHOLDERS` EQUITY (DEFICIT)
----------------------------------------------

CURRENT LIABILITIES:
Accounts payable $ 215,068 $ 237,833
Accrued expenses 401,533 801,920
------------- -------------
Total current liabilities 616,601 1,039,753
------------- -------------
COMMITMENTS AND CONTINGENCIES



STOCKHOLDERS` EQUITY (DEFICIT):

Common stock, $.001 par value; 300,000,000 shares authorized,
119,162,970 and 109,204,339 shares issued and outstanding
at September 30, 2005 and December 31, 2004, respectively 119,163 109,204
Additional paid-in capital 22,639,884 19,530,637
Treasury stock (629,972) (629,972)
Deficit accumulated during the development stage (21,868,554) (19,524,929)
------------------------------
Total stockholders` equity (deficit) 260,521 (515,060)
------------------------------
Total liabilities and stockholders` equity (deficit) $ 877,122 $ 524,693
==============================




The accompanying notes are an integral part of these financial statements.

-3-

--------------------------------------------------------------------------------

CYTOGENIX, INC.
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2005 AND 2004 AND PERIOD
FROM FEBRUARY 10, 1995 (INCEPTION) THROUGH SEPTEMBER 30, 2005
(Unaudited)

Inception
Three Months Nine Months Through
September 30, September 30, September 30,
2005 2004 2005 2004 2005
------------- ------------- ------------- ------------- -------------

REVENUES $ -- $ -- $ -- $ -- $ 82,575


Cost of Revenues -- -- -- -- 264,891
------------- ------------- ------------- ------------- -------------

GROSS MARGIN -- -- -- -- (182,316)

COSTS AND EXPENSES:

Research and development 402,208 223,193 1,075,869 545,993 7,157,742
General and administrative 367,963 232,306 957,438 704,404 12,382,897
Consulting expense 290,000 20,180 290,000 50,576 1,518,481
Depreciation and amortization 6,088 9,325 21,363 28,446 265,565
Impairment expense -- -- -- -- 345,588
Equity in losses of joint venture -- -- -- -- 10,000

------------- ------------- ------------- ------------- -------------

LOSS FROM OPERATIONS (1,066,259) (485,004) (2,344,670) (1,329,419) (21,862,589)


OTHER INCOME:

Gain on sale of security -- -- -- -- 881
Interest Income 993 -- 1,413 40 1,694

Loss on disposal of property -- -- (368) -- (10,173)
Dividend income -- -- -- -- 1,633
------------- ------------- ------------- ------------- -------------

NET LOSS $ (1,065,266) $ (485,004) $ (2,343,625) $ (1,329,379) $ (21,868,554)
============= ============= ============= ============= =============

Net loss per share:
Basic and diluted $ (0.01) $ (0.00) $ (0.02) $ (0.01)
============= ============= ============= =============

Weighed average shares outstanding:
Basic and diluted 116,034,303 101,590,591 112,843,190 100,212,094
============= ============= ============= =============




The accompanying notes are an integral part of these financial statements.

-4-

--------------------------------------------------------------------------------

CYTOGENIX, INC.
(A DEVELOPMENT STAGE COMPANY)

Consolidated Statement of Cash Flows
NINE MONTHS ENDED SEPTEMBER 30, 2005 AND 2004 AND PERIOD
FROM FEBRUARY 10, 1995 (INCEPTION) THROUGH SEPTEMBER 30, 2005
(UNAUDTIED)

Inception Through
September 30,
2005 2004 2005
------------ ------------ ------------

OPERATING ACTIVITIES:
Net loss $ (2,343,625) $ (1,329,379) $(21,868,554)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 21,363 28,446 262,190
Impairment expense -- -- 345,588
Stock issued for services 301,000 193,592 7,443,478
Stock option expense -- -- 2,062,191
Loss on disposal of property & equipment 368 -- 10,173
Equity in losses of joint venture -- -- 10,000
Changes in operating assets and liabilities:
Prepaid expenses (8,046) -- (8,046)
Deposits -- -- (6,399)
Accounts payable & accrued expenses 118,974 (109,615) 1,421,820
------------ ------------ ------------
Net cash used in operating activities (1,909,966) (1,216,956) (10,327,559)
------------ ------------ ------------

INVESTING ACTIVITIES:
Purchase of property and equipment (16,987) (11,179) (303,266)
Issue note receivable -- -- (25,100)
Investment in long-term CD (116,913) (116,913)
Investment in joint venture -- -- (10,000)
------------ ------------ ------------
Net cash used in investing activities (133,900) (11,179) (455,279)
------------ ------------ ------------

FINANCING ACTIVITIES:
Proceeds from notes payable -- -- 250,000
Payments on notes payable -- -- (250,000)
Treasury shares sold -- -- 1,290,568
Purchase of treasury shares -- -- (60,000)
Buyback of Stock Warrants -- (571) (571)
Sale of common stock, net fundraising 2,276,080 776,051 9,288,790
Sale of common stock for exercised warrants -- 348,000 797,000
Contributions to capital -- -- 152,500
------------ ------------ ------------
Net cash provided by financing activities 2,276,080 1,123,480 11,468,287
------------ ------------ ------------
NET CHANGE IN CASH 232,214 (104,655) 685,449
CASH, beginning of period 453,235 236,962 --
------------ ------------ ------------
CASH, end of period $ 685,449 $ 132,307 $ 685,449
============ ============ ============
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid $ -- $ -- $ --
============ ============ ============
Income taxes paid $ -- $ -- $ --
============ ============ ============
NONCASH TRANSACTIONS:
Common stock issued for debt $ 542,126 $ -- $ 805,219
Received treasury stock for note receivable -- -- 25,100
Common stock issued for patent -- -- 375,000




The accompanying notes are an integral part of these financial statements.

-5-

--------------------------------------------------------------------------------

CYTOGENIX, INC.
(A DEVELOPMENT STAGE COMPANY)

NOTES TO FINANCIAL STATEMENTS
(UNAUDTIED)

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited interim financial statements of CytoGenix, Inc. ("CytoGenix") have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission ("SEC"), and should be read in conjunction with the audited financial statements and notes thereto contained in CytoGenix`s latest annual report filed with the SEC on Form 10KSB. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for fiscal year ending December 31, 2004, as reported in the 10KSB, have been omitted.

NOTE 2 - Reclassifications

Certain amounts in the 2004 and 2005 financial statements have been reclassified to conform with the September 30, 2005 financial statement presentation.

NOTE 3 - COMMON STOCK

In the nine months ending September 30, 2005, CytoGenix issued a total of 300,452 shares of common stock for services valued at $301,000.

In the nine months ending September 30, 2005 $2,276,080 was collected for 8,366,878 shares of common stock as part of a private placement.

NOTE 4 - Long-Term Investment - Restricted

CytoGenix filed a Declaratory Judgment action in March, 2004, to obtain a finding of nonliability with respect to two license agreements, one for shrimp, and one for horses, originally issued in 1998 to William B. Waldroff. Waldroff and Applied Veterinary Genomics, Inc. ("AVGI"), a party in interest as a sublicensee of Waldroff`s, in Willam B. Waldroff and Applied Veterinary Genomics, Inc. vs. Cytogenix, Inc. counterclaimed for damages, attorneys fees, unrelated torts, and a permanent injunction to honor the purported licenses. A jury trial was held in February, 2005. Both Waldroff and AVGI also sued three directors of CytoGenix for interfering with the licenses. The jury did not assess any damages against any of the directors or against CytoGenix. The court has preliminarily entered a judgment ordering CytoGenix to perform according to the licenses, and for attorneys fees in an amount of $115,500. Pending appeal Cytogenix has established a long-term CD in the amount of $115,500 to comply

-6-

--------------------------------------------------------------------------------

with the judicial ruling. Accrued Interest for the nine months ending September 30, 2005 is $1,413.

ITEM 2. MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

IN ACCORDANCE WITH THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995, THE COMPANY NOTES THAT CERTAIN STATEMENTS IN THIS FORM 10-Q WHICH ARE FORWARD-LOOKING AND WHICH PROVIDE OTHER THAN HISTORICAL INFORMATION, INVOLVE RISKS AND UNCERTAINTIES THAT MAY IMPACT THE COMPANY`S RESULTS OF OPERATIONS. THESE FORWARD-LOOKING STATEMENTS INCLUDE, AMONG OTHERS, STATEMENTS CONCERNING THE COMPANY`S GENERAL BUSINESS STRATEGIES, FINANCING DECISIONS, AND EXPECTATIONS FOR FUNDING CAPITAL EXPENDITURES AND OPERATIONS IN THE FUTURE. WHEN USED HEREIN, THE WORDS "BELIEVE," "PLAN," "CONTINUE," "HOPE," "ESTIMATE," "PROJECT," "INTEND," "EXPECT," AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE EXPECTATIONS REFLECTED IN SUCH FORWARD-LOOKING STATEMENTS ARE BASED ON REASONABLE ASSUMPTIONS, NO STATEMENTS CONTAINED IN THIS FORM 10-Q SHOULD BE RELIED UPON AS PREDICTIONS OF FUTURE EVENTS. SUCH STATEMENTS ARE NECESSARILY DEPENDENT ON ASSUMPTIONS, DATA OR METHODS THAT MAY BE INCORRECT OR IMPRECISE AND MAY BE INCAPABLE OF BEING REALIZED. THE RISKS AND UNCERTAINTIES INHERENT IN THESE FORWARD-LOOKING STATEMENTS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED IN OR IMPLIED BY THESE STATEMENTS.

READERS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN, WHICH SPEAK ONLY AS OF THE DATE HEREOF. THE INFORMATION CONTAINED IN THIS FORM 10-Q/A IS BELIEVED BY THE COMPANY TO BE ACCURATE AS OF THE DATE HEREOF. CHANGES MAY OCCUR AFTER THAT DATE, AND THE COMPANY WILL NOT UPDATE THAT INFORMATION EXCEPT AS REQUIRED BY LAW IN THE NORMAL COURSE OF ITS PUBLIC DISCLOSURE PRACTICES.

IMPORTANT RISK FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THE EXPECTATIONS REFLECTED IN ANY FORWARD-LOOKING STATEMENT HEREIN INCLUDE AMONG OTHER THINGS: (1) THE ABILITY OF THE COMPANY TO QUICKLY PENETRATE THE MARKET WITH ITS CURRENT THERAPEUTIC PRODUCTS AGAINST LARGER, WELL-FINANCED COMPETITORS WITHIN THE MARKETPLACE; (2) THE ABILITY OF THE COMPANY TO GENERATE REVENUES IS SUBSTANTIALLY DEPENDENT UPON CONTINUED RESEARCH AND

-7-

--------------------------------------------------------------------------------

DEVELOPMENT FOR, AND FDA APPROVAL OF, THERAPEUTIC PRODUCTS; (3) THE ABILITY OF THE COMPANY TO ATTRACT AND RETAIN KEY OFFICERS, KNOWLEDGEABLE SALES AND MARKETING PERSONNEL AND HIGHLY TRAINED TECHNICAL PERSONNEL; (4) THE ABILITY OF THE COMPANY TO OBTAIN ADDITIONAL FINANCING FROM PUBLIC AND PRIVATE EQUITY MARKETS TO FUND OPERATIONS AND FUTURE GROWTH; AND (5) THE ABILITY OF THE COMPANY TO GENERATE REVENUES TO COVER OPERATING LOSSES AND POSITION THE COMPANY TO ACHIEVE POSITIVE CASH FLOW.

RESULTS OF OPERATIONS

Three Months Ended September 30, 2005 Compared to Three Months Ended September 30, 2004

For the three months ended September 30, 2005, we reported a net loss of $1.065 million, or $0.00 per share, on no revenue as compared with a net loss of $485,004, or $0.00 per share, on no revenue for the three months ended September 30, 2004.

Research and Development Expenses. Research and development expenses increased to $402,208 for the third quarter of 2005 as compared to $223,193 compared to the same period in 2004 due to the hiring of additional R&D employees and increased research activity. Approximately $98,000 of the increase is a result of the increased staff and the remaining difference of $82,000 results from the increased activity cost of antibacterial and DNA vaccine research.

General and Administrative Expenses. General and administrative expenses increased to $367,963 for the third quarter of 2005 compared to $232,306 for the same period in 2004 primarily due to increase in legal fees and board of director fees. The legal fees increase of $58,000 is due primarily to increased patent attorney fees and litigation fees for the legal proceeding described in Part II, Item 1 below. The remaining increase is related to the increased fees of the Board of Directors.

Consulting Expenses. Consulting expenses increased from $290,000 for the third quarter of 2005 compared to $20,180 for the same period in 2004 primarily because of a one year consulting contract where Cytogenix engaged a firm to consult on various business matters.

Depreciation and Amortization Expenses. Depreciation and amortization expenses decreased to $6,088 for the third quarter of 2005 compared to $9,325 for the same period in 2004 primarily due to office furnishings purchased in previous years becoming fully depreciated in 2005.

Nine Months Ended September 30, 2005 Compared to Nine Months Ended September 30, 2004

For the nine months ended September 30, 2005, we reported a net loss of $2,343,625, or less than $0.02 per share, on no revenue as compared with a net loss of $1,329,379, or less than $0.01 per share, on no revenue for the nine months ended September 30, 2004.

-8-

--------------------------------------------------------------------------------

Research and Development Expenses. Research and development expenses increased to $1,075,869 for the nine months ending September 30, 2005 compared to $545,993 for the same period in 2004 primarily due to hiring of additional R&D employees and increased research activity. Approximately $256,000 of the increase is a result of the increased staff and the remaining difference of 274,000 results from the increased activity cost of antibacterial and DNA vaccine research.

General and Administrative Expenses. General and administrative expenses increased to $957,438 for the nine months ending September 30, 2005 compared to $704,404 for the same period in 2004. The increase of $253,034 primarily due to an increase in legal fees. The legal fees increase of $199,000 is due primarily to increased patent attorney fees and litigation fees for the legal proceeding described in Part II, Item 1 below.

Consulting Expenses. The increase in consulting expense from $290,000 for the nine months ending September 30, 2005 compared to $50,276 for the same period in 2004 is primarily attributed to a one year consulting contract where Cytogenix engaged a firm to consult on various business matters.

Depreciation and Amortization Expenses. Depreciation and amortization expenses decreased to $21,363 for the nine months ending September 30, 2005 compared to $28,446 for the same period in 2004 primarily due to office furnishings purchased in previous years becoming fully depreciated in 2005.

LIQUIDITY AND CAPITAL RESOURCES

The Company has budgeted approximately $4,100,000 for operations in fiscal year 2005, of which approximately $1,300,000 has been allocated for general and administrative costs and $1,800,000 for research and development and $1,000,000 for plant facilities. We will rely on equity financing to satisfy its working capital requirements, and has as of September 30, 2005 $685,449 of cash on hand for fiscal year 2005. Of the $1,800,000 budgeted for research and development expenses, the Company anticipates $1,600,000 will be utilized for pre-clinical development.

There are currently over 800 U.S. patents for Antisense molecules with therapeutic potential, each of which is a prospective licensee for the Company. The Company anticipates entering into licenses for revenues upon successful completion of phase I/II FDA clinical studies of its pre-clinical product candidates.

The Company`s ability to continue operations through December 31, 2005 depends on its success in obtaining equity financing in an amount sufficient to support its operations through that date. There is substantial doubt that the Company will be able to generate sufficient revenues or be able to raise adequate capital to remain a going concern through December 31, 2005. Based on historical yearly financial requirements, operating capital of approximately $4.1 million will be needed for each of the calendar years 2005 and 2006.

-9-

--------------------------------------------------------------------------------

The Company expects its sources of revenue for the next several years to consist primarily of payments under future product development joint ventures and of licensing agreements as well as possible royalties. The process of developing the Company`s products will require significant additional research and development, preclinical testing and clinical trials, as well as regulatory approvals. These activities, together with the Company`s general and administrative expenses, are expected to result in operating losses for at least two more years. The Company will not receive product revenue from therapeutic products unless it completes clinical trials and successfully commercializes or arranges for the commercialization of one or more products, the accomplishment of which no assurance can be given.

CytoGenix has begun animal testing of its first DNA drug product candidate. The topical cream to be evaluated will have applications against genital herpes (HSV-2) and labial herpes or cold sores (HSV-1). The HSV virus is known to be highly evolved and its genome contains instructions for several phases of viral activity including infection, replication, production, and latency. CytoGenix proprietary gene regulation technology is being applied to inhibit key genes that control one or more of these functions, which are critical for the Herpes virus survival in the body.

During the past few months, the Company has continued to refine its course of developing applications for its core technology. Most significant is the pre-clinical program for an anti-viral HSV topical preparation. We have teamed-up with a group of leading herpes and STD investigators at a large academic medical center to conduct a comprehensive cell and animal study program designed to yield safety and efficacy data in preparation for an IND submission planned for December 2005 and subsequent human trials.

The Genomics field has expanded the number of potential drug targets to several thousand. The CytoGenix proprietary gene down-regulation system is a powerful tool in confirming gene target function. In July 2002, we inaugurated a service geared towards assisting pharmaceutical and biotech companies improve drug discovery efficiency. In addition to our work on in-house targets, we are conducting a pilot studies for several companies. For a fixed fee, we will knockdown a gene in a cell system. This will confirm the gene`s relevance to the disease of interest. Those genes found to be highly disease-related become targets for new drug or molecular therapies.

CytoGenix is confident about the Company`s technology`s ability to inhibit these genes. This six to nine month program includes extensive toxicology and efficacy studies in various model animals.

The Company is subject to risks common to biopharmaceutical companies, including risks inherent in its research and development efforts and clinical trials, reliance on collaborative partners, enforcement of patent and proprietary rights, the need for future capital, potential competition and uncertainty in obtaining required regulatory approval. In order for a product to be commercialized, it will be necessary for the Company and its collaborators to conduct pre-clinical tests and clinical trials, demonstrate efficacy and safety of the Company`s product candidates, obtain regulatory clearances and enter into distribution and marketing arrangements either directly or through sublicenses. From the Company`s inception through the date of this document, the major role

-10-

--------------------------------------------------------------------------------

of management has been to obtain sufficient funding for required research, monitoring research progress and developing and licensing intellectual property.

The Company expects to incur losses for the foreseeable future due to the ongoing activities of the Company to develop new products through research and development and to develop joint ventures and licensing agreements with third parties. The Company expects its existing operations to continue to result in negative cash flow and working capital deficiencies that will require the Company to continue to obtain additional capital. There can be no assurance that the necessary financing will be available to the Company or, if available, that the same will be on terms satisfactory or favorable to it. It is possible that additional equity financing will be highly dilutive to existing shareholders.

The Company is currently operating at a loss and expects to continue to depend on cash generated from the sale of debt and equity securities to fund its operating deficit. There can be no assurance that the Company will be able to generate sufficient revenues to meet its operating cash and growth needs or that any equity or debt funding will be available or at terms acceptable to the Company in the future to enable it to continue operating in its current form.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The Company holds no financial instruments that are sensitive to changes in interest rates. As of September 30, 2005, we held no investments other than amounts held in our cash operations accounts. We are not subject to any other material market risks.

ITEM 4. CONTROLS AND PROCEDURES

CONCLUSION REGARDING THE EFFECTIVENESS OF DISCLOSURE CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2005.

CHANGES IN INTERNAL CONTROLS

There has been no change in our internal control over financial reporting during the nine months ended September 30, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

-11-

--------------------------------------------------------------------------------

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

PHANUEL PURSUITS, LLC V. CYTOGENIX, INC.

Phanuel Pursuits, LLC had entered into Option Agreements pursuant to obtaining licenses to commercialize the Company`s anti-herpes product in China and India. Phanuel withdrew from the China option. Phanuel owes unpaid sums due under the remaining Option Agreement, including a specific payment due to purchase the Company`s data they would need for submission to the Indian authorities. Phanuel filed suit October 8, 2004 alleging the Company withheld that data and therefore breached the agreement. The Company believes the suit is completely without merit.

WILLIAM B. WALDROFF AND APPLIED VETERINARY GENOMICS, INC. V. CYTOGENIX, INC.

CytoGenix filed a Declaratory Judgment action in March, 2004, to obtain a finding of nonliability with respect to two license agreements, one for shrimp, and one for horses, originally issued in 1998 to William B. Waldroff. Waldroff and Applied Veterinary Genomics, Inc. ("AVGI"), a party in interest as a sublicensee of Waldroff`s, counterclaimed for damages, attorneys fees, unrelated torts, and a permanent injunction to honor the purported licenses. A jury trial was held in February, 2005. Both Waldroff and AVGI also sued three directors of CytoGenix for interfering with the licenses. The jury did not assess any damages against any of the directors or against CytoGenix. The court has preliminarily entered a judgment ordering CytoGenix to perform according to the licenses, and for attorney`s fees in the amount of $110,000. Post judgment motions will be filed in the trial court.

ITEM 2. CHANGES IN SECURITIES

The Company issued 500,000 shares of common stock to Stonebridge Holding LLC for services provided in the third quarter pursuant to the exemption from registration provided by Section 4(2) of the Securities Act of 1933 for transactions not involving a public offering.

The Company issued 5,226,000 shares of common stock for an aggregate cash price of $1,306,500 (or $0.25per share) in a private placement to accredited investors pursuant to the exemption from registration provided by
Section 3(b) of the Securities Act of 1933 and Rule 504 thereunder. The consideration for these shares was received during the third quarter.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

On July 14, 2005, the Company held the 2005 annual meeting of the shareholders for purposes of the following:

(1) ELECTION OF DIRECTORS. To elect two directors to hold office until the 2008 Annual Meeting of Shareholders or until their successors are elected and qualified;

-12-

--------------------------------------------------------------------------------

(2) RATIFICATION AND APPROVAL OF THE APPOINTMENT OF INDEPENDENT AUDITORS. To ratify and approve the appointment of Lopez, Blevins, Bork & Associates, LLP. as the independent auditors for the Company for the fiscal year ending December 31, 2005.

(3) APPROVAL OF THE 2005 STOCK OPTION PLAN. The approval of the 2005 Stock Option Plan of the Company.

A majority of the shares entitled to vote, present in person or represented by proxy, constituted a quorum at the Annual Meeting. For the approval of Proposal No.1 (the election of directors), the two candidates receiving the greatest number of affirmative votes were elected. The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting was required to ratify and approve Proposal No. 2 (appointment of independent auditors) and Proposal No. 3 (approval of the 2005 Stock Option Plan).

On June 14, 2005, the record date for the annual shareholder meeting held on July 14, 2005, there were 113,259,470 shares of the Company`s common stock issued and outstanding. All outstanding shares were entitled to vote on the three proposals. On July 14, 2005, a quorum was reached totaling 96,180,016 shares voted.

The results of the voting on the above matters presented to the shareholders were as follows:

(1) ELECTION OF DIRECTORS. The three directors submitted to the shareholders for approval were elected as follows:

Frank Vazquez: 95,815,360 shares voting for, 364,656 shares withheld.

Cy A. Stein, M.D., Ph.D.: 95,831,960 shares voting for, 348,056 shares withheld.

(2) RATIFICATION AND APPROVAL OF THE APPOINTMENT OF INDEPENDENT AUDITORS. The appointment of Lopez, Blevins, Bork & Associates, LLP as the independent auditors for the Company for the fiscal year ending December 31, 2005 was approved by the shareholders, with 95,984,456 shares voting for, 160,460 shares voting against and with 35,100 shares abstaining.

(3) APPROVAL OF THE 2005 STOCK OPTION PLAN. The 2005 Stock Option Plan of the Company was approved by the shareholders, with 63,543,885 shares voting for, 4,111,802 shares voting against and with 454,150 shares abstaining.

-13-

--------------------------------------------------------------------------------

ITEM 6. EXHIBITS.

Exhibit Number Description


3.1* Articles of Incorporation of Cryogenic Solutions, Inc.

3.2* Certificate of Amendment dated November 1, 1995 of Articles
of Incorporation of Cryogenic Solutions, Inc.

3.3* Certificate of Amendment dated January 13, 2000 of Articles
of Incorporation of CytoGenix, Inc.

3.4 Certificate of Amendment dated April 6, 2004 of Articles of
Incorporation of CytoGenix, Inc. (incorporated by reference
to Exhibit 3.5 to the Company`s annual report of Form 10-KSB
for the year ended December 31, 2004)


3.5 Certificate of Amendment dated March 7, 2001 of Articles of
Incorporation of CytoGenix, Inc. (incorporated by reference
to Annex II of the definitive proxy statement on Schedule
14A filed with the Securities and Exchange Commission on
December 23, 2003)

3.6* Bylaws of Cryogenic Solutions, Inc.

3.7 Amendments to Bylaws of CytoGenix, Inc. (incorporated by
reference to Annex I of the definitive proxy statement
on Schedule 14A filed with Ahe Securities and Exchange
Commission on December 23, 2003)

31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive
Officer

31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial
Officer

32.1 Section 1350 Certification of Chief Executive Officer

32.2 Section 1350 Certification of Chief Financial Officer




* Incorporated by reference to the corresponding Exhibit in the Form 10-SB of the Company filed on January 31, 2001.

-14-

--------------------------------------------------------------------------------

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CYTOGENIX, INC.

Date: November 14, 2005 By: /s/ Malcolm Skolnick
---------------------
MALCOLM SKOLNICK
PRESIDENT AND CHIEF
EXECUTIVE OFFICER




-15-

--------------------------------------------------------------------------------

Exhibit 31.1

CERTIFICATION PURSUANT TO


SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lawrence Wunderlich, Chief Financial Officer certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytoGenix, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant`s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant`s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant`s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant`s auditors and the audit committee of registrant`s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant`s ability to record, process, summarize and report financial data and have identified for the registrant`s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant`s internal controls; and

6. The registrant`s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 14, 2005



/s/ Lawrence Wunderlich
-----------------------
LAWRENCE WUNDERLICH
CHIEF FINANCIAL OFFICER





--------------------------------------------------------------------------------

EXHIBIT 31.2

CERTIFICATION PURSUANT TO


SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Malcolm Skolnick, President and Chief Executive Officer certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytoGenix, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant`s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant`s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant`s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant`s auditors and the audit committee of registrant`s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant`s ability to record, process, summarize and report financial data and have identified for the registrant`s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant`s internal controls; and

6. The registrant`s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 14, 2005



/s/ Malcolm Skolnick
--------------------
MALCOLM SKOLNICK
PRESIDENT & CEO





--------------------------------------------------------------------------------

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytoGenix, Inc. (the "Company") on Form 1O-Q/A for the period ending June 30, 2005 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Malcolm H. Skolnick, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Malcolm H. Skolnick
-----------------------
MALCOLM H. SKOLNICK
CHIEF EXECUTIVE OFFICER



November 14, 2005





--------------------------------------------------------------------------------

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytoGenix, Inc. (the "Company") on Form 1O-Q/A for the period ending June 30, 2005 as filed with the Securities and Exchange Commission on the date hereof` (the "Report"), I, Lawrence Wunderlich, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes- Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/Lawrence Wunderlich
-----------------------
LAWRENCE WUNDERLICH
CHIEF FINANCIAL OFFICER


November 14, 2005







--------------------------------------------------------------------------------
End of Filing

© 2005 | EDGAR Online, Inc.

[crashpoet]

Noch immer keine News , aber den Kurs scheint es nicht zu stören

[amk912]

[posting]19.118.542 von crashpoet am 01.12.05 13:29:50[/posting]Hi crashpoet,

damit Du im Board nicht so alleine bist
Ich bin auch in cytogenix investiert.

Gruesse

[crashpoet]

[posting]19.146.630 von amk912 am 03.12.05 19:57:51[/posting]schön, nicht mehr so allein zu sein

weiß auch nicht, warum sich da kaum jemand für interessiert.
ist aber auch relativ egal, das ding wird auch so laufen

[amk912]

[posting]19.156.550 von crashpoet am 05.12.05 11:10:07[/posting]... ist halt wirklich ein kleiner wert, ich bin da auch nur daruebergestolpert und hatte zugeschlagen.. die waren auf americanbulls.com auf buy gesetzt..

[Mambo6]

Bin auch schon seit 2 Jahren dabei und hab alle Höhen und Tiefen mitgemacht... doch jetzt scheint wirklich die Post abzugehen

[Mambo6]

trotzdem interessant in US hat die Aktie die letzten beiden Tage 15 % zugelegt in Frankfurt allerdings nur 11 %.. ???

[amk912]

[posting]19.282.406 von Mambo6 am 14.12.05 09:43:27[/posting]Hi Mambo,
dafuer gibt es mehrere gruende:
- der dollar ist ueber nacht ziemlich schwach geworden
- die prozent sind immer vom schlusskurs, und wenn der tief geprinted wird passiert das
- ausserdem ist der umsatz in fft so gering, dass man die kursfeststellung fast nicht als referenz nehmen kann, ich schau immer auf usa und rechne um !

gruesse aus london

[crashpoet]

[posting]19.275.615 von Mambo6 am 13.12.05 17:07:26[/posting]fehlen nur noch die news zum kurs...

[Mambo6]

ich denke mal es gibt keine News... die Kursentwicklung ist sicher eine Folge der Quartalszahlen die Ende November veröffentlicht wurden. Könnte ich mir wenigstens vorstellen...

http://finance.yahoo.com/q/is?s=cygx.ob

[crashpoet]

[posting]19.300.449 von Mambo6 am 15.12.05 14:56:49[/posting]ich rechne mit einer meldung zur dna-produktion.
wenn die läuft und klar ist, was der markt für das produkt zu zahlen bereit ist, dürfte der kurs erstmal kein halten mehr kennen.

CytoGenix Initiates Second Phase of $2 MM DNA Production Plant Construction Program
Houston, TX, (August 16, 2005) Cytogenix, Inc. (CYGX: OTC: BB)

CytoGenix, Inc. (CYGX: OTC: BB) announced today the signing of a contract with the engineering firm of Alfa Laval Biokinetics for the design and construction of a prototype production module for CytoGenix` proprietary, high throughput DNA manufacturing technology. The production module will be a self-contained, closed-loop system that will produce gram quantities of high purity DNA in a single pass. Delivery is planned for fourth quarter 2005.

[amk912]

[posting]19.302.152 von crashpoet am 15.12.05 16:21:14[/posting]So meldung ist da....!




CytoGenix and Aldevron Announce Positive Results of synDNA(TM)
2005-12-19 17:04 (New York)

Hepatitis Vaccine Study


HOUSTON & FARGO, N.D.--(BUSINESS WIRE)--Dec. 19, 2005
CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced
positive results of a pilot study using CytoGenix synDNA(TM) as the
active ingredient in a Hepatitis B vaccine, demonstrating that it is
highly effective in generating an immune response.
DNA vaccines are comprised of genes that confer immunologic
protection by producing antigens without the need to expose the body
to pathogenic organisms. For this study, CytoGenix scientists prepared
a synthetic DNA vaccine derived from a plasmid provided by Aldevron
that produces a Hepatitis B viral surface antigen. Aldevron`s
scientists tested CytoGenix synDNA(TM) vaccine`s activity in a rabbit
model using Aldevron`s proprietary Genetic Immunization and Antibody
(GIA(TM)) technology.
Aldevron scientists compared levels of gene-specific serum
immunoglobulin produced by the synDNA(TM) vaccine to its traditional
plasmid DNA vaccine. The synDNA(TM) vaccine generated immunoglobulin
levels in the test animals up to five times greater than a comparable
plasmid DNA vaccine produced by bacterial fermentation.
Frank Vazquez, CytoGenix, Inc.`s Executive Vice President and COO,
commented, "These results are very important because they confirm the
effectiveness of synDNA(TM) that we have seen in other animal studies
of DNA vaccines. It is clear that our synDNA(TM) process produces
bio-active DNA. This latest result is a major step forward in our
efforts to accelerate CytoGenix` Rapid Response Vaccine Development
Program against H5N1 avian flu, smallpox and other infectious disease
targets."
Michael Chambers, Aldevron President and CEO, stated, "Aldevron
has supported the DNA vaccine field for the past seven years by
providing quality DNA, antibody and protein products as well as by
sponsoring scientific forums and maintaining the DNAvaccine.com web
site. The synDNA(TM) process is potentially a big step forward in the
DNA vaccine and gene medicine fields. We look forward to expanding
Aldevron-CytoGenix scientific and business collaboration."
About CytoGenix: CytoGenix, Inc. is a Houston-based
biopharmaceutical company that develops and markets innovative
products and services based on its proprietary ssDNA expression
technology. The company has developed a breakthrough synthetic process
for large-scale production of high purity DNA at a fraction of the
cost of traditional fermentation methods. CytoGenix currently has one
issued US patent and 41 international or US pending patent
applications claiming methods and materials in connection with this
platform technology.
About Aldevron: With facilities in the United States and Europe,
Aldevron offers products and services to DNA vaccine and gene therapy
scientists. These include contract bio-manufacturing, genetic
immunization and antibody production, and a complete line of gene
therapy plasmids. More information can be found at
http://www.aldevron.com.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company`s filings with the
Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be
found on the website at www.cytogenix.com.

CONTACT:
CytoGenix, Inc.
Juan Ferreira, 800-677-5707
-0- Dec/19/2005 22:04 GMT

[amk912]

...wooooowww .. 1 euro bezahlt !

[wayne99]

Court Rules in Favor of CytoGenix in $500 Million Breach of Contract Suit
Tuesday December 20, 4:02 pm ET

HOUSTON--(BUSINESS WIRE)--Dec. 20, 2005--CytoGenix, Inc. (OTCBB:CYGX - News) announced today that a suit brought by the US Virgin Island firm of Phanuel Pursuits, L.L.C. against CytoGenix, Inc., the officers and one director has been vacated and dismissed by the District Court of Harris County, Texas 334th Judicial District.

ADVERTISEMENT
The Court granted summary judgment motions in favor of CytoGenix and against Phanuel Pursuit`s cause of action. The Court also found no evidence to support Phanuel Pursuit`s allegations and dismissed claims against the individual officers and director. Phanuel Pursuits was demanding damages in excess of $500 million claiming breach of option contracts calling for Phanuel Pursuits to obtain regulatory approval for the distribution of CytoGenix` herpes product in India and in China.

Dr. Malcolm Skolnick, CytoGenix, Inc.`s President and CEO, commented, "We are pleased to put this suit behind us. We welcome the opportunity to devote our full attention to advancing our science, developing our products and running our business."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


Contact:

CytoGenix, Inc.
Juan Ferreira, 800-677-5707

Source: CytoGenix, Inc.

[Fortschritt]

Ist das der Durchbruch

[amk912]

[posting]19.358.249 von Fortschritt am 20.12.05 23:02:56[/posting]..bin eher gespannt ob das wieder so abgeht wie gestern... war ja total verrueckt.. hoch bis 1.20 ?!? Da war der Kursmakler wohl etwas ueberfordert in FFT.

[mfierke]

[crashpoet]

[posting]19.358.249 von Fortschritt am 20.12.05 23:02:56[/posting]nee, der wirkliche durchbruch kommt erst noch

[lassevegas]

denke ich auch. ich hab die schon so lange, daß ich völlig schmerzfrei geworden bin, aber sobald man in einer mitteilung mal den namen einer großen company als partner lesen kann, ist die finanzielle zukunft gesichert und das ding geht ab.
bis dahin ist man der üblichen schwankungen der otc unterworfen. das potential rechtfertigt aber das risiko, imho.

[crashpoet]

Die News ist zwar schon in einem anderen Thread eingestellt worden, aber da ich diesen Thread vollständig halten möchte und die News WIRKLICH WICHTIG ist, hier nochmal:

CytoGenix Announces Completion of synDNA(TM) Production Module Prototype



HOUSTON--(BUSINESS WIRE)--Dec. 22, 2005--CytoGenix, Inc. (OTCBB:CYGX) announced that the prototype version of the synDNA(TM) production module was completed on schedule.

The device was designed specifically for the commercial production of cell-free DNA by the leading international biopharmaceutical plant design, engineering and construction firm of Alfa Laval Biokinetics, Philadelphia, Pennsylvania. It was tested by Alfa Laval engineers and CytoGenix senior scientists. The final version will be mounted on a stainless steel cart and have the capacity to produce up to 10 grams of high-purity DNA in 24 hours.

Kurt Berens, CytoGenix, Inc. Vice President of Product Development, commented, "This is an important step in our overall plan to construct a cGMP manufacturing facility. We plan to install several synDNA(TM) production modules to meet the growing demand for clinical-grade DNA internally and from customers."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CONTACT: CytoGenix, Inc.Juan Ferreira, 800-677-5707

SOURCE: CytoGenix, Inc.

[crashpoet]

Das Interesse an der Aktie scheint so gestiegen zu sein, daß der Untenehmensserver zusammengebrochen ist

[martini81]

Grüß euch...!

In der Aktie steckt nächstes Jahr sicher ordentlich Potenzial!

Wenn diese zwei Mittelchen nächstes Jahr Produktionsreif werden, kann das nicht sondern muss das gut für den Kurs sein.

-Antivirenmittel CY301 gegen Herpessimplexbetrieb (HSV), Phase Vor-Pre-IND

-CY401 antibakterielles therapeutisches Mittel gegen beständige bakterielle Infektion der Multidroge, preclinical Phase

->da noch 5 weitere Arzeneimittel in der Pipeline sind, glaub ich nicht das der Kurs in die Knie geht und wenn doch wird nachgekauft.

Ich hab mir mal n paar von den Teilen rein gelegt.
Mein Kursziel sind 4€ bis 2007
Wäre ja nicht schlecht.......

[crashpoet]

[posting]19.392.181 von martini81 am 23.12.05 11:47:05[/posting]Du hast die DNA-Produktion nicht berücksichtigt.
Mittelfristig gesehen ist das der wichtigste potenzielle Profitbringer, die Pharmaka kommen quasi noch obendrauf!!!

[crashpoet]

[posting]19.392.181 von martini81 am 23.12.05 11:47:05[/posting]...außerdem ist CY401 nicht irgendein Medikament, sondern eine mögliche Lösung für eines der drängendsten medizinischen Probleme, nämlich die zunehmende Resistenz von Bakterien gegen fast alle verfügbaren Antibiotika.

[martini81]

na dann wäre es ja noch besser...
bin nur vor ein paar Tagen drüber gestolpert und hab gleich für 0,74 nen Posten gecheckt - mal sehen, bei 0,90 werd ich evtl. nachlegen

erstmal zurück gelehnt und den Januar abgewartet....

[martini81]

ne Zeitmaschine wäre jetzt nicht schlecht, dann müsste man nicht so lang warten....

hast du auch eine personliche Prognose?

[martini81]

Oder hast du noch eine andere Aktie die du empfehlen kannst? Ich hab mir vor ein paar Tagen mal Cardero angesehen, da sind abhängig von bestimmten Bohrungen locker mal 500% drin... wenn die los geht -

[crashpoet]

[posting]19.393.337 von martini81 am 23.12.05 13:06:04[/posting]bei planmäßiger entwicklung halte ich 4-5 $ ende 2006 für realistisch.
wenn die dna-produktion läuft und/oder die aktie analystenmäßig gecovert wird, kann es m.e. sehr schnell bis 2-3$ gehen.
alles meine persönliche meinung.

meine anderen beiden persönlichen favoriten sind gw2 und gej.
gej ist aber schon ziemlich gut gelaufen, die luft nach oben ist mittlerweile dünn.
gw2 hat noch mächtig potenzial, birgt aber aufgrund der aktuellen diskussionen auch erhebliche risiken.
ach ja, und mdg ist m.e. vielversprechend.

[martini81]

Mit diesen Kürzlis kann ich nicht viel anfangen...
gw2 hat mich aber auf GW PHARMACEUTICALS gebracht.
Der Wert ist auch nicht ganz schlecht-
mdg ist wohl medigene? Da hatte ich schon meinen Gewinn...

[crashpoet]

[posting]19.393.611 von martini81 am 23.12.05 13:28:36[/posting]richtig.
gej ist gasco energy.

[crashpoet]

[posting]19.393.611 von martini81 am 23.12.05 13:28:36[/posting]ansonsten bin ich aber überwiegend in cygx investiert, ist m.e. momentan das vielversprechendste.

[martini81]

Gasco kannte ich auch schon irgendwo her....
der € schleppt ganzschön hinter dem $Kurs her oder seh ich das falsch? Da wär ja schnell mal n Euro drin wie mir scheint..... gibts da fette INFOS?

[martini81]

Vocaltec wäre vor ein paar Tagen noch n schönes Investment gewesen... wenn ich den Kurs sehe könnte ich mich prügeln das ich paar Tage nicht rein geschaut hab.
Bei 4,90€ hab ich über einen Einstieg nachgedacht und als ich bei der TAN eingabe war, dache ich "ne schaust lieber nochmal genauer nach" ob es auch irgendwo schlechte Nachrichten gibt. Zu dumm, da hätte ich locker 120% machen können..... naja, was solls.

[crashpoet]

Für die, die noch mehr Infos zu CYGX haben wollen (u.a. amerik. Messageboard):
http://www.investorshub.com/boards/board.asp?board_id=1835

[martini81]

[posting]19.393.720 von crashpoet am 23.12.05 13:38:18[/posting]Hast du dir schonmal O2diesel angeschaut? Die Konsolidierung scheint vorbei.....

[crashpoet]

[posting]19.393.999 von martini81 am 23.12.05 13:59:21[/posting]ich beschränke mich auf die bereiche pharma/biotech und explorer (von `altlasten` mal abgesehen). sonst verliere ich den überblick.

[martini81]

[posting]19.394.053 von crashpoet am 23.12.05 14:04:23[/posting]Jo, genau das mache ich nicht.

[crashpoet]

[posting]19.394.308 von martini81 am 23.12.05 14:23:04[/posting]dich beschränken oder den überblick behalten?

[martini81]

Ich will mir zur besseren übersicht n Programm in Excel zusammen basteln... mal sehen wie das so wird. Wenn meine Ausbildung nur noch nicht so lang her wäre.....

[martini81]

Nachdem ich vor einigen Tagen von einem 170% Anstieg zur 14% abbekam, (IQ Power) hab ich mir da was ausgedacht - mal sehen.
Das dumme an der ganzen Sache war ja - weiß garnich ob ich das erzählen kann - ich war bis 3 Tage vor der Kursexplosion investiert...

[martini81]

So, ich geh dann erstmal nen schönen Ostdeutschen Kaffee trinken.... ahoj.

[crashpoet]

Der Artikel ist zwar `gekauft`, aber trotzdem nicht schlecht

http://estreetjournal.net/vol_5/issue7_cygx/index.html

[crashpoet]

jetzt wirds spannend...
hat jemand us-rt?

[loui2005]

rt 0,86 !

[crashpoet]

[posting]19.395.574 von loui2005 am 23.12.05 15:36:06[/posting]danke!
volumen?

[loui2005]

RT 0,88 !!! Volumen 110.250 !!!

[loui2005]

Heute könnten wir den $ packen.

[emmi2004]

was ist in Berlin los?
bekomme keine Order durch.
bitte um Hilfe
Danke

[emmi2004]

RT BERLIN



+ USA CHART

[seeensation]

RT USA von 17.57Uhr ---> 0,89$ (=0,752€)
Volumen 491.480 Aktien

RT Berlin 0,73

Bid 0,72
ASK 0,74 (10.000 Stück)

Wir sind also sogar noch etwas (3 %) unter pari!

Der Chart sieht echt super aus und ich denke bis Silvester können 1,20 ohne weiteres drin sein!
Der positive Newsflow hält an...

[seeensation]

Volumen zieht an... 538.648

Bid 0,89
Ask 0,899

[seeensation]

neues Tageshoch unter immer zunehmenden Volumen..

0,90

Volumen: 613.000

Jetzt gibt es sogar größere Blöcke...

Ich habe das Gefühl das es heute sogar noch über 1 $ gehen könnte...

[seeensation]

0,905

Ask 0,909

[martini81]

[posting]19.395.621 von crashpoet am 23.12.05 15:37:56[/posting]UUuuii....

Das Teil könnte ja echt explodieren?!
Wird wohl besser sein gleich nach zu legen...

[seeensation]

0,909

Ask 0,91

[seeensation]

0,91

[seeensation]

Sind hier gerade schon wieder positive NEWs gekommen??

[seeensation]

0,92

[seeensation]

0,93

[martini81]

[posting]19.398.116 von seeensation am 23.12.05 18:16:55[/posting]Kannst du mal bitte RT Kurse von Berlin rein stellen?

[seeensation]

Ask 0,94

[seeensation]

Volumen bereits bei 782.000

Das wird wohl DER Weihnachtsknüller!!

[seeensation]

in Berlin gibt es immer noch 1000 Stück für 0,77

in USA Bid 0,93, ASK 0,94 = 0,79 €

[sozialverband]

Also bei mir zeigt der RT in Berlin
Bid:0,74
Ask:0,77
Vieleicht hat einer das Orderbuch!!

[martini81]

Weshalb kann ich nicht in FFT nachkaufen.... Mist hier.:O

[sozialverband]

Warum willts du in Frankfurt kaufen?

[martini81]

[posting]19.398.214 von sozialverband am 23.12.05 18:25:07[/posting]Keine Ahnung, weil ich meinen ersten Posten auch schon von da hab?
EGAL - mich wundert es nur...

[seeensation]

Schon 850.000 Shares gehandelt...

[martini81]

So, jetzt muss die Rakete nurnoch zünden, damit es n schönes Weihnachtsgeschenk wird... (10€ bis 20 Uhr wäre nicht schlecht - wollen aber nicht übertreiben)

[sozialverband]

Wie ist der RT in USA??

[seeensation]

[posting]19.398.278 von martini81 am 23.12.05 18:29:55[/posting]Von FFM hab ich weder Umsatz von heute, noch Taxen..
Glaube das man die Aktie in FFM gar nicht handeln kann!
Also bleibt nur Berlin!

Berlin gibt es akt. noch 1000 Stück für 0,80 !

[martini81]

Erst runter in die Knie und dann rauf...

[seeensation]

akt. ASK in Berlin 0,79 mit nur noch 5000 Stück.

[sozialverband]

Kann das sein das die jetzt bei 0,90 in Amie Land stehen und weiter fallen??

[loui2005]

[posting]19.398.480 von sozialverband am 23.12.05 18:50:20[/posting]RT 0,92 ! Ask / Bid 0,92 / 0,93 ... tendenz steigend !

[Fortschritt]

Kurse CYGX kann man verfolgen über www.investorshub.com und dann einfach CYGX eingeben und rechts "Quote/Chart/Ticker" anklicken. Hier ist auch ein interessantes Diskussionsboard zu sehen und mann kann so auch nach "Knobias" gelangen mit interessante Inofmationen!
Euch allen schöne Feiertagen und einen guten Rutsch ins Neue Jahr!

[martini81]

[posting]19.394.053 von crashpoet am 23.12.05 14:04:23[/posting]GUTEN MORGEN Crashpoet!

Was sagst du denn zu Biopharm?
Ist scheinbar am Ende einer schönen Konsolidierung....
Kurs 1,35€, Ziel 3,40€ in 2006 und mächtig Potenzial-

[taekwondo72]

Very BIIIGG NEWS !!!

CytoGenix and GE Healthcare Ink BioDefense Support Agreement
Tuesday December 27, 4:18 pm ET


HOUSTON--(BUSINESS WIRE)--Dec. 27, 2005--CytoGenix, Inc. (OTCBB:CYGX - News) announced today the signing of a contract with the Fast Trak BioDefense group of GE Healthcare, a unit of General Electric Company (NYSE:GE - News).
ADVERTISEMENT


GE Healthcare`s Fast Trak BioDefense group has a diverse staff of highly qualified technical and regulatory experts who will collaborate with CytoGenix in seeking, obtaining and executing bio-defense related federal contracts.

Frank Vazquez, CytoGenix, Inc. Executive Vice President and COO commented, "Our association with GE Healthcare, a $14 Billion entity of GE, as partners in competing for federal research projects sends a very positive message to grant reviewers and granting agencies at the Department of Homeland Security, the Department of Defense and the Department of Health and Human Services. We are very excited about this relationship and expect to see very positive results soon."

Dr. Sandy Weinberg, Senior Director, Fast Trak BioDefense GE Healthcare commented, "CytoGenix`s innovative DNA vaccine and antimicrobial technology can be applied to many critical needs in bio-defense. The company has an excellent team of scientists, and we expect with that with our assistance we can attain substantial results."

About GE Healthcare: GE Healthcare is a $14 billion unit of General Electric Company (NYSE:GE - News) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit the company`s website at www.gehealthcare.com.

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

[lassevegas]

genau so was meinte ich. jetzt werden sie die finanzierung leicht sichern können. diese nachricht ist vielleicht die beste die die company jemals hatte.
ich sag nur: nice gap !

[rainmann]

morgen zusammen
könnte einer den text in wenigen sätzen übersetzen

[taekwondo72]

ich denke das wir heute die 1 Dollar vor dem , sehen werden !
Ich habe so ein Gefühl das wir noch dieses Jahr eine bessere Nachricht bekommen werden !

[FinancialServices]

[posting]19.427.083 von taekwondo72 am 28.12.05 09:55:39[/posting]

Luft nach oben ist genug vorhanden !

Gruß FS

[FinancialServices]

....and expect to see very positive results soon

..na wenn das nicht $$$$ heißt ....

Gruß FS

[martini81]

Moin Moin...

Es geht los - wir sitzen auf nem Pulverfass und die Lunte brennt!


Auf zu neuen Kursen

[FinancialServices]

...gibt es vorbörslich bewegung

Gruß FS

[wayne99]

[posting]19.431.231 von FinancialServices am 28.12.05 14:42:07[/posting]ja - RT von 14:43

CYGX.OB Dec 27 0.93 0.00 0.00% b 0.96 a +0.975

[FinancialServices]

Sauber

Danke

[FinancialServices]

0.97 (25) 0.98 (25)

[FinancialServices]

...der Dollar ist schon Geschichte

[FinancialServices]

Last:1.04
cygx - CYTOGENIX INC
Volume:393,415

[martini81]

Sehen wir heute noch 1,10$....?

[FinancialServices]

[posting]19.432.544 von martini81 am 28.12.05 16:02:21[/posting]...eher nicht ....hier nehmen erst mal viele Ihre Gewinne mit in das neue Jahr..

Gruß FS

[martini81]

Na wenn die da mal keinen Fehler machen....

[martini81]

[posting]19.432.598 von FinancialServices am 28.12.05 16:05:34[/posting]Und der Kurs steigt wieder.... 1,02!

[martini81]

1,05!

[FinancialServices]

[posting]19.432.690 von martini81 am 28.12.05 16:11:21[/posting]

[martini81]

Ja Fett schon 1,06.... wer da verkauft ist selber ist nich sauber. Da geht was krasses ab.

[FinancialServices]

[posting]19.432.731 von martini81 am 28.12.05 16:14:26[/posting]...welches Volumen

Danke FS

[martini81]

1,05 würde für heute aber auch ausreichen - so liegt die Aktie gut im Verlauf..... muss nur noch in Berlin was gehen.

[martini81]

649,700 Shrs wenn ich das richtig sehe...

[martini81]

652,907

[FinancialServices]

Stockguru.com: Guru Alerts for Wednesday, December 28, 2005 HDRX, FLWE, CYGX, UGNE.

ich bin schon bei 850K an Volumen

[martini81]

http://www.investcom.com/cgi-bin/redir.cgi?url=http://financ…

Da kannst du ein eine Minute lang kostenlos RT ansehen
-- unter CYGX

[martini81]

Wenn es so weiter geht, sehen wir diese Woche noch die
1,2$ und vielleicht auch den Euro. Wäre nicht schlecht für die Kasse

[martini81]

Nun muss ich mit meiner fetten Geldbörse erstmal n Kaffee trinken gehen.... der Kurs hat sich ja erstmal beruhigt.

[FinancialServices]

Kurs in Berlin immer noch unter pari ,88E wäre eigentlich der Wert

[wayne99]

[posting]19.433.383 von FinancialServices am 28.12.05 17:11:52[/posting]SK CYGX.OB 4:01pm 1.08 +0.15 +16.13% 1.08 + 1.08 2,059,022

Nicht schlecht Herr Specht - hat sich mein US-Kauf vor einigen Tagen doch gelohnt

[Fortschritt]

CytoGenix Announces Results of Influenza synDNA™ Vaccine Trial

Houston, (Decmber 30, 2005) CytoGenix, Inc. (CYGX.OB) announced today the successful completion of a genetic immunization animal trial using a synDNA™ vaccine against an H1N1 influenza strain. The studies were conducted by Dr. Frank Orson, Associate Professor in the Departments of Medicine and Immunology at Baylor College of Medicine Houston, Texas.

This study demonstrates that a synDNA™ vaccine is effective in conferring immunologic protection against a highly virulent pathogen. For this study, Cytogenix scientists prepared a synDNA™ vaccine that produces influenza virus hemagglutinin or HA, a viral surface protein that is essential for infection and replication. Natural mutation of the HA gene is the virus’ most important mechanism of escaping from control by the body’s immune system. This gene is changed by natural selection every flu season, thus requiring a new vaccine every year.

Dr. Orson, a clinical immunologist and scientific investigator commented, “We have considerable experience and interest in genetic immunization. We have studied plasmid DNA for a number of years, and the CytoGenix cell-free DNA experiments should be a significant advance toward the clinical application of this vaccine methodology. The synDNA™ vaccine for influenza stimulated a potent neutralizing antibody response to protect against virus infection.”

Dr. Yin Chen, CytoGenix, Inc. Vice President and Chief Scientific Officer, commented, “We have completed several animal synDNA™ vaccine studies against different viruses with very promising results. We are now accelerating our preclinical development of vaccines designed to protect specifically against various individual influenza strains, including the H5N1 avian influenza virus.”

[FinancialServices]

Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
1.13 0.09 (8.65) 15:59 1.13 (5) 1.135 (5)
Latest Ticks Prev Close Open Low High
-=== 1.04 1.04 0.99 1.15
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
1,788,635 336,800 1.0672 0.34 1.08
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
761 5,000 2,350 0 135

[FinancialServices]

[posting]19.465.566 von FinancialServices am 30.12.05 22:32:23[/posting]1,13 30 Dez 0,8441 0,9538 Euro

Schnappi in Berlin am Montag

Schönes Wochenende

FS

[FinancialServices]

Nur um mal zu Zeigen worum es geht und warum GE Helthcare bei cytogenix mitmischt....

A-H5N1 ist die Bezeichnung für den Erreger des aktuellen Ausbruchs der so genannten Vogelgrippe in Asien und Osteuropa. Es ist ein als hoch pathogenes aviäres Influenzavirus (HPAIV) bezeichnetes Influenza-Virus (also Grippevirus) und damit ein behülltes Einzel(-)-Strang-RNA-Virus [ss(-)RNA] aus der Familie der Orthomyxoviren. Bei diesen Influenzaviren gibt es vier Gattungen: Influenza-A, Influenza-B, Influenza-C und das Thogotovirus. Vögel werden nur von Influenza-A-Viren und deren Varianten bzw. Subtypen befallen.

Durch ständige Genveränderungen entstehen fortwährend neue Varianten der Grippeviren. Diese werden nach bestimmten Oberflächeneigenschaften in Subtypen eingeteilt (zur genauen Erläuterung der Variabilität der Erreger siehe unter Influenza). Bisher wurden 16 H-Untertypen und 9 N-Untertypen erkannt. Der Subtyp A/H5N1 etwa hat auf seiner Oberfläche die 5. Variante des Hämagglutinins (H5) sowie die 1. Variante der Neuraminidase (N1). Diese Untertypen befallen üblicherweise jeweils nur bestimmte Wirte, während sie von einer weiteren Anzahl an Infektionsvektoren verbreitet werden können, ohne dass diese Tiere erkranken.

Der Subtyp A/H5N1 gilt heute als besonders aggressiv (HPAI, High Pathogenic Avian Influenza). Ein verändertes Nichtstruktur-Gen führt bei ihm dazu, dass bestimmte Botenstoffe des Immunsystems, welche normalerweise Viren abwehren, keine Wirkung mehr gegenüber dem A/H5N1-Subtyp erzielen. Deshalb tötet er heute sehr schnell befallene Vögel, die nicht zu seinem Virusreservoir gehören, und er wird daher von Wissenschaftlern wegen seiner pathogenen Eigenschaften auf Interdependenzen mit anderen Stämmen und Überschreitungen der Artenbarriere aufmerksam beobachtet.

Vor der erwähnten und vor zwei weiteren nachgewiesenen Genveränderungen (die nach Expertenmeinung 1997 und 2003 geschahen) war der Erreger bereits mehrfach in Europa aufgetreten, er galt aber als wenig aggressiv. Auch heute noch werden vereinzelt Wildvögel gefunden, die mit dieser minder pathogenen Variante infiziert sind, aber kaum Krankheitssymptome zeigen, so u.a. im Jahr 2004 in Frankreich und Mitte November 2005 bei einer Ente in der Nähe von Padua.


Und hier die News vom Freitag über die erfolgreichen Tierversuche von CytoGenix.....


CytoGenix Announces Results of Influenza synDNA(TM) Vaccine Trial

HOUSTON, Dec 30, 2005 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB: CYGX) announced today the successful completion of a genetic immunization animal trial using a synDNA(TM) vaccine against an H1N1 influenza strain. The studies were conducted by Dr. Frank Orson, Associate Professor in the Departments of Medicine and Immunology at Baylor College of Medicine Houston, Texas.
This study demonstrates that a synDNA(TM) vaccine is effective in conferring immunologic protection against a highly virulent pathogen. For this study, CytoGenix scientists prepared a synDNA(TM) vaccine that produces influenza virus hemagglutinin or HA, a viral surface protein that is essential for infection and replication. Natural mutation of the HA gene is the virus` most important mechanism of escaping from control by the body`s immune system. This gene is changed by natural selection every flu season, thus requiring a new vaccine every year.

Dr. Orson, a clinical immunologist and scientific investigator, commented, "We have considerable experience and interest in genetic immunization. We have studied plasmid DNA for a number of years, and the CytoGenix cell-free DNA experiments should be a significant advance toward the clinical application of this vaccine methodology. The synDNA(TM) vaccine for influenza stimulated a potent neutralizing antibody response to protect against virus infection."

Dr. Yin Chen, CytoGenix, Inc. Vice President and Chief Scientific Officer, commented, "We have completed several animal synDNA(TM) vaccine studies against different viruses with very promising results. We are now accelerating our preclinical development of vaccines designed to protect specifically against various individual influenza strains, including the H5N1 avian influenza virus."


Hier ist noch viel Luft nach oben -.....



Gruß FS

[FinancialServices]

zellfreie DNA-Experimente sollten ein bedeutender Fortschritt in Richtung zur klinischen Anwendung dieser vaccine Methodenlehre sein. Der synDNA(TM)impfstoff für Grippe regte eine starke neutralisierende Antikörperantwort an, um sich gegen Virusinfektion zu schützen.",


das heißt $$$$$$$$

[crashpoet]

Nachdem meine Lieblingsaktie in den letzten Wochen 2005 angedeutet hat, was in ihr steckt, hier meine Prognose für Ende 2006:
4,20 $
Gegenvorschläge?

Ich wünsche allen ein erfolgreiches 2006!

[Mambo6]

wär ich mit einverstanden... ohne wenn und aber

[FinancialServices]

[posting]19.502.509 von crashpoet am 02.01.06 15:50:17[/posting]Akzeptiert ohne wenn und aber

Gruß fs

[gony2]

Hallo und Servus, ich wünsche allen ein erfolgreiches neues Jahr. Mein Vorschlag wäre an alle die sich mit Cytog beschäftigen, dies alles in einem Thread zu tun und nicht in 3 oder 4 verschiedenen. Zum Einstieg ist es sicher nicht zu spät, denkt mal an Viropharma da habe ich auch immer gedacht das es zu spät ist und die Aktie bereits gelaufen sei...und irgendwann war die Aktie bei 20 Euro,...........

[FinancialServices]

Alles Gute für 2006 auch an Dich !

Gruß FS

Was wir wohl Heute mit Cyto erleben...Konsolidierung bis 0,80 $ oder Feuerwerk bis 1,25 $

Gruß FS

[seeensation]

Aktie jetzt im N-TV Text auf Seite 316 aufgetaucht...

Ich finde diese aber nicht auf den anderen Seiten... - kommt vielleicht noch...

[crashpoet]

@gony2 in diesem thread ist doch alles wesentliche gesammelt

@fs ja, das wird heute spannend. mittelfristig wird es sicher noch zu (auch deutlichen) rücksetzern kommen, insgesamt dürften wir uns aber in einem langfristigen und stabilen aufwärtstrend befinden (vermutlich bis ca. 4$)

cp

[janfer]

[posting]19.511.276 von seeensation am 03.01.06 10:34:21[/posting]Wann kam denn die News raus am 30.12.2005. Spät oder früh?
Warum ist Dein Thread gelöscht worden vorhin?
Was glaubt ihr was geschehen wird heute?

[FinancialServices]

[posting]19.511.391 von janfer am 03.01.06 10:43:43[/posting]...die News kam etwa 1 Stunde vor Börsenschluß raus...da ich denke das die meisten da schon im Winterurlaub waren rechne ich mit einem deutlichen Kaufsignal...wie immer werden aber auch einige die hohen Kurse nutzen um Gewinne zu realisieren was ja auch sinnvoll ist ...es wird wohl Heute ein Hin und Her werden ....wichtig wäre eine News die Auskunft gibt über die weitere Finanzierung des Unternehmens aussagt ...die 4 $ von crashpoet ende 2006 halte ich ebenfalls für möglich ... in den amiboards reden sie schon über 10-20$ aber die verrückten gibt es hier auch

Gruß FS

[Mambo6]

es gibt 119 Mio Cytogenix Aktien... und ich denke es kommt ganz drauf an wer diese Aktien momentan besitzt...können die 7 oder 8 Mio die in den letzten Tagen gehandelt wurden den Kurs langfristig entscheiden????

[FinancialServices]

[posting]19.511.561 von Mambo6 am 03.01.06 10:57:31[/posting]...schwere Frage....ich denke wir lassen Sie erst mal laufen

Gruß FS

[FinancialServices]

http://www.worldofinvestment.com/uploads/1079166516/qpwoixuo…


Info stammt aus 2004 ist aber für jemanden wie mich als Neuling sehr Aufschlussreich gewesen .. wer will kann ja mal in das Firmenportrait ( auf Deutsch ) einlesen..Gruß FS

[martini81]

Morgäähn... der Kurs sieht ja wieder richtig lecker aus.
Vielleicht läuft der Kurs ja wie der von IQ Power im Dez.?
2,2 bis Freitag und dann im Sturzflug zurück.
Da wär ich echt einverstanden.....

[FinancialServices]

...ist von Euch jemand in der Lage Vorbörsliche Kurse einzustellen

...wäre Prima !

danke FS

[FinancialServices]

[posting]19.512.678 von martini81 am 03.01.06 12:17:06[/posting]...Du Langschläfer

[thebull 2]

http://www.otcbb.com/asp/quote_module.asp?qm_page=18765&qm_s…

[gony2]

so noch 10 minuten
spannung steigt
kurs in b heute gleichmäßig bei ca. 1 euro
umsatz dort auch ganz gut
13:49:56 0,990 2.900
12:40:53 0,990 5.000
10:16:01 0,990 600
10:03:23 1,010 700
09:54:36 1,000 2.000
09:52:58 1,010 400
09:45:30 1,000 4.000
09:42:06 0,980 430

Spannung steigt

[FinancialServices]

...erste Kurse

Gruß FS

[martini81]

[posting]19.512.996 von FinancialServices am 03.01.06 12:41:02[/posting] ...so,der Mittagsschlaf ist nun auch vorbei. Mal sehen wie sich die AMIS nun entscheiden.
Hab mein Kapital vorsichtshalber mal etwas verringert und derweil mit wcm nen schnellen Rubel geschoben.

[FinancialServices]

Time & Sales most recent next page
Rec. Time Action Price Volume
9:23:18 AM Ask 1.175 500
9:20:54 AM Bid 1.16 500
9:20:34 AM Ask 1.165 500
9:15:16 AM Bid 1.15 500
9:15:08 AM Ask 1.16 500
9:15:04 AM Ask 1.155 500
9:14:50 AM Ask 1.15 500
9:14:26 AM Ask 1.145 500
9:12:32 AM Ask 1.135 500
9:12:22 AM Ask 1.125 500

most


wo geht die Reise hin

[crashpoet]

sieht nach konsolidierung auf hohem niveau aus (1.14 $).
allerdings liegen da viele auf der lauer.

[martini81]

[posting]19.515.875 von FinancialServices am 03.01.06 15:47:33[/posting]Ich würde mir noch keine Platte machen...
da sind sicher paar GROSSE dabei den Kurs bissl zu drücken.
Mal sehen wie es in 2 Stunden aussieht.
Die Sorgen gehen eigentlich erst bei 10ct Abschlag los....

[crashpoet]

geht schon wieder aufwärts, bei rel. hohem volumen

[martini81]

Schon ist der Kurs wieder auf 1,14

[FinancialServices]

....habt Ihr euch mal das Volumen angesehen ...wird alles aufgesogen ...ich sag mal heute Abend ..10% im grünen Bereich ...Gruß FS

[gony2]

heute geht es echt ab
super volumen
das wir nen fettes plus
sind wohl in berlin ein paar nervös geworden
ich glaube 2006 wird cytogenix jahr

[FinancialServices]

[posting]19.516.177 von gony2 am 03.01.06 16:02:47[/posting]

[crashpoet]

[posting]19.516.177 von gony2 am 03.01.06 16:02:47[/posting]sach ich doch schon seit einem jahr

[FinancialServices]

[posting]19.516.216 von crashpoet am 03.01.06 16:05:59[/posting]....JA

[gony2]

und schon wieder bei 1,12
ihr hattet recht damit, das es heute rauf und runter geht
aber das macht ja gar nix

[gony2]

aktueller habe ich es auch nicht
http://www.pcquote.com/stocks/quote.php?symbol=CYGX

[crashpoet]

[posting]19.516.367 von gony2 am 03.01.06 16:16:51[/posting]die paar cent hin oder her sind wirklich nicht bedeutsam.
wichtig ist, was da in den nächstzen monaten noch ansteht, und das könnte gigantisch sein

[martini81]

Da hat ja vorhin jemand nen fetten Anteil in Berlin verkauft.... Kurs war kurz auf 81ct.
Ist wohl heute mal mein Glückstag -

[martini81]

So, hab jetzt erstmal n Date....
bis 19 Uhr sollte der Oiro der Vergangenheit angehören.
Alles klar Jungs?
Bis dann.....

PS: vielleicht schafft ihr es ja noch zu den most posted Treads....?

[FinancialServices]

[posting]19.516.611 von martini81 am 03.01.06 16:33:02[/posting]...geht LOS

[gony2]

,95 war heute der günstigste kurs in berlin

[FinancialServices]

Time & Sales most recent next page
Rec. Time Action Price Volume
10:36:42 AM Bid 1.1 500
10:36:30 AM Ask 1.11 500
10:36:24 AM Bid 1.105 500
10:36:20 AM Bid 1.11 500
10:36:16 AM Bid 1.12 500
10:36:12 AM Bid 1.13 500
10:36:08 AM Bid 1.12 500
10:35:58 AM Trade 1.11 500

ich Hasse 500er Blöcke

[crashpoet]

in berlin versucht jemand welche für 93€ loszuwerden. vertippt?

[FinancialServices]

[posting]19.517.074 von crashpoet am 03.01.06 17:01:06[/posting]...der meint wohl schon den Kurs ende 2006 zu kennen...

Gruß FS

[FinancialServices]

Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
1.09 0.04 (3.54) 10:44 1.08 (5) 1.10 (5)
Latest Ticks Prev Close Open Low High
+-== 1.13 1.1525 1.08 1.16
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
471,253 451,700 1.1338 0.34 1.15
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
170 1,500 2,772 0 130

[crashpoet]

ich vermute, wir werden heute ungefähr da enden, wo wir angefangen haben.
gut ding will weile haben...

[martini81]

So, ging schneller als gedacht.
Der blöde € steht ja immernoch..... hmm.
Bei den Amis stockt es irgendwie etwas - ne leichte Steigerung wäre heute schon nicht schlecht.

[martini81]

Irgend eine Stimme hat mir gerade erzählt das wir zum Wochenausgang brachial nach oben gehen werden. Schlecht wär das ja nicht.....

[martini81]

@FinancialServices

Bist du nur in CYGX investiert?

[martini81]

Ist noch jemand da? Der Kurs kann ja morgen nur besser werden.........

[martini81]

Greetz..... An der Amex wurde gestern echt der ungünstigste Kurs angepeilt. Nach der Charttechnik sollte es dann wieder aufwärts gehen... bei uns wird der Kurs heute sicher auf 0,85ct fallen. Noch eine Gelegenheit zum nachkaufen?

[martini81]

So, das ging ja noch schneller als gedacht. Nun bleibt nur die Hoffnung auf den Chart - sonst wird es heiß im Depot.

[FinancialServices]

Tuesday , January 03, 2006 14:15 ET

This is the 4th VOLUME alert for CYGX in the past 7 calendar days.

Trading for Cytogenix Inc (OTCBB: CYGX) has been heavier than usual in today`s session. By 14:15 ET, the stock had already traded 787,300 shares via 147 trades. The cumulative volume is 45.64% above its 20-day average of 540,567. Normally the stock experiences around 74 individual trades per session.

So far, today`s volume surge has caused a net decline in CYGX`s stock price. At the time of this alert, the stock was trading at $1.065, down $-0.065 (-5.75%).

One year ago, the Company`s shares closed at $0.820. The price has gained more than 29 percent since then.

Over the last 10 trading session CYGX has traded in a range between $0.700 and $1.150 and is currently trading 7.39% below its 52-week high of $1.150 set on December 30,2005 and 213.24% above its 52-week low of $0.340 from August 04,2005.


Wir haben es hier immer noch mit einem höchst Spekulativen Invest zu tun - die Schwankungen sind da ganz Normal - diese Werte hängen immer stark von ihren News ab und die werden bei CytoGenix noch kommen und dann ist die Aktie nicht zu halten - ich für meinen Teil halte die Kurse im Moment immer noch für Kaufkurse denn ein richtiger Abwärtstrend ist nicht zu erkennen.

Viel Erfolg

FS

[FinancialServices]

December 30,2005 and 213.24% above its 52-week low of $0.340 from August 04,2005.

Plus 213% muß man auch erst mal halten können - Gruß FS

[crashpoet]

[posting]19.526.063 von FinancialServices am 04.01.06 10:48:59[/posting]Stimme dir zu. Bei der Aktie ist Nervosität fehl am Platz.

Bislang sind hier nur Perspektiven eingepreist, die allerdings rosig sind. Nichtsdestotrotz: Bislang verbrennt die Company Geld, das erst wieder reinkommen muss.

Ich bleibe bei meiner Prognose von über 4$ zum Jahresende, zwischenzeitliche Abschläge im Bereich von bis zu 0.8$ sind aber programmiert.

[martini81]

Hm... wäre natürlich möglich das es heute Nachmittag noch weiter runter geht. News komm ja wohl diese Woche nicht...
ich kauf immer gern am Tiefstpunkt ein und warte daher erstmal auf den Börsenstart im Land der Amis.
SEEYA

[FinancialServices]

[posting]19.526.169 von crashpoet am 04.01.06 10:56:01[/posting].....stimme Dir zu - obwohl wir auch unter die ,80 fallen können - ,60 halte ich auch für gut möglich denn die Spielchen der MM an der Pennybörse sind ja wohl bekannt.

Grüße an alle
FS

[gony2]

Peking. DPA/baz. In China ist erneut die Vogelgrippe ausgebrochen. Wie die chinesischen Behörden am Mittwoch mitteilten, wurde der auch für den Menschen gefährliche Virus vom Typ H5N1 in der südwestlichen Provinz Sichuan nachgewiesen. Seit Ende Dezember seien im Gebiet um die Stadt Dazhu mehr als 1800 Vögel verendet. Daraufhin hätten Arbeiter damit begonnen, knapp 13 000 Tiere auf umliegenden Geflügelfarmen vorsorglich zu töten. Seit Anfang vergangenen Jahres ist dies der 32. offiziell bestätigte Ausbruch der Vogelgrippe in China. Sieben Menschen haben sich dort bisher mit der Vogelgrippe infiziert, drei von ihnen starben an der Krankheit.

[unoscarpe]

Ein sehr interessanter Wert,mit einem riesen Potenzial ,ich steige mit auf!!

[FinancialServices]

[posting]19.526.419 von unoscarpe am 04.01.06 11:12:40[/posting]Herzlich Willkommen !

Gruß FS

[FinancialServices]

Charttechnik


VectorVest Stock Analysis of Cytogenix Inc as of 12/30/2005


This report has five major sections.
Capital Appreciation Analysis
Dividend Analysis
Price-Volume Data
Sales / Market Capitalization Information
Summary






Business: Cytogenix Inc, (CYGX) is a biotechnology research and development company focusing on the intracellular expression of single stranded DNA. The Company holds exclusive rights to technology that produces single stranded DNA in bacteria, plants, and animals. CytoGenix seeks to incorporate this procedure into the antisense gene therapy market.
Business Sector: CYGX has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Industry Group: CYGX has been assigned to the Drug (BiomedicalGenetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

Capital Appreciation Analysis Back to top

Value: Value is a measure of a stock`s current worth. CYGX has a current Value of $0.08 per share. Therefore, it is overvalued compared to its Price of $1.13 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock`s Price and Value always will converge.

RV (Relative Value): RV is an indicator of long-term price appreciation potential. CYGX has an RV of 0.05, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.

RS (Relative Safety): RS is an indicator of risk. CYGX has an RS rating of 0.77, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company`s financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.

RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock`s price trend. CYGX has a Relative Timing rating of 1.92, which is excellent on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock`s price movements over one day, one week, one quarter and one year time periods. Once a stock`s price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.

VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. CYGX has a VST rating of 1.27, which is very good on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.

Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. CYGX has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.





Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. CYGX has a Stop of $0.76 per share. This is $0.37 below CYGX`s current closing Price. A stock`s Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock`s fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a `B` or `H` recommendation if its Price is above its Stop and an `S` recommendation if its Price is below its Stop.

GRT (Earnings Growth Rate): GRT reflects a company`s one to three year forecasted earnings growth rate in percent per year. CYGX has a forecasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock`s future price trend. If a stock`s GRT trend is upward, the stock`s price will likely rise. If GRT is trending downward, the stock`s Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (9.10%).

EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. CYGX has a forecasted EPS of $-0.12 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. CYGX has a P/E of -9.42. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 26.52. P/E is computed daily using the formula: P/E = Price/EPS.

EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. CYGX has an EY of -10.54 percent. This is below the current average of 3.77% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).

GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. CYGX has a GPE rating of -0.74. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.60%, the operative GPE ratio is 0.31. Therefore, CYGX may be considered to be overvalued.

Dividend Analysis Back to top

DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. CYGX does not pay a dividend.

DY (Dividend Yield): DY reflects dividend per share as a percent of Price. CYGX does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.

DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. CYGX does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.


DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company`s financial performance. It also provides some insight into the board`s outlook on the company`s ability to increase earnings. CYGX does not pay a dividend, so it does not have a Dividend Growth rating .

YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. CYGX does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.

Price-Volume Data Back to top

Price: CYGX closed on 12/30/2005 at $1.13 per share

Open: CYGX opened trading at a price of $1.04 per share on 12/30/2005.

High: CYGX traded at a High price of $1.15 per share on 12/30/2005.

Low: CYGX traded at a Low price of $0.99 per share on 12/30/2005

Close: CYGX closed trading at price $1.13 per share on 12/30/2005. (Close is also called Price in the VectorVest system)

Range: Range reflects the difference between the High and Low prices for the day. CYGX traded with a range of $0.16 per share on 12/30/2005.

$Change: CYGX closed up 0.09 from the prior day`s closing Price.

%PRC: CYGX`s Price changed 8.65% from the prior day`s closing price.

Volume: CYGX traded 1,788,635 shares on 12/30/2005.

AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. CYGX has an AvgVol of 334,300 shares traded per day.

%Vol: %Vol reflects the percent change in today`s trading volume as compared to the AvgVol. %Vol equals ((Volume - AvgVol) / AvgVol ) * 100. CYGX had a %Vol of 435.04% on 12/30/2005

CI (Comfort Index): CI is an indicator which reflects a stock`s ability to resist severe and/or lengthy price declines. CYGX has a CI rating of 1.33, which is very good on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock`s long-term price history. VectorVest advocates the purchase of high CI stocks.

Sales / Market Capitalization Information Back to top

Sales: CYGX has annual sales of $

Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. CYGX has a Sales Growth of 15.00% per year. This is very good. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company`s operations.

Sales Per Share (SPS): CYGX has annual sales of $0.00 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.

Price to Sales Ratio (P/S): CYGX has a P/S of 0.00. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.

Shares: CYGX has 100,000,000 shares of stock outstanding.

Market Capitalization: CYGX has a Market Capitalization of $114,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.

Summary

CYGX is overvalued compared to its Price of $1.13 per share, has somewhat below average safety, and is currently rated a Hold.

GrußFS

[martini81]

Hört sich irgendwie nach einer `Halten` Meldung an.

Nach meinen Beobachtungen steigt der Kurs meist nach einer Hold Meldung. Ich bin gespannt.

Werde trotzdem noch nicht nachkaufen - ein verpasster Gewinn ist nach meiner Meinung immernoch besser als ein Verlust.

[FinancialServices]

[posting]19.528.289 von martini81 am 04.01.06 13:04:46[/posting]Ja

[Fortschritt]

And up, up and ....away

[martini81]

N guter Start...

[FinancialServices]

9:58:42 AM Trade 1.09 45000 schöner Block

Gruß FS

[FinancialServices]

..MM Spielchen - schön den Kurs mit kleinen Stückzahlen drücken - na egal - wir sehen uns in einem Jahr wieder Jungs - Gruß FS

[Mambo6]

was´n mit dem Kurs los??? seit 17:39 keine neuen Werte????

[gony2]

Letzter Trade lt. Stockhouse war um 15-43 uhr US zeit.
1,09 $ bei 447000 Volumen. Komisch, habe auch noch keine Meldung gefunden.

[FinancialServices]

CytoGenix Announces Results of synDNA(TM) Smallpox Vaccine Study

HOUSTON, Jan 04, 2006 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB: CYGX) announced positive results of an animal study designed and conducted by the laboratory of Dr. David Weiner at the University of Pennsylvania Medical School Philadelphia. These tests demonstrated that a CytoGenix technique for generating synthetic DNA vaccines called synDNA(TM) as an smallpox vaccine, was highly potent in generating an immune response.
DNA vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, CytoGenix scientists prepared a synDNA(TM) vaccine containing a gene sequence provided by Dr. Weiner that produces a protein that is an essential component of the smallpox virus.

Scientists in Dr. Weiner`s laboratory tested and compared levels of antibodies and killer T cells produced in mice by the synDNA(TM) smallpox vaccine to a traditional plasmid DNA vaccine. The synDNA(TM) vaccine generated immunoglobulin and T cell levels in test animals several times greater than a comparable plasmid DNA vaccine produced by bacterial fermentation.

Dr. David B. Weiner, Associate Professor, University of Pennsylvania Medical School, Department of Pathology and Laboratory Medicine, a leading expert in DNA vaccines, commented, "We are impressed with the results from this study, the data, while preliminary are exciting."

Frank Vazquez, CytoGenix, Inc.`s Executive Vice President and COO, commented, "These results confirm the effectiveness of synDNA(TM) vaccines in producing substantial immunologic activity. The positive results we have achieved with our DNA vaccine tests are an excellent foundation for developing vaccines against biodefense related targets and for Avian Influenza H5N1."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

[Fortschritt]

The positive results we have achieved with our DNA vaccine tests are an excellent foundation for developing vaccines against biodefense related targets and for Avian Influenza H5N1.”

[FinancialServices]

Schaut Euch die Kurse von Gestern gut an - die werden bald der Verganganheit angehören !

Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
1.10 0.06 (5.77) 2006-01-04 1.09 (5) 1.10 (5)



Der Trend für Heute ist eindeutig up !

Gruß FS

[FinancialServices]

Diese Ergebnisse bestätigen die Wirksamkeit von synDNA (TM) Impfstoffen im Produzieren wesentlicher immunologic Tätigkeit. Die positiven Ergebnisse, die wir mit unseren DNA-Impftests erreicht haben, sind ein ausgezeichnetes Fundament, um sich zu entwickeln, Impfstoffe gegen biodefense verbanden Ziele und für Vogelgrippe H5N1. "


"Wir sind mit den Ergebnissen von dieser Studie und den Daten beeindruckt und diese sind sehr aufregend "

Bekanntgegebene positive Ergebnisse einer Tierstudie entwarfen und führten durch das Laboratorium von Dr David Weiner an der Universität der Medizinischen Fakultät von Pennsylvanien Philadelphia. Diese Tests demonstrierten, dass eine CytoGenix Technik, um synthetische DNA-Impfstoffe zu erzeugen, synDNA (TM) als ein Pocken-Impfstoff nannte, war im Erzeugen einer geschützten Antwort hoch stark.



fs

[FinancialServices]

Wer ist Dr.Weiner aus der Mitteilung..


Professor David Weiner of the University of Pennsylvania is a world-renowned leader in viral pathology and genomics. As a pioneer in the field of DNA vaccines to treat infectious diseases and cancer, he has over 300 peer-reviewed publications in scientific journals to his credit and publication in mainstream scientific journals such as Scientific American. He is the editor of three published books and is currently working on his fourth. Dr. Weiner’s many credits attest to the level of recognition he has received for his pivotal role in the development of gene-based vaccines and therapies. Dr. Weiner serves and has served as an advisor to and collaborator with leading companies such as American Home Products, 3M, J&J, GSK, Mobil and Centocor. Dr. Weiner also played a key role in the start-up of biotechnology companies such as Apollon, Synbiotics, Immune Pharmaceutics, Verigen, and Symphony Pharmaceutics. He is a special employee and an advisor for FDA/CBER, and the NIH-NIAID-DAIDS Grant Review process.

Chairman of Scientific Advisory Board.

Description of Research

The laboratory of Dr. Weiner helped to found the field of DNA vaccines. His group and collaborators are responsible for the first DNA vaccine IND’s. These IND’s were for HIV immune therapy and the first IND approved as a prophylactic for any indication, in this case HIV-1. Over 160 individuals have been vaccinated with HIV-1 DNA vaccines that his group and his collaborators developed in collaboration with Wyeth. These studies established that DNA vaccines appear well tolerated and are immunogenic in humans. Current work focuses on developing a new set of more potent second generation DNA which have exhibited dramatically improved potency in non human primates. These vaccines are being moved into the clinic for HIV prophylaxis as well as immune therapy. Another line of study in his laboratory is the study of the contribution of HIV accessory genes to viral pathogenesis. His group is investigating the role of the Vpr gene product in modulation of host cell immune responses during HIV infection.

[crashpoet]

Tja, CYGX hat seine Wundertüte ein Stück weiter geöffnet.
Die News kam NACHBÖRSLICH!

[crashpoet]

gestern noch keine Reaktion!

[gony2]

1,10$ sind ,91 €
es lagen die ganze zeit 3000 in B zu ,88 und welche zu ,92. die sind aber anscheinend schon zurückgezogen. wenn die news nach börsenschluss kommen, heist das meist up and up für heute.

[gony2]

Ankara (Reuters) - In der Türkei ist einem Regionalvertreter zufolge vom Donnerstag zufolge ein zweites Kind an der Vogelgrippe gestorben.

Das Mädchen sei am Morgen gestorben, sagte der Gouverneur der osttürkischen Provinz Van, Niyazi Tanilir, dem Nachrichtensender CNN Türk. Es handle sich um die Schwester des zuvor an der selben Krankheit verstorbenen 14-Jährigen Jungen. Mediziner des Landes hatten zuvor den Tod des Jungen bestätigt und mitgeteilt, seine Schwester leide ebenfalls an der Krankheit. Es war das erste Mal, dass die Vogelgrippe außerhalb von Südostasien und China bei Menschen diagnostiziert wurde. Zeitungsberichten zufolge soll das Mädchen 15 Jahre alt gewesen sein.

"Wir sind ziemlich sicher, dass es unglücklichweise ein Fall von H5N1 beim Menschen ist", sagte WHO-Experte Guenael Rodier zum Tod des Jungen. Es seien aber noch weitere Tests nötig. Die Geschwister waren in ein Krankenhaus in Van im Osten der Türkei eingeliefert worden. Der Junge verstarb am Sonntag. Zunächst hatte es geheißen, er sei den Folgen einer Lungenentzündung erlegen.

In Asien sind seit 2003 mehr als 70 Menschen an der Vogelgrippe-Variante H5N1 gestorben. Wissenschaftler befürchten, das Virus könne sich verändern und von Mensch zu Mensch übertragen werden, womit eine weltweite Erkrankungswelle drohe. Die Türkei liegt im Fluggebiet von Zugvögeln, die für die Verbreitung der Vogelgrippe verantwortlich gemacht werden. In den vergangenen drei Monaten hat das Land zwei Fälle des Ausbruchs der Krankheit bei Tieren bestätigt.

[gony2]

Noch mal nachträglich zu dem Deal

28.12.2005 - 19:12


CytoGenix hat heute mitgeteilt, eine Vertriebskooperation mit GE Healthcare eingegangen zu sein. Die Unternehmen wollen sich künftig gemeinsam um staatliche Aufträge in Zusammenhang mit der Abwehr von Bio-Terrorismus bemühen. Insbesondere das US-Heimatschutz-Ministerium, das Verteidigungsministerium und das Gesundheitsministerium sollen für die Anti-Mikroben-Technologie von CytoGenix gewonnen werden.

Wie ein hochrangiger Mitarbeiter von CytoGenix erklärte, erwarte man sich aus der Allianz mit der General-Electric-Tochter, die es auf einen Jahresumsatz von 16 Milliarden Dollar bringe, sehr bald positive Ergebnisse.

Im OTC-Handel ziehen CytoGenix aktuell um 12,9 Prozent auf 1,05 Dollar an.

[gony2]

und ne alte studie von 2004

CytoGenix heilt mit genetischen Botenstoffen
Extrem breite Produktpalette möglich

CytoGenix (WKN 922173, ISIN US2328251093, www.cytogenix.com) ist ein Gentechnologie-Unternehmen mit Hauptsitz in Houston Texas und wurde 1995 gegründet. CytoGenix hat sich darauf spezialisiert, die Übermittlung genetischer Botenstoffe zu beeinflussen. Die Gene selbst bleiben bei dieser Technologie unbeeinflusst. Die Unternehmung entwickelt Produkte für Anwendungen auf der Haut, z. B. gegen Herpes, Gürtelrose, Schuppenflechte. In einem weiteren Schritt soll ein Produkt gegen Sepsis entwickelt werden, welches lebensrettend immer antibiotikaresistentere Bakterien im Blut bekämpfen soll. CytoGenix hat eine Marktkapitalisierung von derzeit 57,9 Mio. Euro bei 96.476.476 Aktienanteilen.

Das US-amerikanische Unternehmen entwickelt derzeit drei verschiedene Produkte:

Simplevir bekämpft genitalen, labialen und okularen Herpes sowie Schindeln (Herpes zoster).
Inflamox ist eine Hautcreme gegen Schuppenflechte, Kontaktdermities, Akne, Druckgeschwüre, Gelenkschwellungen, akneähnliche Rosazea (Kupferfinnen)
Ebenfalls geplant ist ein antiseptisches Produkt.
Schwerpunkt bilden derzeit die beiden Hautcremes Simplevir und Imflamox zur Behandlung von Herpes bzw. von Entzündungen. Simplevir ist eine antivirale Creme, die Herpes 1 und 2 (genital, labial und okular) sowie Schindeln heilen soll. Vorklinische Studien in lebenden Zellen haben nach Angaben des Unternehmens eine Reduktion der Viren um 99% erwiesen. Für Simplevir wurde im Juli 2003 vorklinische Tests begonnen. Inflamox ist eine vielseitig einsetzbare entzündungshemmende Hautcreme für die Behandlung von Schuppenflechten, Kontaktdermitits (=Entzündungsreaktion der Haut auf äussere Substanzen und Einflüsse), Akne, Dekubitus (=wundgelegene Stelle), Rosazea (=Akne rosazea, Kupferfinnen) und Gelenkschwellungen.
Als besonders Aufsehen erregend befindet der Frankfurter Finance Newsletter die Forschungsbemühungen des Unternehmens zur Bekämpfung der Sepsis, also der Blutvergiftung durch verschiedenartig aggressive und immer antibiotikaresistentere Bakterien. Bei derzeit ca. einem Prozent aller Krankenhauspatienten kommt es zur Infektion mit Bakterien. Sepsis ist die Haupttodesursache in der Intensivmedizin. Die zum Patent angemeldete Technologie des Unternehmen könnte für Patienten mit einem zu 30-40% tödlich verlaufenden septischem Schock lebensrettend sein. Das Unternehmen hat in Experimenten erwiesen, dass es Bakterien vernichten, das Wachstum aufhalten oder die toxischen Stoffe verhindern kann. Erste Pilotstudien mit Tieren sind im Gange.

DNS-Einzelstrang-Technologie überlegen gegenüber anderen Gentherapieverfahren

Mit ihren Produkten unterscheidet sich CytoGenix von anderen Gentherapieunternehmen hinsichtlich der Zielsetzung, die genetischen Botenstoffe zu manipulieren. Die Gene selbst bleiben unbeeinflusst. Außerdem wird durch die Technologie der Produktion von Desoxyribonukleinsäure-Einzelsträngen (DNS-Einzelstränge) innerhalb der Zelle ein entscheidendes Manko anderer Verfahren umgangen. Bei anderen Methoden wird, damit überhaupt eine therapeutische Wirkung erreicht wird, der geschwächte Körper mit Vektoren bzw. Genproduktträgern überflutet und zum Teil zu stark belastet. CytoGenix muss nur ein einziges Molekül in der kranken Zelle installieren. CytoGenix konzentriert sich darüber hinaus zunächst auf die Behandlung der Hautoberfläche und damit auf ein lokal leicht erreichbares Ziel. Mit der sich teilenden Zelle verschwindet das Molekül überdies und es können auch keine Nachwirkungen entstehen. Gegenüber den herkömmlichen chemischen Medikamenten der Pharmaindustrie funktionieren die anvisierten Produkte von CytoGenix zielgenauer und ohne Nebenwirkungen. Das geplante Produkt gegen Sepsis bzw. bakterielle Blutvergiftung zum Beispiel hat den entscheidenden Vorteil der spezifischen Wirksamkeit gegenüber den derzeit eingesetzten Antibiotika und Antiseptika. Die Baktieren können sich der Bekämpfung nicht durch Mutation entziehen.

CytoGenix hat eine einzigartige Technologie der Produktion von Einzelstrang-DNS innerhalb von Zellen entwickelt. Erreicht das Medikament Simplevir oder Inflamox die Zelle, wird innerhalb der Zelle ein Molekül installiert, welches kontinuierlich spezifische Sequenzen einer bestimmten Einzelstrang-DNS (single stranded DNA = ssDNA) aussendet. Der Signalweg des genetischen Botenstoffes Boten-Ribonukleinsäure (Boten-RNS = messenger RNA = mRNA) verläuft vom Zellkern zum Ribosom. Die vom Medikament ausgelöste Produktion von Einzelstrang-DNS innerhalb der Zelle verhindert die Produktion schädlicher bzw. krankheitsauslösender Proteine, indem sich in den befallenen Zellen die Einzelstrang-DNS an die genannte Boten-RNS haftet und die Boten-RNS die Information zur Produktion schädlicher Proteine nicht weitergeben kann. Für die Bekämpfung der bakteriellen Blutvergiftung kommen die Erkenntnisse dieses Verfahrens und die Technologie der Prorduktion von DNS-Einzelsträngen in abgewandelter Weise zum Einsatz.

Anstehende Finanzierung bei Investment-Bank

Bei einer Investment-Bank soll bis Mitte des Jahres genügend Geld aufgenommen werden, so der CFO Lawrence Wunderlich im Exklusiv-Interview mit dem Frankfurter Finance Newsletter, um idealerweise für die nächsten drei bis vier Jahre möglichst ohne eine weitere Kapitalerhöhung finanziell gewappnet zu sein. Derzeit arbeitet man mit einer Cash-Burn-Rate von 2,5 bis 3 Mio. USD pro Jahr. Bis Ende 2007 will das Unternehmen in signifikantem Umfang Umsätze mit Vorabzahlungen bzw. der Lizensierung seiner Produkte erzielen. Wenn die Produkte Simplevir und Inflamox die Phase II der klinischen Tests durchlaufen haben, wird gezielt nach einer strategischen Partnerschaft mit einem großen Pharmaunternehmen gesucht. Von dem vom Unternehmen geschätzten Marktvolumen für Herpes-Produkte von 1,5 Mrd. USD und für Entzündungshemmer von 3-4 Mrd. USD wird sich CytoGenix bei erfolgreichen Tests mit seinen überlegenen Produkten Simplevir und Inflamox sicherlich einen bedeutenden Anteil sichern können. Später soll unter anderem auch ein Mittel gegen Sepsis folgen, bei dem sogar ein noch viel höheres Marktvolumen lockt. Weitere Einnahmen könnten aber auch ganz simpel durch die geplante DNS-Plasma-Produktion oder die wertvolle Technologie der Screening-Datenbank generiert werden. Die klinischen Tests der Unternehmung sind mit Unsicherheiten behaftet und CytoGenix ist ein risikoreicher und marktenger Wert. Aber selbst wenn die Kurse der Aktie bei derzeit 55 Euro-Cents temporär unterschritten werden sollten, stufen wir CytoGenix unter Berücksichtigung der starken Volatilitäten auf "Kaufen" ein und sehen auch auf derzeitigem Niveau langfristiges Kurspotenzial

[crashpoet]

[posting]19.541.471 von gony2 am 05.01.06 10:23:14[/posting]Bemerkenswert ist, daß bis Ende 2005 noch keine Rede davon war, in den Bereich BioDefense einzusteigen. Das hat CYGX still und heimlich vorangetrieben und präsentiert jetzt erste Ergebnisse.
Bislang war ich davon ausgegangen, daß der erste Kursschub durch eine Veröffentlichung zur erfolgreichen SynDNA-Produktion ausgelöst wird. Diese News steht noch aus! Da aber die letzten Veröffentlichungen audf der erfolgreichen Anwendung eben dieser Technologie beruhen, sollte das nur noch eine Frage kurzer Zeit sein.
Die ganze BioDefense-Geschichte / Kooperation mit GE Healthcare kommt da noch hinzu

[crashpoet]

Berlin zeigt erste Reaktionen.

Best Bid Best Ask
Volumen Taxe
Taxe
Volumen

- 0,94 1,03 -

Kauf Orders Verkauf Orders
Stücke Limit
Limit
Stücke

3.000 1,04 1,05 3.900

6.400 0,94 1,10 3.000

1.000 0,92 - -

2.000 0,85 - -

500 0,71 - -

- -

[martini81]

Fuck! Da ist man einmal nich da und schon verpasst man günstig nach zu kaufen.
Komisch das sowas immer mir passieren muss...

Ob die heute auf 1,5€ klettert?

[martini81]

Ich werd heute mal aus dem Fenster springen, damit mir sowas nich nochmal passiert.
Trotzdem ein sauberer Gewinn.....

[martini81]

Schön wärs wenn die Amis heut mal an der 2$ Marke kratzen würden.... aber nun gibt es erstmal Stillstand bis zur Eröffnung

[FinancialServices]

[posting]19.544.285 von martini81 am 05.01.06 12:31:05[/posting]....warte mal ab wenn Ammiland öffnet - Deinen Kaufkurs um 1 € siehst Du Heute wieder - die Nachricht ist zwar sehr positiv aber hier viel zu hoch Bewertet - die Ammis kennen Cytogenix schön länger und wissen um die Probleme der Finanzierung - es fehlt noch die entscheidende News Cooperation und Finanzierung - ich bin seht positiv Gestimmt halte die Kures in Berlin allerdings für vollkommen überzogen....


Gruß FS

[FinancialServices]

[posting]19.544.542 von FinancialServices am 05.01.06 12:47:23[/posting]...ich will damit nur sagen das du Heute noch für dünnes Nachlegen kannst - Gruß FS

[FinancialServices]

....das ist der Stand von Gestern -

Last 1.10 $ gesammt Volumen 502.000


allso Kaufkurse um 1€ - Gruß FS

[martini81]

[posting]19.544.582 von FinancialServices am 05.01.06 12:50:06[/posting]Mein Kaufkurs-Schnitt liegt bei 0,76ct.
Sind allerdings nur 5000st. Es waren mal 10000.
Hab heute nicht nachgekauft..... schade um die verpasste Kohle.

[martini81]

Ich glaub nicht das wir den Oiro als Kaufkurs noch sehen werden. Wenn die Karre hier nach der Eröffnung auf 2$ zieht, müssen die sich bald keine Sorgen mehr um die Finanzierung machen....

[FinancialServices]

[posting]19.544.996 von martini81 am 05.01.06 13:15:21[/posting].... - wait and see

[FinancialServices]

...sieht mir irgendwie nach einem RIESEN W aus ....

Gruß FS

[martini81]

Nur lässt sich die Charttechnik nicht immer mit der Realität verbinden. (News)
Wir werden schon noch unser blaues Wunder erleben....

[martini81]

@ FinService @

Mal was anderes.... ich hab vielleicht schon den nächsten Renner aus der Rohstoffbranche gefunden....
....falls du mit Rohstoffen was anfangen kannst.
> Forsys Metals < 0,62ct
Vielleicht bestehen da Verbindungen zu Frick´s neuer 0,60ct Rakete für ende Januar.
Schön wäre es jedenfalls-----GM81

[martini81]

[posting]19.547.079 von FinancialServices am 05.01.06 14:52:54[/posting]Du hast wirklich richtig gelegen.....

[FinancialServices]

...leider ja

[martini81]

Vielleicht hab ich ja auch Recht, mit meinen 2$

[Boerse24]

Was glaubt ihr wie hoch die Aktie heute noch kommt?

[ketsie]

leute - können wir uns mal auf einen thread einigen ... vorschlag bitte?

[FinancialServices]

[posting]19.548.179 von Boerse24 am 05.01.06 15:59:37[/posting]...es wird eine range zwischen 1,15$ und 1,20$ sein...

Gruß FS

[Boerse24]

Welches Kursziel siehst du denn für die nächste Woche oder morgen?

[FinancialServices]

[posting]19.548.588 von Boerse24 am 05.01.06 16:21:48[/posting]Ich bin kein Wahrsager !!! Habe auch keine Glaskugel - das überlasse ich anderen hier !!!


Ohne Die News - weitere Finanzierung - dümpeldümpel - wenn die kommt - up and away !


Die Frage ist nur wann - und das weis KEINER !

Ich hätte allerding keine Angst um mein Geld auch wenn ich Heute bei 1,15-1,20 eingestiegen wäre - CYTOGENIX ist es auf jeden Fall WERT - mit einem langen ATEM.

Gruß FS

[Boerse24]

das ist gut zu hören... ich habe nämlich heute 5000 Stück zu 1,2 Euro gekauft..., die ich jetzt leider 20 Prozent billiger hätte haben können:O

[crashpoet]

[posting]19.548.706 von FinancialServices am 05.01.06 16:28:16[/posting]doch, ich weiss wann, auf den tag genau

[FinancialServices]

[posting]19.549.171 von Boerse24 am 05.01.06 16:54:16[/posting].....ich kann Dich sehr Gut verstehen....aber wie Du dein Geld anlegst hast Du selbst zu verantworten ....Gruß FS


....sie ist ja Grün in Ammiland - großes Volumen und der Kurs hält sich sehr Gut ....wird schon ....wir sind ja alle bei DIR !

Gruß FS

[FinancialServices]

[posting]19.549.196 von crashpoet am 05.01.06 16:55:41[/posting]BITTEBITTEBITTE ich will es auch wissen gebe auch 100 Stück ab


Gruß FS

[crashpoet]

aus dem amerik. board, SEHR aufschlussreich

Unfortunately, I have a bit of a checkered background. While I am not a biochemist, I have known more than my fair share of crooks and con-artists. I attended the Share Holder`s Meeting and requested and received a tour of the facilities last spring. Before and after the meeting I spoke with several of the principals and other investors. My wife sat next to Mrs. Skolnick at the meeting. There were hard questions asked and serious answers given. NO ONE, repeat, NO ONE expressed any dissatisfaction with the answers in the sense that they were incomplete or evasive.
At the facilities and during the meeting I was struck with the penurious, financially cautious attitude. I went early in the morning and prowled the parking lot looking for luxury cars. I checked the level of furnishings in public spaces and private offices of the corporation. ( The space itself is in a simple office park like you might see a orthodontist`s office. The building you see on this website holds multiple businesses. ) I made sure I was aware of the suits et cetera people were wearing. During the meeting, several people including myself, expressed the opinion that cygx should consider moving into it`s own space and I talked with LW about this also. They didn`t want to incur the expense. These are NOT what a scam artist does.
Overall, I went down there with 12,000 shares and a lot of questions. I now own 66,000 shares. I am on record on this board recently that I think we may have another drop in price, so I am not a "pumper". This is a good company and I expect it to make me wealthy.

[crashpoet]

[posting]19.549.266 von FinancialServices am 05.01.06 16:59:46[/posting]genau an dem tag, an dem ich den thread

CYTOGENIX: DIE WENDE IST GESCHAFFT

eröffne

nix für ungut

cp

[Boerse24]

Danke für das Mitgefühl.
Man darf sich einfach nicht von Emotionen leiten lassen und den Kauf nicht überstürzen sonst zahlt man immer drauf!

[crashpoet]

[posting]19.549.171 von Boerse24 am 05.01.06 16:54:16[/posting]zu deiner beruhigung:
nach meiner einschätzung ist die aktie gut auf kurs und, ich wiederhole mich, es würde mich sehr wundern, wenn cygx ende 2006 nicht bei 4$ + X steht.

[FinancialServices]

[posting]19.549.306 von crashpoet am 05.01.06 17:01:12[/posting]...schön wir lesen das selbe

[FinancialServices]

[posting]19.549.328 von crashpoet am 05.01.06 17:02:25[/posting]Spielverderber

[FinancialServices]

[posting]19.549.372 von crashpoet am 05.01.06 17:04:46[/posting]...kann es auch ein Y sein

[ketsie]

börse24 - ich bin dein leidensbruder. leider gibt´s dafür keine medizin als zu warten. sehe aber potenzial in dieser aktie, ein riesiges. wir müssen uns nur gedulden.

[ketsie]

hat denn nun jemand mal einen link zu rt - kann auch verzögert sein - usa. bitte, bitte ...

[crashpoet]

[posting]19.549.659 von ketsie am 05.01.06 17:19:52[/posting]http://www.pcquote.com/stocks/quote.php?symbol=cygx

[ketsie]

danke - retter in der notketsie

[crashpoet]

[posting]19.549.844 von ketsie am 05.01.06 17:28:46[/posting]leider ist der link oft überlastet.
verzögerte quotes gibt es unter nasdaq.com

[FinancialServices]

[FinancialServices]

[posting]19.550.372 von FinancialServices am 05.01.06 17:53:02[/posting]Volumen ist Klasse - der Tag ist noch sehr lang - wir schließen wahrscheinlich wieder über dem Durchschnittsvolumen - und das ist wichtig - wenn das so weiter läuft SK 1.20$ heute Abend....

Gruß FS

[Mambo6]

RT um 19:38 Uhr bei 1.20 Dollar bei 852 000 Umsatz

[ketsie]

wie sieht es aus jungs und mädels ...

[Mambo6]

Kurs mit dem Schlußgong

1.13 cygx - CYTOGENIX INC
Change:

+0.03 % Change:

+2.73% High:

1.2 Low:

1.09 Volume:

1,191,693

[ketsie]

es kommen bessere tage ... ketsie

[gony2]

war ein schöner tag für mich und cytogenix. mir tun die armen teufel leid die da nur so draufgesprungen sind heute morgen.
ich habe meine 7000 stück zu 1,10 verkauft. ok wäre auch teurer gegangen aber wer erwischt schon den höchstkurs. hatt wirklich einer geglaubt das so eine allgemeine meldung einen 30 prozentigen vorsprung vor den usa bringt. mann oh mann das muss mann doch wissen. ich habe heute vormittag davor gewarnt und die millionen zahl in den raum gestellt, die die teuren käufern den amis zubilligen. umgerechnet waren es ca. 28 mio die wir in d schon eingeplant hatten, ich meine die gesamtkapitalerhöhung durch unseren prognostizierten anstieg. gier frisst hirn. tschuldigung , aber ich hoffe für alle investierten das die einstiegskurse wieder kommen . und nun? nun sind alle meldungen erst mal raus.
was soll da die nächsten wochen kommen? schöne seitwärtsbewegung. naja mit glück........
egal, allen eine gute nacht und verdammt gutes traden

gony

[FinancialServices]

Guten Morgen !

Alle neuen CytoGenixten die Gestern zu den Kursen zwischen 1.15 und 1.25 eingestiegen sind darf ich zur Beruhigung mal sagen das Gestern in Ammiland rund 500.000 Stück in einer Range zwischen 1.15 und 1.20$ gehandelt worden sind.Es gibt kein Grund zur Beunruhigung Cytogenix macht seinen Weg und ich halte die Kursprognose eines Insiders aus dem Ammiboard von 4$ Ende des Jahres für realistisch.

Der Institutionelle Anleger CSI hat am 30.09.2004 300.000 Shares gekauft die er noch hat - warum wohl ?

Keine Bange auch wenn der Kurs auf 0,70€ mal absacken sollte - Gruß FS - Think long !!


Gruß FS

[FinancialServices]

US Dollar Wechselkurs Euro € Geldkurs Briefkurs
USDEUR=X 1,13 6 Jan 0,8272 93,4695 0,8272 0,8273


0,93 da wird Sie wohl Heute bleiben - bei Verkäufen auch unter 0,90 nicht ERSCHRECKEN

Gruß FS

[Mambo6]

jetzt ist es wieder wie immer bei den Deutschen... zuerst die übertriebene Euphorie und dann jämmerliche Panik... Schlußkurs in US von 1,13 Dollar entspricht Kurs 0,93 Euro.
Weshalb da jemand für 0,88 Euro verkauft ist mir vollkommen schleierhaft.

[ketsie]

Türkei - ein weiteres kind an vogelgrippe gestorben. schlimm - aber am impfstoff muss gearbeitet werden. bin 1,20er einstiegsmensch ... denke wir haben jetzt eine seitwärtsbewegung, aber auch hoch und runter - fakt ist, ich bleibe drin. brauche ja die kohle nicht heute oder morgen. think long. ketsie

[Wertpapierexperte]

bin gestern mit Schnittkurs 0,97 mit einer kleinen Pos. eingestiegen, leider haben die Amies bei umgerechnet
ca. 1,935 Euro geschlossen. Alles um die 1,9 Euro sind Kaufkurse. Wenn Amiland aufmacht, geht´s erst mal ein paar % hoch. Dann müssen wir abwarten, wie´s weiter geht.
Wer bei 0,9 Euro kauft, ist direkt mit 3,5% im Plus. Wer die zu 0,89 Euro kauft ist 4,5% im Plus !
Mal schauen ob ich noch ein wenig Zocker-Geld freimachen kann, dann kauf ich se mir. Momentan habe ich aber mein Zocker-Budget voll ausgeschöpft.

gruß WPE

[Wertpapierexperte]

Der MM in Berlin hat momentan keine Möglichkeit die gekauften Stücke wieder loszuwerden, Das ändert sich um 15:30 wenn Amiland aufmacht schlagartig. War gestern im neg. Sinne genauso. Da passte sich der Kurs in Deutschland umgehend dem Kurs in Amiland an. Wird heute genauso sein.
Sprich Kurs 15:30h 0,93+x. Wahrscheinlich kaufen kurz vorher schon einige alles bis 0,9 Euro.

gruß WPE

[lassevegas]

@Wertpapierexperte
Wenn du schon solche merwürdigen Rechnungen anstellst, dann solltest Du wenigstens den Geldkurs aus den Usa nehmen und der liegt bei 1,11, also 0,918 Cent. Ob es nach dem Closing gleich erst mal etwas raufgeht halte ich für sehr fragwürdig, wie kommst Du darauf.
Der MM in Berlin hat damit garnichts zu tun, das sind ganz sicher nicht seine Stücke die da im Brief liegen.
Warum sollte er gestern Stücke gekauft haben ? Im Gegenteil, er hat sicherlich Stücke verkauft die er später deutlich billiger wieder
bekommen hat. Mit ging es mit meinen 20.000 Stück übrigens genauso.
Aber immerhin habe ich alle wieder zurückgekauft, denn für mich ist das der Wert des Jahres, nicht mehr und nicht weniger.
Das Kursziel für dieses Jahr sehe ich auch bei mind. $4, vorrausgesetzt die Finanzierung wird gesichert, das halte ich aber für sehr wahrscheinlich.
Trotzdem kein Grund hier panisch zu kaufen wenn mal eine Nachricht kommt, aber trotzdem danke dafür (das meine ich ohne Häme)

lassevegas

[ballalo]

[posting]19.563.099 von lassevegas am 06.01.06 11:01:06[/posting]Es scheint ja wirklich kein Interesse derzeit zu bestehen.
Wäre doch nett, wenn mal jemand die 3000 aus dem ask zu 0,88€ kauft. Dann würde es doch gleich viel besser aussehen. Aber ohne Käufer kann der Kurs nicht laufen.

[Wertpapierexperte]

lassevegas,

welchen Geldkurs ?

Amiland macht erst um 15:30 auf, vorbörsliche Angaben sind uninteressant. Was zählt ist der Schlusskurs gestern, der dient zur Orientierung. Mal sehen wo AMI-LAnd heute eröffnet. Ich habe nicht viele Aktien, eigentlich lohnt das posten nicht. Mein Einstiegskurs mit ca. 0,97 Euro war zu riskant gewählt, aber Ami-LAnd sah bis ca. 20:00h sehr gut aus. In Berlin stehen auch nur 3000 Stücke zu 0,88 Euro und danach nix mehr bis 0,97.

gruß WPE

[ballalo]

[posting]19.563.795 von ballalo am 06.01.06 11:25:27[/posting]Da hat mich ja jemand erhört!! Jetzt haben wir doch schon ein ask bei 0,96€. Wenn jetzt noch ein paar Käufer angelockt werden können, schaffen wir den Euro vielleicht auch wieder.

[FinancialServices]

Cytogenix Inc DL (Jan 06 5:18 AM EST)

CYGX 1.13

Today 5 Dy 1 Mo 3 Mo 1 Yr more
Last Price
1.13
Change $

Change %

Tick up


Bid
1.11
Bid Size
500
Ask
1.13
Ask Size
500

Open
1.13
High
1.20
Low
1.09
Prev Close
1.13

Last Trade
1/5/06
Volume
105.6 k
52 Wk Hi
1.20
52 Wk Lo
0.34

Market Cap
134.65 m
Ex-Div Date
N/A
Div. Rate
N/A
Yield
N/A

Shares
119.16 m
EPS (TTM)
-0.03
PE Ratio
N/A
Exchange
OBB




Cytogenix Inc Headlines As of Jan 06 5:33 AM EST


Nicht streiten Freunde - Ihr habt doch Gestern gesehen über 1 Millionen Aktien gehandelt - da kommt was - da bin ich mir ganz sicher - wir werden alle belohnt - Gruß FS

[lassevegas]

wertpapierexperte

wenn du hier jemanden zum kauf ermutigst, dann ist nicht der schlußkurs sondern der geldkurs von gestern 22.00 uhr
entscheidend.
und einmal für alle zum mitschreiben: WAS HIER IM ORDERBUCH STEHT ODER LIEGT IST VÖLLIG EGAL !
die umsätze in den usa liegen bei über 1 mio aktuell, da spielen diese paar stücke hier überhaupt keine rolle und nehmen
absolut null einfluß auf den handel in den usa. vergeßt berlin, käufe und verkäufe sollten bei so einem wert direkt in den usa
gemacht werden.
und ballao. es ist doch wurscht, ob hier jetzt jemand einen euro bezahlt macht oder nicht, die kursentwicklung hier spielt
keine rolle.
unfassbar, wieviel hier einige darauf gucken was noch im ask liegt oder nicht.

[FinancialServices]

[posting]19.564.167 von FinancialServices am 06.01.06 11:38:38[/posting]Pennybörse - glaubt mir .....die ammis haben es im Urin...nur Geduld

GE Healthcare .....denkt drann !

Gruß FS

[ballalo]

[posting]19.564.375 von lassevegas am 06.01.06 11:47:27[/posting]Grundsätzlich hast du ja recht. Aber wenn hier ein paar Käufer auftachen, könnte ich doch einen Teil für nen Euro verkaufen. Wäre doch ein schöner Gewinn.

[lassevegas]

FS
Ich stimme Dir voll zu.
Ich hab die aktien seit fast 3 Jahren im Depot
und zwischendurch hatten wir harte Zeiten.
Aber jetzt ?
Ich habe genug, deswegen kaufe ich keine mehr, aber
schon zur Jahresmitte wird die Firma eine andere sein als heute.
Ich rechne mit dem ersten Big Deal schon im ersten Quartal, dann Wechsel an
die Amex und Ende des Jahres nur noch Freude.
Vielleicht ist mein Blick über die Jahre getrübt, aber ich muß mich beherrschen den
Wert nicht komplett überzugewichten.
Man muß sich eben im klaren sein, daß die Kursentwicklung an der OTC schwer voherzusagen ist,
aber dieses Problem sollten wir bald nicht mehr haben.....

lassevegas

[FinancialServices]

[posting]19.564.904 von lassevegas am 06.01.06 12:09:21[/posting]...Vielleicht ist mein Blick über die Jahre getrübt, aber ich muß mich beherrschen den
Wert nicht komplett überzugewichten.

Das spricht sehr für Dich .. ehrlichkeit macht sehr sympatisch!

Ich bin erst seit Oktober 2005 dabei - die Zukunftsperspektiven von CYGX sind GIGANTISCH - wenn alles eintrifft was erwartet wird .....Du siehst es sindt wie immer zu viele wenn und Zukunft blablabla.....ich stimme Dir vollkommen zu wenn CYGX es schafft und zwar dieses Jahr mit der Produktion zu beginnen - haben wir einen ( und das ist kein Spruch ) 6er im Lotto und ich lege nach bis $5 - denn dann ist der Weg offen bis 100$(natürlich auf einen langen Zeitraum gesehen ) geschweige denn die Übernahmespekulationen die dann noch dazu kommen...

Jetzt muß aber auch mal ein Abschluß her - Finanzierung - Produktion - Klinische Testphase (Human)....


Gruß FS

[Wertpapierexperte]

die 49000 auf 0,9 sind meine, kauft eh keine vor 15:30h.

gruß WPE(warum ich das mache ? Na warum wohl)

[Boerse24]

Was muss Cytogenix denn noch machen, um das Produkt zu vermarkten? Suchen die einen Investor zur Finanzierung der Tests oder wo liegt das Problem?

[lassevegas]

@wpe
und wo sind sie jetzt ?
typen wie du sind besonders beliebt.
stell doch nochmal 10.000 rein, kauf ich dir ab.

lassevegas

[FinancialServices]

[posting]19.566.746 von Boerse24 am 06.01.06 13:31:19[/posting]....so viel wie ich bis jetzt gelesen habe hibt es noch keine Humantests....da wir es aber hier mit einem syntetischen Stoff zu tun haben sind diese Test viel kürzer ( normal etwa 2 Jahre )man spricht hier von wenigen Monaten da syntetische Stoffe weniger Nebenwirkungen haben...HIV test laufen im Tierversuch sehr erfolgreich ohne Nebenwirkungen...ich weis Boerse24 das Hilft Dir nicht wirklich weiter es müßen hald Handfeste News kommen ...Gruß FS

[FinancialServices]

[posting]19.567.292 von lassevegas am 06.01.06 13:57:40[/posting]....

Gruß FS

[FinancialServices]

[posting]19.566.746 von Boerse24 am 06.01.06 13:31:19[/posting]http://bigcharts.marketwatch.com/industry/bigcharts-com/focu…

Hier kannst Du dich mal schlau machen ( und nachher uns ) - Gruß FS

[FinancialServices]

[posting]19.567.690 von FinancialServices am 06.01.06 14:16:50[/posting]CYTOGENIX INC
Daily Commentary


Our system posted a HOLD today. The previous BUY recommendation that was confirmed was made on 12.20.2005 (17) days ago, when the stock price was 0.7700. Since then CYGX has gained 46.75% .

Are you eager to sell your shares? Well we say: “Stick to them for the moment!” Market mood is again bullish. Our SELL-IF alert is not confirmed. It is now null and void and should be ignored.

The current tag is HOLD and it already tells you what to do. Keep holding your stocks until the next signal. Did you already sell without waiting for the confirmation? Do not worry.


Ich rechne mal Heute mit einer Seitwärtsbewegung zwischen 1,09 und 1,17 $

Gruß
FS

[FinancialServices]

Ich habe aber auch noch ein buy.....

http://quote.barchart.com/texpert.asp?sym=CYGX

[FinancialServices]

[Mambo6]

nach Eröffnung 1,09 jetzt schon wieder 1,15 Dollar

[martini81]

Es könnten heute durchaus noch Kurse um 1,22 drin sein.
Ich glaube nicht das die letzte Nachricht nur so geringe Auswirkungen auf Onkel Sam hat.....
....die brauchen eben etwas Zeit, um ihre Gelder frei zu legen.
Ist ja nicht wie bei uns, wo der Kurs gleich mal um 0,40ct steigt.

Masahn...

[FinancialServices]

....mal 1,20 zum Wochenabschluss wären schön.

Gruß FS

[ketsie]

war nix mit 1,20 - vogelgrippe wird immer mehr zum globalen thema ... wir sehen bald die kommastelle eine weiter rechts

[FinancialServices]

Date Open High Low Last Change Volume % Change
01/06/06 1.1000 1.1500 1.0900 1.1400 +0.0100 544300 +0.88%


Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 667095

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 390646

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 261280

Overall Average: 96% - Buy

[martini81]

[posting]19.613.152 von ketsie am 09.01.06 08:26:40[/posting] Da würde sich sicher jeder hier freuen.....!

Wie steht es mit den Prognosen zum heutigen Schlußkurs?
Ob H5N1 in der Türkei Punkte bringt? -ich glaub es zwar nicht, aber man kann ja nicht wissen -


Ich hoffe nur, das die 1,2 ziemlich schnell fällt!?

[ketsie]

hier gibt es ja kein interesse ... brrrr. wahrscheinlich mal daneben gegriffen, oder belehrt mich eines besseren ...

[Mambo6]

falls du auf das schnelle Geld aus warst, so wars sicher ein Griff ins Klo.... doch warte einfach bis Ende des Jahres und du wirst staunen....

[martini81]

Die Leute, die zu 0,76 rein sind und beim letzten Hype um 1,20 ein paar Teile zu Gold verwandeln konnten, war das schnelle Geld schon drin....

Sind ja nun schon wieder Kaufkurse - nur ist mein Hauptkapital gerade in Teleplus investiert....hmmm
Vielleicht sinkt es ja noch bis ende der Woche.

Seeya

[gony2]

woher kennst du meinen ein und austiegskurs?

[ketsie]

[posting]19.635.909 von Mambo6 am 10.01.06 14:10:43[/posting]mambo6 - dein wort in gottes gehörgang. ich brauche das geld nicht und werde dir ende des jahres um den hals fallen oder ...

























... auch nicht.

ketsie

[martini81]

[posting]19.639.579 von gony2 am 10.01.06 17:39:15[/posting] wohl zwei schlaue und ein Gedanke?

Nur zu dumm, dass mein Geiz mich dazu bewogen hat nur einen Teil bei 1,18 raus zu nehmen.... naja - solang noch n Plus davor steht mach ich mir keine Sorgen.

4$ wir kommen!

[FinancialServices]

....erst mal tauchen wir tieeeeeeeeeeffffffff ab

gruß fs

[Boerse24]

gibt es denn neue Nachrichten oder weshalb fällt die Aktie so?

[rainmann]

hallo
bin zwar nicht mehr investiert und habe auch mit gewinn
verkauft, aber hier sind einige klugschei... an bord
die die aktie erst hochgezogen haben und sich dann
damit brüsten mit gewinn verkauft zu haben. machen sich
innerlich noch lustig über diejenigen die über 1 euro
gekauft haben. eure werte, sprich menschliche veranlagung,
falls überhaupt vorhanden, befindet sich auf einem
äusserst niedrigen niveu. ihr seit aber nicht alleine,
von euch gibt es noch viele die darauf spezialisiert sind,
aktien zu pushen und den dicken gewinn einfahren, während
die anderen lemminge lehrgeld bezahlen.
in diesem sinne

[gony2]

also wenn du mich meinst dann sage ich dir ganz ehrlich das ich mich über niemanden lustig gemacht habe denn ich weis wie es ist zu verlieren.
nur mitleid habe ich auch nicht, denn als seeensation den pusch angefeuert haz und wir bis 1,30 an dem tag liefen habe ich bereits geschriebn das die leute sich mal gedanken darüber machen sollten, was sie mit so einer steigerung anstellen:

war ein schöner tag für mich und cytogenix. mir tun die armen teufel leid die da nur so draufgesprungen sind heute morgen.
ich habe meine 7000 stück zu 1,10 verkauft. ok wäre auch teurer gegangen aber wer erwischt schon den höchstkurs. hatt wirklich einer geglaubt das so eine allgemeine meldung einen 30 prozentigen vorsprung vor den usa bringt. mann oh mann das muss mann doch wissen. ich habe heute vormittag davor gewarnt und die millionen zahl in den raum gestellt, die die teuren käufern den amis zubilligen. umgerechnet waren es ca. 28 mio die wir in d schon eingeplant hatten, ich meine die gesamtkapitalerhöhung durch unseren prognostizierten anstieg. gier frisst hirn. tschuldigung , aber ich hoffe für alle investierten das die einstiegskurse wieder kommen . und nun? nun sind alle meldungen erst mal raus.
was soll da die nächsten wochen kommen? schöne seitwärtsbewegung. naja mit glück........
egal, allen eine gute nacht und verdammt gutes traden

und ein paar stunden vor meinem ausstieg hatte ich auch schon gewarnt.
gier frisst hirn sagt man und manchmal sollte man auch gewinne realisieren oder denkst du das man mit jeder aktie millionär werden kann?
moregn ist auf jeden fall cytogenix tradingtag.

[rainmann]

gony2
werde keine namen nennen, wird jeder selbst wissen
wer gemeint ist, falls die hohlköpfe überhaupt
noch etwas merken.

[gony2]

egal wie bei den kursen kann man getrost sammeln, denn wenn die aktie in den usa ohne aktuelle meldung so runter geht dann sind heute locker 6 % drinnen.

[martini81]

Uui, da hab ich ja gestern nochmal Glück gehabt mit meinem Ausstieg bei 84ct.
Die Aktie folgt ja echt der Charttechnik.... Aufwärtskanal durchbrochen und ab nach unten.

Und zu Reinmann:

Jeder weiß doch das die Kurse in Europa nur nachlaufen...
Wer das schnelle Geld machen will, muss unten rein und oben raus. Ganz einfach.

Und wenn sich in den Tagen jetzt ein kleiner Boden bildet, wird wieder eingestiegen und gut ist.
Bei den Amis wird auch jemand mit mächtig Kohle verkauft haben und wenn alle Angsthasen mit Verlust raus sind, gehen diese Leute wieder rein.

Ich hab früher auch einige Scheine verloren. Aber man lernt ja dazu. Auch bei dieser Partie hätte ich viel mehr Kohle machen können.... aber beim nächsten mal.

Kursziel bleit trotzdem bei 4$ bis 2007!

[crashpoet]

wer sich den längerfristigen chart der aktie ansieht bemerkt, daß solche an der otc meist recht heftigen rücksetzer immer wieder vorkommen.
wem das zuviel nerven kostet, sollte sich nicht mit solchen aktien abgeben. für die anderen gilt: entweder zum traden nutzen oder aussitzen.
übrigens kann man selbst auf dem jetzigen niveau mit der 3monatsperformance noch zufrieden sein.

[martini81]

[posting]19.654.749 von crashpoet am 11.01.06 13:04:53[/posting]Meine Meinung...

[crashpoet]

wird doch schon wieder (+0.06$ in 5 min)

[gony2]

da war ich doch heute morgen nicht schlecht mit den progn. 6 %, oder?
guckt euch mal jaguar nickel an

[crashpoet]

die amerikaner sind schon ein lustiges völkchen.
statt sich über den heftigen kursrücksetzer zu ereifern, wird überlegt, in welchen staat man ziehen sollte, um möglichst wenig steuern auf die gigantischen mit cygx zu erwartenden gewinne bezahlen muss
http://www.investorshub.com/boards/read_msg.asp?message_id=9…

[FinancialServices]

....wir sind an der OTC...die Spielchen kennen wir doch alle...laßt Sie mal laufen unsere CYGX die wird Ihren Weg machen...ich kaufe immer unter ,80€ wieder nach und freu mich ...Gruß FS

....aber ich halte CYGX auch long

[FinancialServices]

[posting]19.658.854 von crashpoet am 11.01.06 17:05:23[/posting]Fred, Florida tax on intangible assets, that`s the name I think. It is not about a gain. It is about holding securities with a value greater than the 250,000 dollar deductable. Anything over that amount, you pay this tax on - every year, even before selling it. Whether you are up or down is of no consequence, as I imagine, because the tax is not based on your profit but rather on merely having the asset.

[FinancialServices]

[posting]19.644.897 von Boerse24 am 10.01.06 22:01:08[/posting]CYGX is FINE in long term. The long-term prospects of the COMPANY have no connection at all to the short-term movements of the STOCK PRICE.

It is hard to watch, but when stock prices rise in a nearly vertical fashion, they often fall in a nearly vertical fashion as well.

This is NORMAL. Look at any stock chart of a BB stock which has a huge price spike. It comes back down. That`s why the end result looks like a "spike". In order to have a "spike" shape eventually on a chart, it must both rise and fall vertically, leaving a sharp-looking high-point on the price graph.

People who bought low takes profits on these spikes, making them a poor place to buy. When people become pessimistic, and new buyers are done buying, sellers dominate and prices fall.

To repeat, CYGX is FINE in long term. The long-term prospects of the COMPANY have no connection at all to the short-term movements of the STOCK PRICE.

Gute Antwort auf Deine Frage !
Gruß Fs

[martini81]

Kann jemand deutsche RT Kurse rein stellen?

[martini81]

Ist denn keiner mehr da?

Sollte doch gerade ein KAUF sein....

[martini81]

Fast 10ct unter pari.... unglaublich.

[martini81]

Schade das ich kein Geld zu kaufen übrig hab.
Wäre ja schön leicht verdientes Geld.....

[martini81]

Hallo?

Wo sind denn alle? Typisch, das beste verpassen alle....

[martini81]

Ich hab extra noch einen Notverkauf getätigt um günstig noch paar Teile zu erwerben...

[martini81]

Na wenn niemand hier ist, geh ich auch wieder....

[FinancialServices]

...die Ammis sind so abgefahren ....alle rausgeschüttelt Stoploss reihenweise ausgelöst und ab gehts wieder nach oben ....coole jungs ...Gruß FS

[crashpoet]

[posting]19.674.076 von FinancialServices am 12.01.06 12:24:24[/posting]alles nur ein sturm im wasserglas?
mag sein, aber das vol vorgestern war schon heftig.
ich frag mich, ob die irgendwelche finanzierungsdeals über die otc abwickeln anfang august war schon mal so ein fall...

[Aymery]

na was meint ihr wann sind wir bei 1,50Euro in nem halben jahr?

[ketsie]

[posting]19.709.399 von Aymery am 14.01.06 14:08:52[/posting]Hallo aymery - noch immer drin. da kann es ja nur nach oben gehen

[Mambo6]

im Moment steht der Kurs in Berlin jedenfalls mit 8 EuroCent unter Par... und keiner will kaufen???

[martini81]

[posting]19.753.467 von Mambo6 am 17.01.06 17:10:44[/posting]Das wird wohl am Briefkurs liegen, der steht gerade so bei 80ct!
Wieso?
Keine Ahnung.... ansonsten hätte ich auch bei 71 zugeschlagen. Mit den nächsten News geht dann die Post auch wieder ab in Richtung 1,5 - bis Juli sollte es auf jeden so weit sein.(Für die Mädels)

Seeya

[Aymery]

DJ VOGELGRIPPE/EU-Gesundheitskommissar warnt vor Pandemie
PEKING (Dow Jones)--Der für Gesundheit und Verbraucherschutz
verantwortliche EU-Kommissar Markos Kyprianou hat erneut eindringlich vor einer
weltweiten Pandemie durch die Vogelgrippe gewarnt. " Seit 1968 war eine
menschliche Grippe-Pandemie niemals so nahe wie heute" , sagte Kyprianou zum
Auftakt der Vogelgrippe-Konferenz am Mittwoch in Peking. Niemand könne
zwar voraussagen, wann die nächste Pandemie ausbrechen werde. Doch seien
nur zehn Mutationsschritte des Vogelgrippe-Virus notwendig, um eine Pandemie
bei Menschen auszulösen. Sieben dieser Mutationen seien bereits in Asien
beobachtet worden, fügte Kyprianou hinzu.

Nie zuvor hätten die weltweiten Organisationen aber auch die
Möglichkeiten und Zeit gehabt, sich auf eine potenzielle Pandemie
vorzubereiten. Es sei daher höchste Zeit, dass die
Weltgesundheitsorganisation WHO, die Welternährungsorganisation FAO, die
Tier- und Futtermittelorganisation OIE und die internationale
Staatengemeinschaft gemeinsam die Herausforderungen angingen. " Die Vogelgrippe
wird nicht bald verschwunden sein" , warnte der EU-Kommissar. Die EU sei bereit,
ihr Wissen, ihre Kompetenz und ihre Technologie mit der internationalen
Staatengemeinschaft im Kampf gegen die Vogelgrippe zu teilen.

Kyprianou forderte in Peking insbesondere eine Koordination nationaler
Pläne zur Bekämpfung der Seuche. Er plädierte auch für
Reformen in der Tierzucht, insbesondere aber eine Verbesserung des
Zusammenlebens von Menschen und Geflügeltieren. Auf Einladung des
chinesischen Ministerpräsidenten Wen Jiabao und mit Unterstützung der
EU-Kommission sowie der Weltbank sind die internationalen Staaten und
Organisationen zur Geberkonferenz in Peking zusammengekommen. Die EU-Kommission
will 100 Mio EUR zur Bekämpfung der Vogelgrippe bereitstellen, im Laufe
des Tages werden weitere Hilfsankündigungen von den 25 EU-Mitgliedsstaaten
erwartet. -Von Ali Ulucay, Dow Jones Newswires; [phone],
[e-mail] DJG/aul/apo

(END) Dow Jones Newswires

January 18, 2006 03:30 ET (08:30 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.

011806 08:30 -- GMT

[ketsie]

[posting]19.763.164 von Aymery am 18.01.06 09:41:49[/posting]na aymery, hast ja den kurz zumindest fast 6 prozent nach oben gebrachtketsie

[Fortschritt]

CYTOGENIX SHAREHOLDER UPDATE

January, 2006


Valued Shareholders:

We at CytoGenix send our best wishes to you for a healthy and prosperous New Year. This update marks six years that we have been working on the gene down regulation and expression technology that began with single stranded DNA expression vectors and has progressed to cell-free production of synthetic DNA. The level of activity has reached a point that it will be more efficient to provide the details of Company progress via our web site. We will include details of progress in product development, scientific research results including recently published papers, presentations and attendance at scientific meetings, patent filing activity and plans for Company expansion. Here are a few highlights that will preview items you can review in more detail as the web site is updated.

The Company continued efforts to commercialize the synthetic DNA production process and we are currently evaluating several synthetic DNA constructs as potential additions to developmental products in our pipeline.

The prototype of the synDNA™ production module designed in conjunction with Alpha Laval Biokinetics was completed and tested on schedule. The tests were positive and provided valuable information about quality control measures and performance monitoring. As the Company prepares to initiate operation and validation of the module, we will also implement the next stage of planning for construction of the synDNA™ processing facility.

Test results show that the synDNA™ constructs for smallpox, HA (influenza) and hepatitis B were all effective in stimulating immune responses in animal tests (mice were tested for smallpox, HA and rabbits for hepatitis B). The synDNA™ constructs were equally or more biologically active than the equivalent fermentation derived plasmids in these pilot studies. Additional tests of DNA vaccines for additional conditions are scheduled.

Negotiations are concluding with a supplier who makes the chemical constituents required for synDNA™ production. The Company expects that it can achieve a long term relationship with terms that enable cost effective manufacture.

Using our screening techniques, we have identified additional bacterial gene targets to extend our anti-bacterial program. Over twenty-five oligonucleotide compounds have been investigated for silencing genes in Escherichia coli, Streptococcus pneumoniae, Streptococcus mutans (the principal cause of sepsis, pneumonia and tooth decay, respectively) and methicillin-resistant Staphylococcus aureus. Several lead compounds are now being tested in animals.

With the capacity to increase production of synDNA™, we will conduct enabling studies required by the FDA pursuant to filing an IND application for Simplivir™ and resume testing of CytoGenix’s anti-inflammatory product, CY303. We will continue these developments using the new synDNA™ constructs rather than conduct the studies with the fermentation derived plasmids which are much more expensive and less effective.

CytoGenix science and technology are both applicable to problems of increasing scope. An agreement has been executed to work with the Fast Trak Biodefense division of General Electric Healthcare to develop grant and contract proposals. The agreement with GE Healthcare is a model for additional partnerships for exploring the use of CYGX technology in bio-defense applications. The Company will accelerate its efforts to secure contracts with the Departments of Health and Human Services and Homeland Security to develop anti-virals and anti-bacterials. This will include expansion of our development of DNA vaccines to test constructs for avian influenza (H5N1) in both rodents and primates. The immunogenic constructs for smallpox, influenza and hepatitis B will be further tested with challenges to immunized animals. Acquisition of necessary data to comply with regulatory requirements to permit clinical evaluation of Simplivir™ will proceed. Advances in the synDNA™ production facility will enable increases in cell-free DNA for our own products and for our clients.

In summary, in the coming year, we will intensify our product development efforts with our own synDNA™, increase our efforts to secure government contracts for bio-defense applications, proceed with development of synDNA™ production and maintain scientific research necessary to move the company forward. It promises to be an exciting time.

Again, best wishes for the year to come and thank you for your continued support.

Very truly yours,

Malcolm Skolnick

[Boerse24]

Gibt es denn irgendwelche Gründe dafür, dass Cytogenix momentan bei 0,68 Euro steht oder hat das nur charttechnische Gründe?

Oder gibt es irgendwelche neuen Nachrichten???

[ketsie]

wie bin ich nur darauf gekommen, diese aktie zu kaufen. muss ja totales black-out gewesen sein. na gut ... dann mal durch.

[Boerse24]

Hallo,

wieso ist es hier eigentlich so still geworden und wann rechnet ihr wieder mit neuen positiven Nachrichten???



Mit freundlichen Grüßen

Boerse24

[cat108]

hallo, aufwachen hier tut sich was und keiner werkt es, schon 1 mill. scheine in usa gehandelt

[Aymery]

[posting]19.898.685 von cat108 am 26.01.06 21:08:22[/posting]CytoGenix Files US Patent Application for synDNA(TM) Vaccines and Other Therapeutic Compounds

2006-01-26 13:01 ET - News Release

HOUSTON -- (Business Wire) -- Jan. 26, 2006

CytoGenix, Inc. (OTCBB:CYGX) announced today that it has
filed a patent application titled Method of Making Nucleic Acid
Therapeutics with the US Patent and Trademark Office.
Malcolm Skolnick, CytoGenix, Inc. CEO, commented, "We will seek
broad protection for the application of our synDNA process and its
applications to DNA vaccines. This application incorporates the
results of our successful animal tests of DNA vaccines against
Smallpox, Hepatitis B, Influenza and HIV and extends the range of the
protection of our technology."
About CytoGenix: CytoGenix, Inc. is a Houston-based
biopharmaceutical company that develops and markets innovative
products and services based on its proprietary ssDNA expression
technology. The company has developed a breakthrough synthetic process
for large-scale production of high purity DNA at a fraction of the
cost of traditional fermentation methods. CytoGenix currently has one
issued US patent and 41 international or US pending patent
applications claiming methods and materials in connection with this
platform technology.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company`s filings with the
Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be
found on the website at www.cytogenix.com.

Contacts:

CytoGenix, Inc.
Juan Ferreira, 800-677-5707

[Mambo6]

das ist sicher die Wende...

[Boerse24]

ja, das glaube ich auch!!!

Bei so stark gestiegenen Umsätzen muss die Aktie eigentlich auch bald steigen, da das Interesse an der Aktie wieder erwacht.

Hoffen wir mal das Beste!!!

[Boerse24]

An der Nasdaq plus 5 Prozent !!!

Das ist doch schon einmal ein guter Anfang, oder?

[ketsie]

ups - was ist los ... investor gefunden

[amk912]

Dutton Associates Announces Investment Opinion: CytoGenix
2006-02-01 12:00 (New York)

Rating Maintained and Price Target Raised By Dutton Associates


NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Feb. 1, 2006
Dutton Associates continues its coverage of CytoGenix
(NasdaqRAX), maintaining its Speculative Buy rating and increasing
its target price to $1.40. The 8-page report by Dutton senior analyst
William R. Prather, R.Ph., M.D., is available at www.jmdutton.com, as
well as from First Call, Bloomberg, Zacks, Reuters, Knobias and other
leading financial portals.
CytoGenix, Inc. recently exceeded our price target of $0.90 per
share and has appreciated approximately 80% since our new analytical
coverage was initiated in April 2005. Despite this increase in
valuation, we are reiterating our rating of Speculative Buy on the
common stock of CytoGenix because we believe the Company is steadily
making progress in developing their cell-free DNA plasmid
manufacturing business. They are also validating that the resultant
synthetic DNA product from this process, termed synDNA(TM), can be
successful and possibly superior in manufacturing DNA vaccines and
other therapeutics. CytoGenix is now developing a "Rapid Response
Vaccine Development Program" using their synDNA(TM) to target
pathogens such as the H5N1 avian flu, smallpox and other infectious
diseases. Additionally, the Company has recently announced a
collaboration with the Fast Trak BioDefense Group of GE Healthcare, a
unit of General Electric Company (NYSE: GE $32.93), with what we
believe is the first of several collaborations. We are also revising
our price target from $0.90 to $1.40 based on the comparative analysis
of other companies participating in this industry and our belief that
CytoGenix`s patent pending synDNA(TM) represents enormous revenue
potential.

About Dutton Associates

Dutton Associates is one of the largest independent investment
research firms in the U.S. Its 27 senior analysts are primarily CFAs
and have expertise in many industries. Dutton Associates provides
continuing analyst coverage of over 120 enrolled companies, and its
research, estimates and ratings are carried in all the major databases
serving institutions and online investors.
The cost of enrollment in our one-year continuing research program
is US $33,000 prepaid before commencement of our research activities.
We received $47,000 from the Company for 8 reports and requisite
Research Notes commencing 7/17/2002, and do not accept payment of our
fees in company stock. Our principals and analysts are prohibited from
owning or trading in securities of covered companies. The views
expressed in this research report accurately reflect the analyst`s
personal views about the subject securities or issuer. Neither the
analyst`s compensation nor the compensation received by us is in any
way relate to the specific ratings or views contained in this research
report or note. Please read full disclosures and analyst background at
www.jmdutton.com before investing.

[Mambo6]

News scheinen im Amiland gut aufgenommen zu werden....

[Fortschritt]

Im Amerikanischen Diskussionsforum wird schon über 1USD80 und 5USD gesprochen

[Mambo6]

[posting]19.999.805 von Fortschritt am 01.02.06 20:26:27[/posting]Kurs steht schon auf 1,01 $....

[Boerse24]

Ja, ich glaube auch, dass in der nächsten Zeit noch positive Nachrichten kommen werden, die dem Kurs wieder einen Ruck geben...

Da der Kursanstieg bei dieser Aktie besonders schnell und schlagartig erfolgt, empfehle ich kein Stück zu verkaufen und eher noch welche zuzukaufen, da man sonst vielleicht das Beste verpasst...

Denn wie schnell diese Aktie steigen kann, hat man ja erst vor einigen Tagen gesehen, wo die Aktie an einem einzigen Tag um ca. 40 Prozent gestiegen ist!!!

Meine Empfehlung lautet: Kaufen !!!

[Mambo6]

in USA geht der Aufwärtstrend weiter... Eröffnung mit 97 Cent!!!!!

[Mambo6]

eigentlich schon witzig... da steigt die Aktie im Amiland und hier scheint es keiner mitzubekommen

[Boerse24]

Ja, das könnte gut sein, dass da was Positives im Busch ist, aber auf der Firmenwebsite steht bisher noch nichts.
Plus 18,28 Prozent ist auf jeden Fall schon mal ein gutes Zeichen...

[ketsie]

ups - was geht hier ab ...

[Mambo6]

[posting]20.023.947 von ketsie am 03.02.06 09:51:23[/posting]bei Cytogenix stehen News an, die drüben wissen schon mehr, aber alles Gerüchte, mehr nicht. Aber ist es nicht das was die Kurse treibt???

[Mambo6]

da gibts doch tatsächlich Menschen die in Berlin zu 95 kaufen obwohl sie´s in Frankfurt für 91 bekommen könnten...

[ketsie]

[posting]20.025.384 von Mambo6 am 03.02.06 11:10:21[/posting]Handelsvolumen 2.300 eus, das ist doch eigentlich nischt.

[ketsie]

woher kriegt man rt-kurse von übersee ...

[Boerse24]

Handelsvolumen von 86.346 Stück bei steigenden Kursen.
Vielleicht ist da ja echt etwas Positives im Busch und wir wissen es nur noch nicht...

Weiß eigentlich von euch jemand ein amerikanisches Diskussionsforum ???
Vielleicht kann man da ja noch was finden...

[crashpoet]

ES GIBT NEWS!!!!


Alfa Laval Biokinetics Announces Delivery of CytoGenix DNA Production Module
PHILADELPHIA--(BUSINESS WIRE)--Feb. 15, 2006--The Alfa Laval Biokinetics office in Philadelphia, PA has just completed the design and construction of a prototype production module for high-quality, cell free DNA. The module has been constructed on behalf of Houston-based company, CytoGenix, Inc.


The prototype module, capable of producing gram quantities in a single pass in 24 hours, will serve as the core piece of equipment for CytoGenix` proprietary, high-throughput DNA GMP manufacturing facility.

Alfa Laval engineers and CytoGenix scientists worked closely to design and produce a remarkably simple yet highly efficient module. The compact nature of the design and the closed-loop architecture of the system will facilitate ease of production in virtually any GMP production facility.

Jennifer DeBerardinis, US Account Manager for Alfa Laval Biokinetics, commented, "Alfa Laval is excited to be at the forefront of this breakthrough in technology for DNA manufacture. This module represents a fundamental improvement to the science of making clinical grade DNA. We look forward to continued design and engineering projects with CytoGenix as they expand their DNA manufacturing capabilities."

Kurt Berens, CytoGenix, Inc. Vice President of Product Development, commented, "CytoGenix is delighted at the rapidity with which the project was completed and the responsiveness of the design team at Alfa Laval. The design, fabrication and time to delivery were exemplary by industry standards and speak to the efficiency and experience of the Alfa Laval team. We will begin scale-up and validation of the manufacturing process using this production module and additional modules will be added to meet the growing demand for clinical-grade DNA to support our product development programs and to accommodate the commercial market for synDNA(TM)."

About CytoGenix: CytoGenix, Inc. (CYGX.OB) is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology.

CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology. CytoGenix has recently filed a US Patent Application for synDNA(TM) Vaccines and Other Therapeutic Compounds.

About Alfa Laval: Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling.

The company`s equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval`s products are also used in power plants, aboard ships, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications.

Alfa Laval`s worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena.

Alfa Laval is listed on the Stockholm Exchange and, in 2004, posted annual sales of about SEK 15 billion (approx. 1.7 billion euros). The company has some 9,500 employees.

For further information, please visit the Alfa Laval website at www.alfalaval.com.

[crashpoet]

[posting]20.031.534 von Boerse24 am 03.02.06 16:33:21[/posting]http://www.investorshub.com/boards/board.asp?board_id=1835

[Mambo6]

na dann kanns ja losgehen.. das aktuelle Kursniveau ist super für weitere Steigerungen...

[Mambo6]

der Kurs in USA steigt langsam mit kleinen Umsätzen... ein sehr gutes Zeichen

[crashpoet]

[posting]20.238.534 von Mambo6 am 16.02.06 16:08:00[/posting]die nachricht ist halt nur ein schritt auf einem langen weg, aber ein schritt in die richtige richtung.

[Mambo6]

am Ende doch noch ein sattes Plus von fast 10%

[ketsie]

berlin gehts heute auch nach oben ...

[crashpoet]

was für ein granatenstart heute

Last:

1.25 cygx - CYTOGENIX INC
Change:

+0.11 % Change:

+9.65% High:

1.25 Low:

1.17 Volume:

386,800

Price Data Table
Open 1.19
Previous Close 1.25
Exchange of Last Sale OTCBB
Time of Last Sale 10:02:48
Tick Up
Bid 1.21
Ask
Size Bid/Ask 5x5

[seppel]

Und nicht zu vergessen: Neues 52-Wochen-Hoch Wenn ich mir Cytogenix anschaue, muss ich immer an ELAN denken

[ketsie]

[posting]20.910.771 von seppel am 22.03.06 17:07:40[/posting]was war mit elan

[ketsie]

1 mio dollar umsatz ... da läuft was, wovon wir noch träumen ... ein leichter push-versuch, sorry.

[seppel]

ELAN CORP. ist auch ein Biotechunternehmen, dass von 2003 bis 2005 von ca. 1US$ bis auf 25US$ gestiegen war. Danach gings dann allerdings wieder steil bergab. Also bitte daran denken, bei 20US$ mit Limit abzusichern

[ketsie]

Antwort auf Beitrag Nr.: 20.914.480 von seppel am 22.03.06 20:28:39

Danke werde bei 20 dollar dran denken.

[amk912]

CytoGenix Enters into a Supply Agreement with GE Healthcare for
2006-03-23 09:00 (New York)

DNA Production Reagents


HOUSTON--(BUSINESS WIRE)--March 23, 2006
GE Healthcare, a unit of General Electric Company
(NYSE:GE), and CytoGenix, Inc. (OTCBB:CYGX) have entered into a supply
agreement in which GE Healthcare will provide CytoGenix with DNA
production reagents for use in the manufacture of vaccines and
therapeutic compounds by CytoGenix.
Under the terms of the agreement, GE Healthcare has agreed that
CytoGenix will be its exclusive customer for these reagents where the
intended application is the manufacture of therapeutic compounds using
CytoGenix' proprietary processes.
CytoGenix' proprietary synDNA(TM) is a cell-free production
process that enables a more efficient manufacturing cycle than
extraction of DNA from bacterial fermentation. CytoGenix expects to
begin production of commercial-scale amounts of synDNA(TM) in April
and continue development of DNA vaccines and therapeutic products
against infectious diseases (herpes infections, multi-drug resistant
bacterial infections), inflammatory disorders (psoriasis) and cancer.
"This guaranteed source of GMP grade reagents is vital to our
product development especially for our pandemic and bioterrorism
vaccine program," said Dr. Malcolm Skolnick, CytoGenix, Inc. President
and CEO. "We are very pleased to enter into this agreement with GE
Healthcare and look forward to working with them to expand the
development of DNA-based pharmaceuticals," added Dr. Skolnick.
"We believe CytoGenix can effectively utilize GE's innovative
disease research technologies with its own ground-breaking research to
ultimately enhance the efficiency of healthcare delivery and increase
the breadth of options for patient care," said Carl W. Fuller, Ph.D.,
Vice President Science Fellow at GE Healthcare.

About CytoGenix

CytoGenix, Inc. is a Houston-based biopharmaceutical company that
develops and markets innovative products and services based on its
proprietary ssDNA expression technology. The company has developed a
breakthrough synthetic process for large-scale production of high
purity DNA at fraction of the cost of traditional fermentation
methods. CytoGenix currently has one issued US patent and over 41
international or US pending patent applications claiming methods and
materials in connection with this platform technology. Additional
information about CytoGenix and its technology can be found on the
website at www.cytogenix.com.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company's filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology can be found on the website at
www.cytogenix.com.

CONTACT:
CytoGenix, Inc., Houston
Frank Vazquez, 713-789-0070
[e-mail]
or
Edelman
Amy Meshulam, 323-202-1065
[e-mail]
-0- Mar/23/2006 14:00 GMT

[ketsie]

Antwort auf Beitrag Nr.: 20.922.690 von amk912 am 23.03.06 15:52:47

sehe licht am ende des tunnels

[amk912]

Antwort auf Beitrag Nr.: 20.917.572 von ketsie am 23.03.06 10:30:37

ketsie.. jetzt bist du gleich im plus !!

[crashpoet]

Das ist -zumindest fast- die Wende, und die News, auf die viele gewartet haben.
Im April beginnt die kommerzielkle Herstellung von synDNA, und das wird Geld bringen. UNd GE als Partner ist auch nicht zu verachten.
KZ kurzfristig 2$
Ende des Jahres mind 4$

[amk912]

Antwort auf Beitrag Nr.: 20.923.401 von crashpoet am 23.03.06 16:29:30

hab mit 1.10 nochmal nachgelegt

[crashpoet]

Antwort auf Beitrag Nr.: 20.923.463 von amk912 am 23.03.06 16:32:10

Du wirst es nicht bereuen!

[crashpoet]

Ist schon merkwürdig hier. Bei trelativ unbedeutenden Meldungen wird hier ein Rieseneiertanz veranstaltet (z.B: wenn dfas Wort Voglegrippe drin vorkommt:cool, aber bei wirklich substanziellen News schläft scheibar alles...

[amk912]

Antwort auf Beitrag Nr.: 20.923.749 von crashpoet am 23.03.06 16:49:10

morgen reiben sie sich die augen... es koennen halt wohl nicht alle andauernd online sein ...

[ketsie]

Antwort auf Beitrag Nr.: 20.923.878 von amk912 am 23.03.06 16:56:28

ich sehe bei wo nicht mehr die umsätze otc ... hat die jemand oder einen link ...

[amk912]

Antwort auf Beitrag Nr.: 20.924.072 von ketsie am 23.03.06 17:08:28

sorry ..ich schau nur auf meinen bloomberg

[crashpoet]

geht momentan wieder etwas runter:

Detailed Quote Snapshot 03/23/2006 11:09 AM
Last:

1.25 cygx - CYTOGENIX INC
Change:

+0.12 % Change:

+10.62% High:

1.32 Low:

1.17 Volume:

1,038,914

Price Data Table
Open 1.18
Previous Close 1.25
Exchange of Last Sale OTCBB
Time of Last Sale 11:10:25
Tick Down
Bid 1.24
Ask
Size Bid/Ask 5x5
Symbol Type Equity

[ketsie]

Antwort auf Beitrag Nr.: 20.924.125 von crashpoet am 23.03.06 17:11:35

danke euch beiden

ketsie

[crashpoet]

bei großen umsätzen gehts rauf, bei kleinen runter. so gehört sich das

[ketsie]

Antwort auf Beitrag Nr.: 20.924.367 von crashpoet am 23.03.06 17:27:33

heute geht´s weiter nach oben ... in kleinen schritten.

[crashpoet]

Antwort auf Beitrag Nr.: 20.935.713 von ketsie am 24.03.06 12:08:14

glaub ich auch.

[ketsie]

Antwort auf Beitrag Nr.: 20.935.857 von crashpoet am 24.03.06 12:17:57

noch 20 cent, dann wieder grün ... vielleicht werde ich noch vor begeisterung platzen und demnächst froh sein, wenn ich überhaupt noch welche zu 1,20 bekommen hatte. wenn im april die produktion beginnt und mit GE als partner ... dann fließt kohle und der wert dieses meines investments steigt. da ich das geld sowieso jetzt nicht brauche und die spekufrist in 288 tagen abläuft, kann ich mich geduldenketsie

[crashpoet]

Detailed Quote Snapshot 03/24/2006 09:31 AM
Last:

1.3 cygx - CYTOGENIX INC
Change:

+0.02 % Change:

+1.56% High:

1.31 Low:

1.29 Volume:

15,350

Price Data Table
Open 1.31
Previous Close 1.3
Exchange of Last Sale OTCBB
Time of Last Sale 09:31:59
Tick Unchanged
Bid 1.29
Ask
Size Bid/Ask 5x5

[crashpoet]

Was zum Lesen

United States
Securities and Exchange Commission
Washington, D.C. 20549
_______________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported): March 22, 2006



CytoGenix, Inc.
(Exact name of registrant as specified in its charter)

0-26807

(Commission File Number)




Nevada

76-0484097

(State or other jurisdiction of incorporation)

(IRS Employer Identification No.)

3100 Wilcrest Drive, Suite 140, Houston, Texas

77042

(Address of principal executive offices)

(Zip Code)

[phone]

Registrant’s telephone number, including area code

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







--------------------------------------------------------------------------------



ITEM 1.01

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On March 22, 2006, CytoGenix, Inc. (the “Company”) entered into a supply agreement (the “Supply Agreement”) with GE Healthcare Bio-Sciences Corp (“GEHC”). The Supply Agreement obligates the Company to purchase from GEHC in 2006 genomic DNA kits for use in the amplification and preparation of cell free plasmid DNA (the “DNA Kits”) at an aggregate cost of $350,000. The initial term of the Supply Agreement is one year and the parties may elect to extend the term for three additional years. Under the present terms of the Supply Agreement, in the event the term is so extended, the Company will be obligated to purchase a minimum number of DNA Kits that would cost $750,000 the second year, $1,200,000 the third year and $2,000,000 the fourth year, subject to GEHC’s right to increase the prices each year up to a percentage equal to the percentage increase of the producer price index for drugs and pharmaceuticals issued by the U.S. Department of Labor. A copy of the Supply Agreement is attached to this Form 8-K as Exhibit 10. The Supply Agreement is incorporated herein in its entirety by reference in response to this Item. The foregoing description of the terms and provisions thereof is a summary only, and is qualified in its entirety by reference to such documents. On March 23, 2006, the Company issued a press release a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS.

(c)

Exhibits.




10 .
Supply Agreement dated March 22, 2006 between CytoGenix, Inc. and GE Healthcare Bio-Sciences Corp.

99 .1
Press Release dated March 23, 2006





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 28, 2006
CytoGenix, Inc.

By /s/ Lawrence Wunderlich

Lawrence Wunderlich, Chief Financial Officer












*** Where this marking appears throughout this Exhibit 10, information has been omitted pursuant to a request for confidential treatment and such information has been filed with the SEC separately.




SUPPLY AGREEMENT




THIS SUPPLY AGREEMENT (this “Agreement”) by and between GE Healthcare Bio-Sciences Corp., a Delaware corporation, located at 800 Centennial Avenue, Piscataway, New Jersey 08855 USA (“GEHC”), and Cytogenix Inc., a Nevada corporation, located at 3100 Wilcrest Drive, Suite 140, Houston, TX 77042 (“Buyer”), is effective as of the date of the last signature hereto.




RECITALS




WHEREAS , GEHC manufactures Custom CYGX Kits (as defined below) and Reagents (as defined below) used in genomic DNA production and preparation;




WHEREAS , Buyer wishes to purchase Custom CYGX Kits and Reagents from GEHC pursuant to terms of this Agreement and the terms and conditions of sale attached hereto; and




WHEREAS , Buyer acknowledges that GEHC owns intellectual property rights in relation to the Custom CYGX Kits and Reagents, which survive the sale to Buyer.




NOW, THEREFORE , in consideration of the mutual premises and covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto intending to be legally bound do hereby agree as follows:




I.

DEFINITIONS




The following expressions shall bear the following meanings:




1.1

“Affiliate” of a party means any entity that, directly or indirectly controls, is controlled by or is under common control with such party. “Control” (and, with correlative meanings, the terms “controlled by” and “under common control with”) means: (i) the ownership of fifty percent (50%) or more of the outstanding voting securities of an entity; or (ii) the power, whether by ownership of voting securities, by contract or otherwise, to direct or cause the direction of the management and policies of an entity or to appoint fifty percent (50%) or more of the members of the governing body of an entity. The preceding notwithstanding, in this Agreement references to Affiliates of GEHC shall be only to any entity which, from time to time, forms part of the GEHC Healthcare business and whose ultimate parent is General Electric Co. In this Agreement references to GEHC shall be deemed to include any Affiliate of GEHC and GEHC agrees to be responsible for the actions and omissions of its Affiliates.




1.2

“Collaborator” means any entity, commercial or academic, or individual that has entered into a written material transfer, sponsored research, collaboration or other similar joint-effort agreement with Buyer for the bona fide purpose of evaluating, developing, improving and/or manufacturing nucleic acid according to Buyer’s U.S. patent application nos: 60/635,418; 60/680,716; 60/705,348 60/762,172, PCT/US05/45028 and US patent application filed March 17, 2006 entitled “Cell Free Biosynthetic Production of Nucleic Acid Therapeutics” (or any continuations, continuations-in-part, divisionals and foreign counterparts thereof) and pursuant to which is also obligated to Buyer under terms of strict confidentiality.




1.3

“Compounds” means drugs and/or biological agents subject to approval for use in humans, animals and plants by national or foreign regulatory agencies such as FDA, USEPA, USDA-APHIS, HPB, EMEA or similar governmental bodies.







--------------------------------------------------------------------------------




1.4

“Confidential Information” shall have the meaning given to it in Section 8.1 herein.




1.5

“Custom CYGX Kit” means the custom GenomiPhi Kit manufactured by GEHC as more specifically described in Schedule 1 and Schedule 2 hereto. The composition and specifications of the Custom CYGX Kit may be changed upon the mutual written agreement of the parties pursuant to Section 9.1 herein or to accommodate improvements and developments to the proprietary production process developed during the Term.




1.6

“Products” means the Custom CYGX Kits and the Reagents supplied to Buyer by GEHC hereunder.




1.7

“Reagents” means those enzymes and other products manufactured by or for GEHC as more specifically described on Schedule 1 hereto.




1.8

“Third Party” means any person or entity, other than Buyer, GEHC or their respective Affiliates.




II.

PURCHASE AND SALE OF PRODUCTS




2.1

Purchase and Sale

During the Term and subject to the terms and conditions hereof, GEHC will manufacture and sell exclusively to Buyer and Buyer will purchase exclusively from GEHC those quantities of Products as ordered by Buyer hereunder. On the date of delivery to Buyer, the Products will meet the specifications set forth on Schedule 2 .




2.2

Exclusivity




2.2.1

GEHC will not knowingly supply to any Third Party the Custom CYGX Kits or any large-scale equivalent kits that comprise the same technology (defined as those kits capable of making at least 0.5 grams of nucleic acid, and referred to herein as “Large Scale Equivalent Kits”) that will be used by such Third Party for the manufacture of DNA under the nucleic acid manufacturing process covered by one or more claims of patent applications owned by Buyer covering its proprietary cell-free nucleic acid production process (being US patent application nos: 60/635,418; 60/680,716; 60/705,348 60/762,172, PCT/US05/45028 and US patent application filed March 17, 2006 entitled “Cell Free Biosynthetic Production of Nucleic Acid Therapeutics” (the “Patent Applications”) and any divisions, continuations, continuations-in-part, reissues and/or foreign counterparts thereof) wherein the nucleic acid product is to be used as the active ingredient or adjuvant in Compounds used in the context of either therapeutics, prophylactics, or ameliorative agents. For the purposes of clarity, GEHC will be deemed to have complied with this Section 2.2.1 if it includes a label on any Large Scale Equivalent Kits supplied to a Third Party that such kits are to only be used for purposes that do not include the purposes stated in the immediately preceding sentence above.




2.2.2

The exclusivity obligations set forth in Section 2.2.1 will terminate at GEHC’s option if (i) the Patent Applications are not allowed or fail to issue, (ii) if a US patent based on the Patent Applications has not issued within four years of the date hereof, (iii) if Buyer relinquishes ownership of the Patent Applications and/or resulting patents or (iv) Buyer has not met its minimum purchase commitments under Section 4.2 herein; provided, that, Buyer will keep GEHC reasonably updated from time to time on the status of its Patent Applications and related foreign applications and will work with GEHC to expedite the issuance of such applications.




2.2.3

Subject to Section 5.2, Buyer will not purchase Custom CYGX Kits (or any substantially similar products) from any Third Party during the Term.




2.3

Restrictions on Use




--------------------------------------------------------------------------------




Buyer agrees and acknowledges that it (i) is not authorized or permitted to sell, supply, distribute or otherwise transfer the Products to any third parties (except for transfers to a Collaborator for no value where such Collaborator is using the Products solely in connection with a bona fide research and development collaboration with Buyer utilizing the Patent Applications and only where such Collaborator has agreed to comply with any Product use restrictions contained herein and has agreed to keep any GEHC Confidential Information learned during such Collaboration confidential) and (ii) will only use the Products at sites owned or leased by Buyer or, if permitted under Section 2.3(i) above, owned or leased by Collaborators of Buyer where such use is solely for the manufacture of nucleic acid under the nucleic acid manufacturing process covered by one or more claims of the Patent Applications (or any current or future related patent applications) wherein the nucleic acid product is to be used as the active ingredient or adjuvant in Compounds used in the context of either therapeutics, prophylactics, or ameliorative agents. Upon reasonable advance written notice from GEHC, Buyer agrees to give access to its relevant stock and sales records to an independent auditor appointed by GEHC, subject to approval by the Buyer (such approval not to be unreasonably withheld), to verify in Buyer’s compliance with the terms hereof. Such audits shall be conducted no more frequently than once per year and shall be at GEHC’s sole expense.




2.4

Labeling

Buyer agrees to comply with all use restrictions applicable to the Products as set forth on the labels thereto; provided, that, such restrictions do not directly conflict with the terms of this Agreement. In the event of such a conflict between such labels and the terms of this Agreement, the terms of this Agreement will prevail. GEHC agrees to provide Buyer with at least thirty (30) days’ prior written notice of any changes to the label restrictions.




2.5

Terms and Conditions of Sale

Buyer will order Products from GEHC under the terms and conditions of sale attached as Exhibit A to this Agreement (“Conditions of Sale”) and GEHC will not accept and objects to any terms and conditions on Buyer’s purchase order or other writing which are different or additional to those contained in the Conditions of Sale. In the event of any conflict between the terms of the body of this Agreement and Exhibit A , the terms of this Agreement shall prevail. No modification or waiver of the Conditions of Sale will be effective unless in writing and signed by both parties. Buyer’s purchase orders will reference and automatically incorporate the terms of this Agreement and orders will be deemed accepted by GEHC upon Buyer’s receipt of GEHC’s order confirmation.




III.

SHIPMENT




3.1

Shipment

GEHC will ship the Products to the location designated by Buyer on its purchase order in accordance with the Conditions of Sale.




3.2

Delivery Dates

Subject to Section 5.1 and to the extent such orders are consistent with the terms of this Agreement and the applicable Forecast (as defined below), GEHC will use commercially reasonable efforts to ship the Products ordered by Buyer hereunder no later than thirty (30) days from the date of such order; provided, that, any orders placed pursuant to the initial purchase order hereunder will be delivered no later than ninety (90) days from the date of such order.




IV.

PRICE, MINIMUMS AND PAYMENT TERMS




4.1

Purchase Price

In consideration for the supply of Products hereunder, Buyer will pay GEHC the applicable transfer prices set forth in Schedule 3 . Commencing on December 1, 2006 and on December 1 of each subsequent year this Agreement is in effect and upon at least thirty (30) days prior written notice to Buyer, the prices for Products for the immediately following calendar year may be




--------------------------------------------------------------------------------




increased by GEHC, with a cap on such adjustment equal to the aggregate change in the Producer Price Index for Drugs and Pharmaceuticals issued by the Department of Labor, Bureau of Labor Statistics over the prior twelve (12)-month period.




4.2

Minimums

Notwithstanding anything herein to the contrary, Buyer shall be required to purchase from GEHC during each calendar year during the Term no less than that number of Custom CYGX Kits for each such calendar year set forth on Schedule 4 . In the event Buyer does not purchase, for any given calendar year hereof, the minimum number of Custom CYGX Kits set forth herein, Buyer shall, within thirty (30) days of the end of such calendar year, pay to GEHC a dollar amount (the “Shortfall Dollar Amount”) equal to the difference between (i) the dollar amount of Custom CYGX Kits that Buyer was required to purchase hereunder for such prior calendar year and (ii) the dollar amount paid by Buyer for Custom CYGX Kits during such prior calendar year. If Buyer does not pay the Shortfall Dollar Amount, GEHC shall be permitted to, at its option, (i) terminate the exclusivity provisions of this Agreement and/or pursue any other remedies available to it under law or (ii) terminate this Agreement immediately and/or pursue any other remedies available to it under law.




V.

FORECASTS; FORCE MAJEURE; QUALITY AUDIT




5.1

Forecasts

Buyer agrees that no later than the first day of each calendar quarter it will provide to GEHC a bona fide reasonable estimate (the “Forecast”) of the quantity of the Products that Buyer expects to purchase from GEHC for each of the next four quarters, of which the initial quarter of such Forecast shall be binding on Buyer. In the event that Buyer places order for Products in amounts greater than the amounts set forth in the applicable Forecast, GEHC shall use its commercially reasonable efforts to fill Buyer’s order in the appropriate time frame, provided that, in any given calendar quarter, GEHC shall have no obligation to supply any amounts in excess of one hundred and twenty percent (120%) of the applicable Forecast. Forecasts for Custom CYGX Kits will be sent to the following address: GE Biosciences, Cardiff Labs, Forest Farm Estate, Whitchurch, Cardiff CF4 7YT, UK, Fax No. [phone], Attention: Richard Kuningas.




5.2

Force Majeure

If GEHC is prevented from performing any of its obligations hereunder due to any cause which is beyond GEHC’s reasonable control, including fire, explosion, perils of the sea, flood, drought, natural calamity, war, terrorism, riot, sabotage, accident, embargo, labor dispute, strike, labor shortage, short or reduced supply of fuel or raw material (to the extent such supply failure or shortage is beyond the GEHC’s control), transportation embargo, judicial action, or compliance with any order, direction or request from any governmental agency or office (a “Force Majeure Event”), GEHC shall not be liable for breach of this Agreement with respect to such non-performance to the extent any such non-performance is due to a Force Majeure Event; provided, that, if due to a Force Majuere Event GEHC is unable to supply Products to Buyer for a period of (a) thirty (30) days from the expected date of delivery, then Buyer shall be permitted to purchase Products from a Third Party without violating its exclusivity obligations hereunder solely for such period of time as GEHC is unable to supply Buyer with Products or (b) six (6) months, then Buyer shall be permitted to terminate this Agreement. If Buyer purchases products comparable to the Custom CYGX Kits from a Third Party as permitted above, then such purchases shall be credited to Buyer in calculating Buyer’s minimum purchase requirements hereunder. For the avoidance of doubt, under no circumstances does GEHC grant Buyer a license (implied or otherwise) to any intellectual property relating to the Products in the event Buyer is permitted to obtain Products from a Third Party as stated above.




5.3

Quality Audit

With at least thirty (30) days advance written notice and no more than once during any calendar year, GEHC will allow Buyer’s external auditors to tour and inspect only those facilities used by GEHC in the manufacturing of substantially all of the Custom CYGX Kits. The inspection will




--------------------------------------------------------------------------------




include access only to policies, equipment, release criteria/data, non-conformance reports, complaints and recall notices concerning the manufacture and distribution of the Custom CYGX Kits. Upon the request of GEHC, audit reports will be sent to GEHC by Buyer within thirty (30) days of the audit. Prior to the commencement of an audit hereunder, Buyer will ensure that the external auditors agree to obligations of confidentiality at least as restrictive as those described herein with respect to any GEHC information learned or discovered in connection with such audit.




VI.

INTELLECTUAL PROPERTY




6.1

IP Ownership




6.1.1

GEHC will acquire no rights under this Agreement to any existing Buyer technology or intellectual property.




6.1.2

Buyer will acquire no rights under this Agreement to any GEHC technology or intellectual property.




6.1.3

Ownership of any new intellectual property created through use of the Products provided by GEHC under this Agreement that results in a new Product application, new procedures or that improves the composition, yield, fidelity, ease of use or physical or chemical stability of the Products (any such Intellectual Property referred to herein as “New IP”) will be based on inventorship determined in accordance with US patent law. In other words, each party will own the inventions made solely by inventors that are employees of that party, and both parties will jointly own inventions that are made jointly by inventors that are employees of both parties. Notwithstanding the foregoing, Buyer will offer GEHC the option (exercisable by GEHC within 90 days of written notice from Buyer to GEHC of a detailed description of the applicable invention) to a paid-up, royalty-free, exclusive (except as to Buyer), non-transferable (except to an Affiliate) but sublicensable, worldwide license to make, have made, use, distribute, sell and commercialize only in the life sciences research and diagnostic markets any and all New IP Buyer may create or otherwise obtain ownership rights in that can be used for purposes other than the manufacture of human, animal or plant therapeutic, prophylactic or ameliorative drugs (e.g., in the life sciences research or diagnostics markets).




6.2

Certain Rights

Subject to Buyer’s compliance with the terms and conditions herein, GEHC represents and warrants that, to the best of its knowledge and as of the date hereof, the Custom CYGX Kits may be used by Buyer for DNA amplification as described in US patent application numbers 10/835,140 and 09/920,571 and US patents 5,576,204; 6,124,120; 5,854,033; 6,280,949; 6,323,009; 5,001,050 and 5,198,543.




VII.

INDEMNIFICATION




7.1

Buyer Indemnification

Buyer hereby agrees to save, defend and hold GEHC and its Affiliates and each of their respective directors, officers, employees and agents harmless from and against any and all claims, suits, actions, demands, liabilities, expenses and/or losses, including reasonable attorneys’ fees and expenses, asserted by a Third Party and resulting directly or indirectly from any act or omission by Buyer, its Affiliates or any of their respective directors, officers, employees or agents, in connection with this Agreement, including, without limitation, any claims of product liability, personal injury (including, but not limited to, death), damage to property or violation of any laws or regulations or negligence.




VIII. CONFIDENTIALITY




8.1

Definition




--------------------------------------------------------------------------------




As used herein, “Confidential Information” shall include all confidential or proprietary information disclosed to one party by the other party, or developed by a party in the performance of activities contemplated by this Agreement, including information regarding Custom CYGX Kits, information regarding the parties’ respective advertising, distribution, marketing or strategic plans, and information regarding their costs, productivity or technological advances. The term “Confidential Information” includes (i) any written proprietary or confidential information or other material in a tangible form that is marked as “confidential” at the time it is delivered to the receiving party, (ii) proprietary or confidential information disclosed orally that is orally identified as confidential or proprietary when disclosed and (iii) this Agreement and the terms hereof. Confidential Information shall not include information that (i) was already known to the receiving party at the time of its receipt thereof, (ii) is independently developed by the receiving party, as evidenced by its written records, (iii) is disclosed to the receiving party after its receipt thereof by a third party who, the receiving party in good faith believes, has a right to make such disclosure without violating any obligation of confidentiality, or (iv) is or becomes part of the public domain through no fault of the receiving party.




8.2

Non-disclosure

During the Term and for ten years thereafter, neither party shall use or disclose to Third Parties any Confidential Information of the other (except to comply with its obligations under this Agreement) and each party shall ensure that its and its Affiliates’ employees, officers, representatives and agents shall not use or disclose to third parties any Confidential Information of the other (except to comply with its obligations under this Agreement). Upon the termination of this Agreement, each party shall return to the other or destroy all Confidential Information of the other in written form, and neither party shall make any further use of the Confidential Information of the other.




8.3

Required Disclosure

If required by law or regulation, a party (“Required Discloser”) may disclose that portion (and only that portion) of the Confidential Information of the other party that, based upon advice of the Required Discloser’s counsel, the Required Discloser is legally compelled to disclose or that has been requested by a governmental agency or body; provided, that, the Required Discloser shall (i) provide prompt written notice to the other party of any such requirement; (ii) cooperate with the other party’s reasonable efforts to obtain confidential treatment of such information and (iii) use reasonable efforts to obtain reliable assurance that confidential treatment will be accorded by any person to whom any Confidential Information is so disclosed.




IX.

TERM AND TERMINATION




9.1

Term; Option to Extend

Subject to the earlier termination of this Agreement pursuant to the terms hereof, this Agreement will be effective for a period of one (1) year from the date hereof (the “Initial Term”). No later than fifteen (15) days prior to the end of the Initial Term, GEHC shall provide Buyer with updated specifications for the Custom CYGX Kit (such specifications to be determined in the sole discretion of GEHC) and Buyer shall have the right, within such fifteen (15) day period, to extend the term of this Agreement by written notice to GEHC for an additional three (3) years (such additional three year period referred to as the “Option Term”, and together with the Initial Term, the “Term”).




9.2

Termination for Breach or other Event of Default

In the event of a breach by either party, then the other party may terminate this Agreement by giving such party notice of such breach. The party receiving such notice shall have thirty (30) days from the date of receipt thereof to cure such breach. If such breach is not cured within such thirty (30) day period, then the non-breaching party shall have the right to terminate this Agreement effective as of the end of such period. In the event such breach is cured during such period, such notice shall be of no force or effect and this Agreement shall not be terminated.




--------------------------------------------------------------------------------







9.3

Termination for Insolvency

In the event that either party files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within ninety (90) days of such action, then the other party may terminate this Agreement effective immediately upon written notice to such party.




9.4

Termination for Failure to Meet Minimums

GEHC shall be permitted to terminate this Agreement pursuant to Section 4.2 herein.




9.5

Termination in the Event of Force Majeure

Buyer shall be permitted to terminate this Agreement pursuant to Section 5.2 herein.




9.6

Effect of Termination; Survival

Termination of this Agreement will not relieve either party from any obligations which have accrued prior to such termination. Sections 4.2, 6, 7, 8 and 9.6 and any other provisions of this Agreement that by their sense should survive this Agreement shall survive the termination of this Agreement in accordance with the respective terms thereof.




X.

MISCELLANEOUS




10.1

Independent Entities

Neither party has any ownership interest in the other, and the relationship between the parties, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the parties. Neither party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever.




10.2

Assignment

This Agreement and any rights and/or obligations hereunder may not be assigned by either party without the prior written consent of the other, except that either party may assign this Agreement and its rights and obligations hereunder to (i) any of its Affiliates or (ii) an entity that purchases all or substantially all of the assets to which this Agreement relates. Any assignment or any attempted assignment in breach of this Section shall be null and void. Subject to the foregoing terms of this Section, this Agreement shall bind and inure to the benefit of the parties hereto and their respective permitted successors and assigns.




10.3

Section Headings

The Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning and interpretation of this Agreement.




10.4

Non-Waiver of Rights

The failure of either party to enforce at any time for any period any provision hereof shall not be construed to be a waiver of such provision or of the right of such party thereafter to enforce each such provision, nor shall any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy. Remedies provided herein are cumulative and not exclusive of any remedies provided at law.




10.5

Invalid Provisions

In the event that any one or more of the provisions (or any part thereof) contained in this Agreement or in any other instrument referred to herein, shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, then to the maximum extent permitted by law, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement.




--------------------------------------------------------------------------------







10.6

Entire Agreement

This Agreement, together with all Schedules and Exhibits attached hereto constitutes the final, complete and exclusive agreement and understanding between GEHC and Buyer relating to the subject matter hereof and supersedes all prior and contemporaneous agreements oral or written. To the extent that there are any conflicts between this Agreement and any Product labels, Schedules and Exhibits hereto, the terms this Agreement will prevail.




10.7

Notices

All notices and other communications hereunder shall be in writing. All notices hereunder shall be delivered personally, or sent by national overnight delivery service or postage pre paid registered or certified U.S. mail, and shall be deemed given: when delivered, if by personal delivery or overnight delivery service; or if so sent by U.S. mail, three (3) business days after deposit in the mail, and shall be addressed:




If to GEHC:

GE Healthcare

800 Centennial Avenue
Piscataway, NJ 08855
Attention: VP, Product Acquisition and Licensing




With a copy to:

GE Healthcare
800 Centennial Avenue
Piscataway, NJ 08855
Attention: General Counsel




If to Buyer:

Cytogenix, Inc.

3100 Wilcrest Drive, Suite 140

Houston, TX 77042
Attention: Kurt Berens




or to such other place as either party may designate by written notice to the other in accordance with the terms hereof.




10.7

Governing Law; Venue

This Agreement shall be governed by the laws of the State of Delaware, without regard to its conflict of laws principles. The venue for any action, proceeding or claim (“Action”) between the parties arising out of or relating to this Agreement or any alleged breach thereof shall be any appropriate state or federal court located in the State of Delaware and such courts will be the exclusive venues for such actions.




10.8

Waiver of Jury Trial

Each party waives their rights to a jury trial of any claim or cause of action based upon, relating to, or arising out of this Agreement. This Agreement may be filed as a written consent to a trial by the court.




10.9

Publicity

No press releases or public disclosure, either written or oral, regarding the execution of this Agreement or the content hereof, shall be made by a party hereto (or its Affiliates or representatives) without the prior knowledge and written consent of other party hereto. Notwithstanding the foregoing, the parties agree that Buyer will be permitted to issue the press release attached hereto as Schedule 5 .




[Remainder of Page Intentionally Left Blank]







--------------------------------------------------------------------------------




IN WITNESS WHEREOF, the parties have executed this Agreement as of the dates written

below.







GE HEALTHCARE BIO-SCIENCES CORP.
CYTOGENIX INC.

By :
/s/
By :
/s/

Name and Title :
Dr. Gerard Brophy, Head of Product Acquisition and Licensing
Name and Title :
Malcolm Skolnick, President and Chief Executive Officer

Date :
March 22, 2006
Date :
March 22, 2006








--------------------------------------------------------------------------------




SCHEDULE 1




DESCRIPTION OF PRODUCTS




Custom CYGX Kit




Custom CYGX Kit, (sufficient to produce ***




Reagents




Restriction enzymes

***
Exonuclease 5 ***

***
BamH1 ***

***
Xho1 ***

***
Nhe1 ***

***
Sma1 ***

***
EcoR1 ***





*** DNA ***

***
***





*** DNA ***

***
***





ATP

***
***

















--------------------------------------------------------------------------------




SCHEDULE 2




PRODUCT SPECIFICATIONS




Custom CYGX kit




Product Code : ***




Kit Components:




Component
Volume
Component Code

*** Buffer
***
***

*** Buffer
***
***

Enzyme ***
***
***





QC Specifications :




Measurement
Method
Specification

1
Raw Materials

1.1
Enzyme

1.1.1
Purity
***
> 92 %

1.1.2
Double-stranded Endonuclease contamination
Incubation of *** at 37 0 C
No change in band pattern upon agarose gel electrophoresis.

1.1.3
Single-stranded endonucleases contamination
Incubation of *** at 37 0 C
No change in band pattern upon agarose gel electrophoresis.

1.1.4
Protein concentration
Comparison to BSA standard curve at A595.
***

1.2
***

1.2.1
Base composition
HPLC analysis ***
***

1.2.2
***
***
***

2
Kit Components

2.1
*** buffer

2.1.1
pH
pH at 18-24 ° C
***

2.1.2
Conductivity
Conductivity using ***
***

2.1.3
*** concentration
***
***

2.1.4
Dispense volume
Volume ***

Weighing ***
***

***

2.2
*** buffer

2.2.1
*** concentration
***
***

2.2.2
Conductivity
Conductivity using ***
***

2.2.3
Dispense volume
Volume ***

Weight ***
***

***

2.3
Enzyme ***

2.3.1
Dispense volume
Volume ***

Weight ***
***

3
Kit

3.1
Yield
*** product *** at 30°C ***
Spec TBD *




--------------------------------------------------------------------------------



3.2
DNA Contamination
Yield and *** product of ***.




Restriction enzyme digestion ***
Spec TBD *




Sample does not digest to any discernable bands.

3.3
Product characterization
Restriction enzyme digestion ***
> 85 % ***





Yield and DNA contamination specifications will be confirmed and added to this agreement after 3 batches of Custom CYGX kits have been manufactured and tested using the same method.




Reagents




Bam H I

Product Code: ***
G¯GATCC

Description: Isolated from Bacillus amyloliquefaciens H.




Heat inactivatable: Yes, 60 °C for 15 minutes.

Concentration: ***

Storage conditions: 200 mM NaCl, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 10 mM 2-mercaptoethanol, 100 µg/ml BSA, 0.15% Triton™ X-100 and 50% glycerol. Store at -20 °C.







Xho I

Product Code: ***
C¯TCGAG

Description: Isolated from Xanthomonas holcicola .

Heat inactivatable: No, use ethanol precipitation.

Concentration: ***

Storage conditions: 100 mM KCl, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 10 mM 2-mercaptoethanol, 100 µg/ml BSA and 50% glycerol. Store at -20 °C.

Unit definition
Ligation-recutting

DNA
Buffer
temp
ligated
recut

l
H
37 °C
> 95%
100%





Nhe I

Product Code: ***
G¯CTAGC

Description: Isolated from Neisseria mucosa heidelbergensis .

Heat inactivatable: Yes, 70 °C for 15 minutes.

Concentration: ***.

Storage conditions: 50 mM KCl, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 10 mM 2-mercaptoethanol, 100 µg/ml BSA and 50% glycerol. Store at -20 °C.

.

Unit definition
Ligation-recutting

DNA
Buffer
temp
ligated
recut

l
M
37 °C
90%
95%





Sma I




--------------------------------------------------------------------------------




Product Code: ***
CCC¯GGG

Description: Isolated from Serratia marcescens Sb .

Heat inactivatable: Yes, 60 °C for 15 minutes.

Concentration: ***

Storage conditions: 50 mM KCl, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 10 mM 2-mercaptoethanol, 100 µg/ml BSA and 50% glycerol. Store at -20 °C.

.

Unit definition
Ligation-recutting

DNA
Buffer
temp
ligated
recut

l
T + BSA
30 °C
> 95%
100%





Eco R I

Product Code: ***
G¯AATTC

Description: Isolated from Escherichia coli RY13.

Heat inactivatable: Yes, 60 °C for 15 minutes.

Concentration: ***

Storage conditions: 400 mM KCl, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 5 mM 2-mercaptoethanol, 100 µg/ml BSA, 0.15% Triton™ X-100 and 50% glycerol. Store at -20 °C.

Unit definition
Ligation-recutting

DNA
Buffer
temp
ligated
recut

l
H
37 °C
100%
100%





Exonuclease V ***

Product Code : ***
Source: Micrococcus luteus .

Description: Multiple activities, all of which may be required for recombination or DNA repair. It will hydrolyze nucleotides from both the 3' and 5'-ends of linear double-stranded and single-stranded DNA, and requires ATP for activity.

Unit definition: One unit produces 10 nmol of acid-soluble nucleotides from 20 nmol DNA in 30 min at 37 °C under standard assay conditions.

Purity: Free of contaminating nicking activity.

Activity: ***

Storage conditions: 20 mM Tris-HCl, pH 7.5, 1 mM 2-mercaptoethanol, 0.1 mM EDTA and 50% glycerol. Store at - 20 °C.







*** DNA ***

Product Code: ***
Source: ***

Description: ***

Unit definition: ***

Purity: *** Typically greater than 95% pure by SDS-PAGE.

Storage conditions: ***
Functional performance testing: ***

Supplied with ***




*** DNA ***




--------------------------------------------------------------------------------




Product Code: ***
Source: ***

Description: ***

Unit definition: ***

Assay conditions: ***

Specific activity: ***

Concentration: ***

Storage buffer: ***




--------------------------------------------------------------------------------




SCHEDULE 3




TRANSFER PRICES







Custom CYGX Kit (sufficient to produce *** DNA)




Initial Term

$ *** /kit




Option Term

Up to 10 kits/year $ *** /kit

10 - 20 kits/year $ *** /kit

20 - 40 kits/year $ *** /kit

More than 40 kits/year $ *** /kit




Reagents *




***
Exonuclease 5 ***
$ ***

***
BamH1 ***
$ ***

***
Xho1 ***
$ ***

***
Nhe1 ***
$ ***

***
Sma1 ***
$ ***

***
EcoR1 ***
$ ***





*** DNA ***

***
*** units)
$ ***





*** DNA ***

***
*** units)
$ ***





ATP

***
*** ATP ***
$ ***





_______________

* Reagent pricing will, subject to any other terms of this Agreement (including price adjustments) apply to the Initial Term and the Option Term.




--------------------------------------------------------------------------------




SCHEDULE 4




MINIMUM PURCHASE REQUIREMENTS




During the Initial Term




*** Custom CYGX Kits as follows: (i) *** Custom CYGX Kits no later than March 31, 2006, (ii) *** Custom CYGX Kits no later than June 30, 2006 and (iii) *** Custom CYGX Kits no later than September 30, 2006.




During the Option Term, if Exercised by Buyer




2007 – *** Custom CYGX Kits




2008 – *** Custom CYGX Kits




2009 – *** Custom CYGX Kits







--------------------------------------------------------------------------------




SCHEDULE 5




PRESS RELEASE




CytoGenix Enters into a Supply Agreement with GE Healthcare

For DNA Production Reagents




Houston, TX (March 23, 2006) – GE Healthcare, a unit of General Electric Company (NYSE: GE), and CytoGenix, Inc. (CYGX. OB) have entered into a supply agreement in which GE Healthcare will provide CytoGenix with DNA production reagents for use in the manufacture of vaccines and therapeutic compounds by CytoGenix.




Under the terms of the agreement, GE Healthcare has agreed that Cytogenix will be its exclusive customer for these reagents where the intended application is the manufacture of therapeutic compounds using Cytogenix’s proprietary processes.




CytoGenix’ proprietary synDNA™ is a cell-free production process that enables a more efficient manufacturing cycle than extraction of DNA from bacterial fermentation. CytoGenix expects to begin production of commercial-scale amounts of synDNA™ in April and continue development of DNA vaccines and therapeutic products against infectious diseases (herpes infections, multi-drug resistant bacterial infections), inflammatory disorders (psoriasis) and cancer..




“This guaranteed source of GMP grade reagents is vital to our product development especially for our pandemic and bioterrorism vaccine program,” said Dr. Malcolm Skolnick, CytoGenix, Inc. President and CEO. “We are very pleased to enter into this agreement with GE Healthcare and look forward to working with them to expand the development of DNA based pharmaceuticals,” added Dr. Skolnick.


“We believe CytoGenix can effectively utilize GE’s innovative disease research technologies with its own ground-breaking research to ultimately enhance the efficiency of healthcare delivery and increase the breadth of options for patient care,” said Carl W. Fuller, Ph.D., Vice President Science Fellow at GE Healthcare.







--------------------------------------------------------------------------------







About CytoGenix

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 41 international or US pending patent applications claiming methods and materials in connection with this platform technology. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com .




###




SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com .







--------------------------------------------------------------------------------




EXHIBIT A




CONDITIONS OF SALE










--------------------------------------------------------------------------------




1.

General

1.1

In these Conditions:

The Buyer means the person, firm, company or other organisation who or which has ordered Products and/or Services from the Company;
The Company means the GE Biosciences group company referred to in the Contract;

The Contract means any contract for the sale and purchase of Products and/or Services between the Company and the Buyer being any quotation of the Company which is accepted by the Buyer or any order of the Buyer’s which is accepted by the Company whichever first occurs;

The Equipment means all items manufactured or supplied by the Company which are of a capital nature including without limitation, instruments, computers, printers and non-expendable accessories/spare parts;
The Goods means all items manufactured or supplied by the Company other than the Equipment including without limitation, biochemicals, enzymes, kits and kit components;
The Products means any Goods or Equipment agreed to be supplied by the Company; and
The Services means all advice given and services performed by the Company.

1.2

These Conditions shall be incorporated into each Contract and shall govern each Contract to the exclusion of any conditions of the Buyer. These Conditions may not be varied or waived except with the express written agreement of the Company. The failure of the Company to enforce its rights under the Contract at any time for any period of time shall not be construed as a waiver of any such rights.

2.

Prices and Quotations

2.1

The price of the Products and/or Services will be the Company's quoted price inclusive of any duties but exclusive of value added or other taxes. All quotations issued by the Company for the supply of Products and/or Services shall remain open for acceptance for the period stated in the quotation or, if none is stated, for ninety (90) days. In all other cases, prices payable are those currently in effect. Unless otherwise agreed in writing, extra charges will be made for all applicable handling, freight, content, packaging, insurance or similar costs and a handling charge may be made for small orders.

2.2

The Company shall not modify prices at any time before delivery to the Buyer unless to reflect any changes to its costs resulting from any alteration in or addition to the Buyer's requirements.

3.

Payment

3.1

Unless otherwise agreed in writing payment in full shall be made to the Company in the currency invoiced no later than thirty (30) days from the date of invoice.

3.2

In the event of late payment the Company reserves the right:

(i)

to suspend deliveries and/or cancel any of its outstanding obligations; and

(ii)

to charge interest at an annual rate equal to 12% on all unpaid amounts calculated on a day to day basis until the actual date of payment.

4.

Changes

4.1

The Company reserves the right to make any change in the specification of the Products which does not materially affect the installation, performance or price thereof.

4.2

Products may only be returned at Company’s option, and with prior authorization. A restocking charge will be applied to shipments returned for exchange or credit.

5.

Delivery

5.1

The Company will select the method of shipment and the carrier to be used, unless otherwise agreed. Unless otherwise agreed, shipment will be F.O.B. (UCC) Company’s shipping point to destinations in US and Canada and CIP (Incoterms 2000) place of destination for all other destinations. The Company will not be responsible for any loss or damage to the Products following delivery to the carrier, save that the Company will, unless otherwise agreed, provide insurance coverage for the Products during transit for the benefit of the Buyer. Damaged items cannot be returned without authorisation.

5.2

If the Buyer fails to accept delivery of the Products within a reasonable period after receiving notice from the Company that they are ready for delivery, the Company may dispose of or store the Products at the Buyer's expense.

5.3

The Company will use all reasonable endeavours to avoid delay in delivery on the notified delivery dates. Failure to deliver by the specified date will not be a sufficient cause for cancellation, nor will the Company be liable for any direct, indirect, consequential or economic loss due to delay in delivery.

5.4

The Buyer shall notify the Company within five (5) working days in writing of any short delivery or defects reasonably discoverable on careful examination. The Company’s sole obligation shall be, at its option, to replace or repair any defective Products or refund the purchase price of any undelivered Products.

5.5

Where delivery of any Product requires an export license or other authorisation before shipment, the Company shall not be responsible for any delay in delivery due to delay in, or refusal of, such licence or authorisation.

6.

Risk and Title

6.1

The Buyer shall bear the risk of loss to the Products after delivery to the carrier. Full legal and equitable title and interest in the Goods and Equipment shall pass to the Buyer on delivery to the carrier. The Buyer agrees not to dispose of or resell the Equipment until it has been paid in full.

7.

Services

7.1

Where the Company is to provide Services, the Buyer shall ensure that adequate and safe facilities exist at its premises and that the Company is properly notified of any relevant regulations.

8.

Restricted Use

8.1

With respect to certain Products, use restrictions are a condition to the purchase which Buyer must satisfy by strictly abiding by the restriction as set forth in the Company's catalogue and/or on the Product and accompanying documentation. In no event shall goods stipulated by Company as intended for research and development use be used in a manufacturing process or in manufactured products. The Products shall in no event be used in medical or clinical applications, unless otherwise expressly stated by the Company, and Buyer is solely liable to ensure compliance with any regulatory requirements related to the Buyer's use of Products. Any warranty granted by Company to the Buyer shall be deemed void if any goods covered by such warranty are used for any purpose not permitted hereunder. In addition, the Buyer shall indemnify Company and hold Company harmless from and against any and all claims, damages, losses, costs, expenses and other liability of whatever nature that Company suffers or incurs by reason of any such unintended use.

9.

Warranty




--------------------------------------------------------------------------------




9.1.

Goods - The Company warrants that its Goods meet the Company’s specifications at the time of shipment. All warranty claims on Goods must be made within thirty (30) days of receipt of the Goods. The Company’s sole liability and Buyer’s exclusive remedy for a breach of this warranty is limited to repair, replacement or refund at the sole option of the Company.

9.2

Equipment - The Company’s Equipment of its own manufacture is warranted from date of shipment to be free of defects in workmanship or materials under normal usage for a period of one year. The Company’s sole liability and Buyer’s exclusive remedy for a breach of this warranty is limited to repair, replacement or refund at the sole option of the Company; provided, that, the Company delivers the purchased Equipment in a reasonable timely manner.

9.3

Services - The Company warrants that all Services will be carried out with reasonable care and skill. The Company’s sole liability for breach of this warranty shall be at its option to give credit for or reperform the Services in question. This warranty shall only extend for a period of sixty (60) days after the completion of the Services.

9.4

THE COMPANY HEREBY EXPRESSLY DISCLAIMS, AND BUYER HEREBY EXPRESSLY WAIVES, ANY WARRANTY REGARDING RESULTS OBTAINED THROUGH THE USE OF THE PRODUCTS, INCLUDING WITHOUT LIMITATION ANY CLAIM OF INACCURATE, INVALID, OR INCOMPLETE RESULTS.

ALL OTHER WARRANTIES, REPRESENTATIONS, TERMS AND CONDITIONS (STATUTORY, EXPRESS, IMPLIED OR OTHERWISE) AS TO QUALITY, CONDITION, DESCRIPTION, MERCHANTABILITY, FITNESS FOR PURPOSE OR NON-INFRINGEMENT (EXCEPT FOR THE IMPLIED WARRANTY OF TITLE) ARE HEREBY EXPRESSLY EXCLUDED.

10.

Limit of Liability

10.1

The Company shall have no liability under the warranties contained in Condition 9 in respect of any defect in the Products arising from: specifications or materials supplied by the Buyer; fair wear and tear; wilful damage or negligence of the Buyer or its employees or agents; abnormal working conditions at the Buyer's premises; failure to follow the Company's instructions (whether oral or in writing); misuse or alteration or repair of the Products without the Company's approval; or if the total price for the Products has not been paid.

10.2

THE COMPANY SHALL IN NO EVENT BE LIABLE FOR ANY INDIRECT OR CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND FROM ANY CAUSE ARISING OUT OF THE SALE, INSTALLATION, USE OR INABILITY TO USE ANY PRODUCT OR SERVICE, INCLUDING WITHOUT LIMITATION, LOSS OF PROFITS, GOODWILL OR BUSINESS INTERRUPTION.

10.3

The exclusion of liability in these terms and conditions shall not apply in respect of death or personal injury caused by the Company’s negligence.

10.4

The Company shall not be bound by any representations or statements on the part of its employees or agents, whether oral or in writing, including errors made in catalogues and other promotional materials.

11.

Intellectual Property Rights

Where the Buyer supplies designs, drawings, and specifications to the Company to enable it to manufacture non-standard or custom made Products, the Buyer warrants that such manufacture will not infringe the intellectual property rights of any third party.

All intellectual property rights in the Products and/or Services shall at all times remain vested in the Company.

12.

Health, Safety and Waste

The Buyer shall ensure that:

(i)

the specification of the Products is safe for the intended use;

(ii)

the Products are handled in a safe manner; and

(iii)

any waste originating from the Products is disposed of in accordance with any relevant regulations.

13.

Indemnities

Except where the claim arises as a result of the intentional, reckless or negligent acts of the Company, the Buyer shall indemnify the Company in respect of any claim which may be made against the Company:

(i)

arising in connection with the Buyer’s use of the Products;

(ii)

alleging that the use to which the Products are put infringes the intellectual property rights of any third party.

14.

Insolvency

In the event that the Buyer becomes bankrupt or, being a company, goes into liquidation (other than for the purposes of reconstruction or amalgamation), the Company shall be entitled immediately to terminate the Contract without notice and without prejudice to any other rights of the Company hereunder.

15.

Force Majeure

15.1

The Company shall not be liable in respect of the non-performance of any of its obligations to the extent such performance is prevented by any circumstances beyond its reasonable control including but not limited to strikes, lock outs or labour disputes of any kind (whether relating to its own employees or others), fire, flood, explosion, natural catastrophe, military operations, blockade, sabotage, revolution, riot, civil commotion, war or civil war, plant breakdown, computer or other equipment failure and inability to obtain equipment.

15.2

If an event of force majeure exceeds one month the Company may cancel the Contract without liability.

16.

Computer Program Licence

Where the Company’s Equipment is intended to be used with a particular licensed computer program supplied by the Company, the use of any other program shall void the Company warranty. The Buyer is hereby granted a non-exclusive, non-transferable licence to use the licensed computer program only with the Equipment supplied by the Company. No rights are granted to produce copies of, reverse-engineer, or create any derivative works based upon the licensed computer programme.




--------------------------------------------------------------------------------













PRESS RELEASE




CytoGenix Enters into a Supply Agreement with GE Healthcare

For DNA Production Reagents




Houston, TX (March 23, 2006) – GE Healthcare, a unit of General Electric Company (NYSE: GE), and CytoGenix, Inc. (CYGX. OB) have entered into a supply agreement in which GE Healthcare will provide CytoGenix with DNA production reagents for use in the manufacture of vaccines and therapeutic compounds by CytoGenix.




Under the terms of the agreement, GE Healthcare has agreed that Cytogenix will be its exclusive customer for these reagents where the intended application is the manufacture of therapeutic compounds using Cytogenix’s proprietary processes.




CytoGenix’ proprietary synDNA™ is a cell-free production process that enables a more efficient manufacturing cycle than extraction of DNA from bacterial fermentation. CytoGenix expects to begin production of commercial-scale amounts of synDNA™ in April and continue development of DNA vaccines and therapeutic products against infectious diseases (herpes infections, multi-drug resistant bacterial infections), inflammatory disorders (psoriasis) and cancer..




“This guaranteed source of GMP grade reagents is vital to our product development especially for our pandemic and bioterrorism vaccine program,” said Dr. Malcolm Skolnick, CytoGenix, Inc. President and CEO. “We are very pleased to enter into this agreement with GE Healthcare and look forward to working with them to expand the development of DNA based pharmaceuticals,” added Dr. Skolnick.


“We believe CytoGenix can effectively utilize GE’s innovative disease research technologies with its own ground-breaking research to ultimately enhance the efficiency of healthcare delivery and increase the breadth of options for patient care,” said Carl W. Fuller, Ph.D., Vice President Science Fellow at GE Healthcare.







About CytoGenix

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 41 international or US pending patent applications claiming methods and materials in connection with this platform technology. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com .




###




SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

[crashpoet]

schon 65T in 10 Min gehandelt, das sieht heute SEHR gut aus

Detailed Quote Snapshot 03/29/2006 09:41 AM
Last:

1.295 cygx - CYTOGENIX INC
Change:

+0.01 % Change:

+0.78% High:

1.3 Low:

1.28 Volume:

64,735

Price Data Table
Open 1.29
Previous Close 1.295
Exchange of Last Sale OTCBB
Time of Last Sale 09:42:48
Tick Down
Bid 1.29
Ask
Size Bid/Ask 5x5
Symbol Type Equity

[wayne99]

Press Release Source: CytoGenix, Inc.

CytoGenix Receives First Order for synDNA(TM)
Thursday March 30, 8:00 am ET

HOUSTON--(BUSINESS WIRE)--March 30, 2006--CytoGenix, Inc. (OTCBB:CYGX - News) announced receiving its first purchase order for synDNA(TM) synthetic DNA. The order was placed by Aldevron (Fargo, North Dakota), a leading worldwide supplier of DNA for research and clinical applications. CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA.

"The CytoGenix synDNA(TM) technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers," said Dr. Michael Chambers, President and CEO of Aldevron. "One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA."

Plasmid DNA is commonly used to make many copies of a particular gene. These genes are used by researchers to test DNA-based treatments for a wide range of diseases. Traditionally, plasmid DNA is manufactured via a complex process that involves processing bacteria to yield high-grade amounts of plasmid DNA. CytoGenix' product is produced synthetically, and no bacteria are required, thereby speeding the production time and increasing the purity and quality of the DNA.

Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA. We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA(TM)."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


Contact:

CytoGenix, Inc., Houston
Kurt Berens, 713-789-0070

Source: CytoGenix, Inc.

[crashpoet]

Das ist das erste mal, dass Cytogenix beweist, dass sie etwas zu bieten haben, mit dem sich Geld verdienen läßt.
Wie groß der Impact sein wird hängt davon ab, wie stark zuvor daran gezweifelt wurde.
Bin kein Prophet, aber Kurse von 1,8 - 2$ erscheinen mir schon für heute realistisch zu sein.

CytoGenix Receives First Order for synDNA(TM)
HOUSTON--(BUSINESS WIRE)--March 30, 2006--CytoGenix, Inc. (OTCBB:CYGX) announced receiving its first purchase order for synDNA(TM) synthetic DNA. The order was placed by Aldevron (Fargo, North Dakota), a leading worldwide supplier of DNA for research and clinical applications. CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA.


"The CytoGenix synDNA(TM) technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers," said Dr. Michael Chambers, President and CEO of Aldevron. "One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA."

Plasmid DNA is commonly used to make many copies of a particular gene. These genes are used by researchers to test DNA-based treatments for a wide range of diseases. Traditionally, plasmid DNA is manufactured via a complex process that involves processing bacteria to yield high-grade amounts of plasmid DNA. CytoGenix' product is produced synthetically, and no bacteria are required, thereby speeding the production time and increasing the purity and quality of the DNA.

Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA. We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA(TM)."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

[crashpoet]

62T bei 1.44$ in der ersten Minute gehandelt!

[Mambo6]

hat jemand ne Ahnung weshalbs bei Cytogenix abwärts geht, obwohl demnächst Geld verdient wird?

[crashpoet]

Antwort auf Beitrag Nr.: 21.161.334 von Mambo6 am 11.04.06 15:56:25

solange das bei so geringem umsatz passiert, hat es nicht viel zu bedeuten.
außerdem ist ein sec-filing überfällig, das könnte für etwas verunsicherung sorgen.

[Mambo6]

Antwort auf Beitrag Nr.: 21.161.945 von crashpoet am 11.04.06 16:25:44

hab mich auch gewundert wie die mit 2000 Stücken den Kurs so drücken können...

.. der Bericht müßte ja dann bis Freitag bei der SEC sein, oder täusche ich mich da?

[crashpoet]

Antwort auf Beitrag Nr.: 21.162.176 von Mambo6 am 11.04.06 16:37:50

soweit ich weiß bis zum 15., das ist aber ein samstag.

[Mambo6]

wenn du mich fragst ist da schon was raus...und so wie es aussieht nichts so besonders gutes.

[ketsie]

Antwort auf Beitrag Nr.: 21.164.674 von Mambo6 am 11.04.06 18:54:01

bitte keine unkenrufe ... von hellgrün bin ich wieder ins rosarot gerutscht.

ketsie

[Boerse24]

Hallo,

ich sehe das ganze ein bisschen lockerer, obwohl es mich natürlich auch stört, dass der Kurs fällt.

Nach einem so starken Anstieg ist es aber normal, dass die Aktie dann erst einmal wieder um die Hälfte des Anstiegs fällt.
Das war bisher noch bei fast jeder Aktie so und deshalb halte ich das für nicht allzu beunruhigend.

Für eine normale Gegenreaktion spricht auch, dass...
-kein oder fast kein Umsatz in Deutschland ist
und in den USA nur 33 000 Stück umgesetzt wurden!!!

Meine Empfehlung lautet: Da diese Aktie sprunghaft steigt, sollte man kein Stück aus der Hand geben und sich auch nicht von kleineren Gegenbewegungen verunsichern lassen, sondern diese zum Kaufen nutzen.

Mein kurz- bis mittelfristiges Kursziel lautet: mindestens 2 Euro!

[ketsie]

Antwort auf Beitrag Nr.: 21.178.854 von Boerse24 am 12.04.06 17:15:12

na, dann mal los - hast du übrigens was mit Tee zu tun?
ketsie

[crashpoet]

Das SEC-Filing ist da!
(habs aber noch nicht gelesen)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

|X| ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2005

|_| TRANSITION REPORT PURSUANT TO SECTION 13 OF 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 000-26807

CYTOGENIX, INC.
(Exact name of registrant as specified in its charter)

NEVADA 76-0484097
(State or other jurisdiction of incorporation (I.R.S. Employer Identification
or organization) No.)

3100 WILCREST, SUITE 140, HOUSTON, TEXAS 77042
(Address of principal executive offices) (Zip Code)

Issuer's telephone number, including area code: 713-789-0070

Securities registered under Section 12(b) of the Exchange Act: NONE

Securities registered under Section 12(g) of the Exchange Act:
COMMON STOCK WITH $.001 PAR VALUE
(Title of Class)

Indicate by check mark if the Registrant is a well known seasoned issuer as
defined in Rule 405 of the Securties Act. Yes |_| No |X| Indicate by check mark
if Registrant is not required to file reports pursuant to Section 13 or Section
15(d) of the Act. Yes |_| No |X|

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No |_|

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. |X|

Indicate by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer |_| Accelerated Filer |_| Non-accelerated filer |X|

Indicate by check mark whether the Registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).

Yes |_| No |X|

The aggregate market value of the voting stock held by non-affiliates of the
Registrant as of June 30, 2005(the last business day of the Registrant's most
recently completed second fiscal quarter) was approximately $113,436,970. The
number of outstanding shares of the Registrant's Common Stock as of the close of
business on March 16, 2006 was 125,377,370.

DOCUMENTS INCORPORATED BY REFERENCE

Selected portions of the definitive Proxy Statement of CytoGenix, Inc., which
will be filed with the Securities and Exchange Commission within 120 days after
December 31, 2005, are incorporated by reference in Part III of this Form 10-K.



1







CYTOGENIX, INC.
FORM 10-K INDEX

PART I

Page
----
Item 1. Description of Business ............................................................... 4

Item 1A. Risk Factors .......................................................................... 15

Item 1B. Unresolved Staff Comments ............................................................. 19

Item 2. Description of Property ............................................................... 19

Item 3. Legal Proceedings .................................................................... 19

Item 4. Submission of Matters to a Vote of Security Holders ................................... 19

PART II

Item 5. Market for Common Equity and Related Stockholder Matters ............................. 21

Item 6. Selected Financial Data .............................................................. 22

Item 7. Management's Discussion and Analysis or Financial Conditions and Results of Operations. 22

Item 7A. Quantitative and Qualitative Disclosures About Market Risk ............................ 27

Item 8. Financial Statements .................................................................. 28

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure... 42

Item 9A. Controls and Procedures ............................................................... 42

Item 9B. Other Information ..................................................................... 42


2



PART III

Item 10. Directors and Executive Officers of the Registrant .................................... 42

Item 11. Executive Compensation ................................................................ 43

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters ............................................................................... 43

Item 13. Certain Relationships and Related Transactions ........................................ 43

Item 14. Principal Accountant Fees and Services ................................................ 43

PART IV

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K ....................... 43


Signatures ............................................................................ 43




3





PART I

ITEM 1. DESCRIPTION OF BUSINESS

GENERAL OVERVIEW
CytoGenix, Inc. ("CytoGenix" or "the Company") is a biopharmaceutical company
whose primary focus is the development and commercialization of its proprietary
technology for identifying and silencing disease causing genes and expressing
proteins for applications such as vaccines. The Company's technology includes
gene silencing techniques applicable to genes from pathogenic organisms or
selected genes from a host to prevent the expression of harmful proteins,
thereby preventing or ameliorating disease. The Company also has developed a
novel process to produce cell free, plasmid DNA for use in its own products and
for sale to the biopharmaceutical market. The Company seeks to generate revenues
and improve the health and well-being of humans, animals and plants by utilizing
its technology to produce molecular therapies. In addition to development and
commercialization of therapeutic compounds, the Company seeks to sell and/or
license its technology to biotechnology companies seeking determination of
specific genes' function and purpose and to consumers of plasmid DNA.

The Company was formed in 1995 as a biomedical research and development company.
The original name of the Company was Cryogenic Solutions, Inc., until the
Company changed its name to CytoGenix, Inc. in January 2000. Equity funding has
been the only source of operational, research and commercialization working
capital since the Company's inception. The Company made a transition to research
and development of its present technologies in 1998. Since then we have
dedicated ourselves to engineering DNA-based molecules for therapeutic and drug
target identification purposes. Our expertise in nucleic acid technology enables
us to focus on the development of new types of nucleic acid-based therapeutics.
Our proprietary technology has beem designed to express single stranded DNA
inside target cells of living organisms to induce synthetic DNA mimetic
constructs into the target cells and thereby either silence selected genes or to
express proteins that can act as antigens to stimulate the immune system.

GENE EXPRESSION AND HUMAN DISEASE

Widely published scientific studies conducted over the last 20 years by leading
universities, government research laboratories, such as the National Institutes
of Health and the National Cancer Institute, and private research laboratories
have established that most diseases are the result of malfunctioning genes in an
organism's genome, or the activities of genes from pathogens such as viruses,
bacteria or funguses. This genetic activity causes the production of harmful
proteins that lead to the symptoms and destructive results of disease. Examples
of diseases caused by the production of such harmful proteins include cancer,
herpes, sepsis (blood poisoning) and a host of others. To produce a protein, a
cell first makes a positive copy of the DNA code containing the information
necessary to produce the protein. This messenger RNA (mRNA) is called the
"sense" molecule. This message-carrying molecule then moves to another part of
the cell where it participates in the assembly of the biochemical components to
produce proteins.

In many instances it is possible to inhibit the production of these harmful
proteins by introducing or producing small molecules of specific genetic
material into the cells themselves. Fortunately, this genetic activity can be
interrupted and controlled at three levels with the introduction of a specific
sequence of ssDNA into the cells; at the level of the genome itself, interfering
with the messenger RNA (mRNA) produced by the genome leading to the production
of the protein for which the mRNA is encoded and at the protein level where a
single strand of DNA may be made that will bind with the protein and disable it.



4





CYTOGENIX GENE SILENCING TECHNOLOGY

CYTOGENIX OWNS PATENTED INTRACELLULAR EXPRESSION SYSTEM TECHNOLOGY (CYGXES(TM))
TO PRODUCE ANY DESIRED SEQUENCE-SPECIFIC, SSDNA(SINGLE STRANDED DNA) MOLECULES
IN INDIVIDUAL CELLS FOR THE PURPOSE OF TRIPLEX, ANTISENSE, CATALYTIC DNA, AND
APTAMER APPLICATIONS.

1. Triplex: As mRNA is transcribed and the DNA strands are still
separated, a single strand of complementary DNA is inserted into
the gap forming a triple helix (triplex) structure, thus
preventing the future production of mRNA from that segment.

2. Antisense: Messenger RNA is intercepted en route by a
complementary ssDNA sequence that it binds to and results in the
destruction of the mRNA by enzymes within the cell, thus
preventing the mRNA from producing the undesired protein.

3. Catalytic DNA: Similar to antisense, a ssDNA sequence containing
sequence regions binds to the mRNA, but also contains a unique
sequence region that acts to cut and destroy the mRNA, thus
preventing it from producing the undesired protein.

4. Aptamer: The ssDNA binds to the protein itself in the cell and
causes the undesired protein to become inactivated or
dysfunctional.

The key to success with these genetic interventions is to insure that sufficient
quantities of the ssDNA molecules ultimately are produced in targeted cells or
induced from external sources. CytoGenix has invented a compound that functions
as a tiny biological "factory" that, after introduction into the cell, actually
produces many copies of specific ssDNA molecules in the cell. The business of
CytoGenix is to refine this technology and apply it to the delivery of various
patented DNA molecules for the development of effective therapeutic drugs.

DEVELOPMENT TO DATE (RESEARCH AND DEVELOPMENT)

The ssDNA expression vector technology originated with the work of Dr. Charles
Conrad, which he developed while at InGene, Inc. This breakthrough technology
was originally protected by issued United States Patent No. 6,054,299 entitled,
"Methods and Compositions for Producing Single-stranded cloned DNA in eukaryotic
cells." In 1999, CytoGenix purchased the rights to Dr. Conrad's patent as well
as other proprietary information from InGene, and has since instituted a broad
research and development program to advance single stranded DNA expression
technology. Shortly after acquisition of the foregoing patent, worldwide
protection was pursued by filing two applications under the Patent Cooperation
Treaty (PCT) entitled, "Enzymatic Synthesis of ssDNA" (World Publication No.
WO00/22113), and "Production of ssDNA in vivo" (World Publication No.
WO00/22114). Applications to protect subsequent improvements and therapeutic
applications of this technology have since been filed to expand the protection
of this technology in both the US and foreign markets. In addition to the
original issued patent, Cytogenix currently holds a patent portfolio including
46 domestic and foreign issued or pending patent applications protecting our
technologies. This assertive approach to protection of the Company's technology
has enabled CytoGenix to expand and refine the development of therapeutics for
human, animal and agricultural use.

These patents are important to the Company because they help form the basis of
the technology needed for the production of the Company's complementary
technology and other products. The technology has been proven in numerous
laboratory and animal experiments and has been widely published as set forth
below. It has been reported in scientific literature, such as in Reuters
Business Insight 2000 publication, Antisense Therapy: Technical Aspects and
Commercial Opportunities by Prof. Dr. K.K. Jain M.D. that other Antisense
molecule delivery methods have failed to provide sufficient quantities to be
therapeutically effective except in limited applications. Laboratory cell
culture studies have demonstrated that the Company's ssDNA expression vector can
adequately deliver sequence specific DNA molecules in sufficient quantities in
virtually all cell types, thereby overcoming many of the challenges previously
experienced. As described under "CytoGenix Gene Silencing Technology" above, the
Company's technology is not limited to only antisense applications, but can
target and enzymatically cleave to target mRNA using DNA enzyme formulations.
The technology can also be used to (i) generate triplex forming


5



oligonucleotides that bind to specific sites in the genome itself to inhibit
expression by the gene at that site, (ii) generate ssDNA that will bind to
specific, targeted proteins to neutralize them and (iii) competitively inhibit
genetic expression/transcription of targeted genes. The Company has extended the
results achieved in cell cultures to cells in live animals.

The genomics field has vastly expanded the number of potential drug targets. The
Company has utilized its ssDNA expression technology to develop a library
screening technique for gene target identification and validation. The CytoGenix
proprietary gene neutralization system is a powerful tool in confirming gene
target function. The screening library technique enables efficient testing of
multiple oligonucleotide sequences. When a sequence silences a targeted gene,
the construct for introducing the identified sequence in cellular and animal
experiments is readily produced. Use of the screening library has led to the
discovery of sequences that have been useful in several of the Company's
products under development.

The Company has developed a separate technology against bacteria using mimetic
oligonucleotides as sequences to silence targeted bacterial genes. Targeted
genes include those necessary for the bacteria's survival, reproduction and/or
for the expression of various toxins.

The Company has also developed a novel technique for producing cell free plasmid
DNA thus bypassing the fermentation process. The cell free synthesis of plasmid
DNA has numerous advantages: CytoGenix, synthetic DNA (SynDNA(TM)) is free of
the endotoxins, bacteriAL DNA, RNA and proteins that must be laboriously removed
in the fermentation process using live bacteria. More importantly, synthetic DNA
can be produced more rapidly and less expensively than in the traditional
fermentation method.

In July 2002, the Company inaugurated a service geared towards assisting
pharmaceutical and biotech companies improve drug discovery efficiency. In
addition to our work on in-house targets, we are conducting pilot studies for
several companies. For a fixed fee, we will knockdown a gene in a cell system.
This will confirm the gene's relevance to the disease of interest. Those genes
found to be highly disease-related become targets for new drug or molecular
therapies.

Using its expanding technological base, the Company is seeking to develop drugs
that address significant and unmet medical needs. The Company is conducting
research and/or preclinical development with product candidates in the following
areas: infectious disease (anti-virals and anti-bacterials), inflammation,
cancer and vaccines.

PRODUCTS UNDER DEVELOPMENT INCLUDE:

INFECTIOUS DISEASE PROGRAM

CY301 (SIMPLIVIR(TM)) anti-herpes topical is anticipated to address the needs of
70 million infected Americans; today's marginalLY effective products have
revenues in excess of $1 billion. The most likely methods of use include
prophylactic and neonatal applications. Our proprietary plasmid DNA sequences
turn-off the HSV ICP4 and ICP47 genes. Found in HSV-1, -2 and Herpes Zoster, the
ICP4 gene is critical for the replication of the virus in the host cell. The
ICP47 gene produces a protein that assists the virus in interfering with a
host's immune system in recognizing the virus and eliminating it. Pre-clinical
in vitro studies have shown a 100-fold reduction in HSV viral load in test cells
containing the Company's proprietary plasmid DNA coded with an ICP4 knockdown
sequence. Mouse trials were initiated in August, 2003 and are continuing.
Pre-clinical toxicology studies are being designed and will enable the filing of
an Investigational New Drug (IND) application with the Food & Drug
Administration (FDA) in the next 2008.

CY401 targets multi-drug resistant bacteria including methicillin-resistant
staphylococcus aureus (MRSA). Recently, MRSA strains that had previously been
confined to hospitals are now appearing in the community. Clinicians are
encountering difficulty in treating MRSA infections, and CY401 is anticipated to
be a leading product in a new class of antibacterial compounds. Studies
conducted in cell culture indicate that CY401 has potent killing capability even
against the most resistant bacterial pathogens such as MRSA. Animal testing has
confirmed this and CytoGenix is preparing to conduct the required safety and
toxicology studies to support the filing of an IND within the next 2008.


6





CY403 specifically targets only the staphylococcus species.

INFLAMMATORY DISEASE PROGRAM

CY303 is a topical anti-inflammatory product that blocks the activity of an
adhesion molecule known as intercellular adhesion molecule or ICAM-1. The
initial medical condition for this topical anti-inflammatory product is moderate
to severe psoriasis. Other medical conditions where CY303 could be
therapeutically beneficial include contact dermatitis, acne, decubitus, rosacea
and joint swelling. Studies to test the ability of CY303 to inhibit the
expression of ICAM-1 are ongoing and assuming success, CY303 will be the third
IND application submitted by CytoGenix.

CANCER PROGRAM


Investigators have used the Company's ssDNA expression vector technology to
knockdown cancer genes as part of projects supported by the National Institutes
of Health Small Business Innovative Research, SBIR program. Some of this work
has progressed to the level of preclinical studies, and success in these studies
will allow progression to clinical applications.


Aerosol Delivery of Anti Metastatic Tumors in Lungs


According to information from MedLinePLus at
http://www.nlm.nih.gov/medlineplus/ency/article/000097.htm: "Metastatic tumors
in the lungs are malignancies (cancers) that developed at other sites and spread
via the blood stream to the lungs. Common tumors that metastasize to the lungs
include breast cancer, colon cancer, prostate cancer, sarcoma, bladder cancer,
neuroblastoma, and Wilm's tumor. However, almost any cancer has the capacity to
spread to the lungs."


The Company has received a federal government grant from the National Institutes
of Health (the National Cancer Institute) to support the Company's work with a
researcher at a major medical school who is using the Company's ssDNA expression
vector with a propietary aerosol delivery system against a cancer gene common to
metatastic tumor cells.


Anti- Solid Tumor Gene Therapy


The Company has entered into an agreement with scientists at a university gene
therapy center for preclinical experiments using the company's ssDNA expression
vector technology to silence a gene that has been shown to cause malignant
transformation of tumor cells.


The combination of a proprietary delivery technology and CytoGenix' gene
silencing technology has great potential for new treatments of malignancies,
particularly in breast, head, neck, and prostate tumors.


NUCLEIC ACID DELIVERY TECHNOLOGY

DNA delivery into cells is a rapidly developing area in gene therapy and
biotechnology. Viral methods of DNA delivery are well-characterized and
efficient, but little is known about the toxicity and immunogenecity of viral
vectors. As a result, the Company is continuing investigation of viral vectors
but concentrating its efforts on non-viral, transfection methods of DNA
delivery. The Company is investigating targeted delivery using synthetic DNA
delivery systems containing histidine-rich peptides and polypeptides and
self-assembled delivery systems based on cationic lipids and polymers.





7







SYNTHETIC DNA PROCESS


Scientists at CytoGenix have developed a novel method for producing large
amounts of high quality therapeutic circular DNA with significant reductions in
residual contaminants compared to traditional fermentation methods.
Specifically, we have identified and optimized a method for in vitro DNA
synthesis and amplification for the production of good manufacturing practices
(GMP) drug substances.


Cell-free amplification of c-DNA has many important benefits beginning with the
size and composition of the plasmid. Under this system, there is no need for
bacterial replication genes or selection markers such as antibiotic resistant
genes. In most cases, this will reduce the size and weight of the therapeutic
c-DNA by at least 3,000 base pairs or a molecular weight of approximately 2,000
kilo Daltons. The total absence of bacteria and growth media assures that there
is no need to employ mechanical or chemical purification methods to extract cell
or animal proteins, RNA, genomic DNA and backbone molecules. This feature allows
the designer more control of coding for non-specific and specific immune
responses.

Greater biological activity

Our experiments have shown that the biological response to c-DNAs with no vector
backbone is approximately one and one-half times higher than traditional
plasmids. Other investigators have reported greater activity levels of in vivo
studies using "DNA mini circles". At the molecular level, 100nano grams of
traditional plasmid DNA is equal to 60ng of bacteria-free c-DNA. This may
explain the result of our transfection experiments and suggest that less in
vitro synthesized DNA may be required to generate the same biological effect as
its plasmid counterpart. In terms of cost, this would translate in substantial
savings.

Low risk, low cost and fast cycle time

Our novel process is bench-scale and requires little equipment, space or human
intervention in comparison to bioprocess manufacturing facilities. No cell banks
are needed and no yield optimization steps that can add weeks or months to the
production process. This process lends itself to liquid-handling automation and
one technician can synthesize gram quantities in a matter of days working in
custom manufacturing suites. The capital costs for physical plant and on-going
fixed and variable operating expenses are a fraction of the costs of large-scale
bioprocess methods. We believe that this synthetic process will be more
consistent, yield material of higher purity, and will enable delivery of higher
concentrations of Active Pharmaceutical Ingredient (API) if needed.

Improved regulatory profile

Benefits provided by the cell-free synthesis from a regulatory agency review and
compliance perspective are significant. By beginning with a well-characterized
synthetic master construct, there is no need for cell bank systems (master or
working cell banks), thus reducing the risk and amount of documentation, space
and cost. Similarly, product cGMP manufacturing procedures detailing methods for
cell collection, processing and culture conditions would no longer be necessary
and would substantially reduce quality assurance and quality control ( QA/QC)
and compliance overhead costs. The synthetic DNA process yields DNA free of
endotoxins, bacterial genomic DNA, DNA or proteins. As such it may encounter
improved regulatory acceptance.

Cytogenix is carrying out a multi-pronged strategy with the objective of
commercializing this technology within the next year. The following summarizes
our plans:

o PROCESS OPTIMIZATION AND SCALE-UP, continued experimentation to
achieve yield optimization, reduced reagent usage and reduced
costs. Manufacture milligram quantities consistently, conduct
several animal studies with various plasmids to verify
bioactivity equal to or greater than plasmids produced via
traditional methods. Scale-up to produce gram quantities.

o DEVELOP REAGENT SUPPLIERS AND SOURCING, establish relationships
with manufacturers of enzymes. Develop quality parameters.



8




o CONSTRUCT CGMP PRODUCTION SUITE, build and equip a side-by-side
manufacturing suite for simultaneous production of batches cGMP
pDNA.

o BUSINESS DEVELOPMENT, we are currently evaluating options for
industry partnership for continued development of the process
including contract manufacturing

All primary research and development at CytoGenix is conducted in the on-site
laboratory located adjacent to the executive offices at the same address. The
Company's primary research and development experiments are being conducted in
human lung cancer cells (A549 cells) and human liver cells (HepG2 cells) to
determine the expression levels of single-stranded catalytic DNA and
single-stranded Antisense DNA targeting c-raf kinase mRNA transcripts, bcl-2mRNA
transcripts, and mouse double minute oncogene 2 (MDM2) MRNA transcripts

The Company is currently supporting four Sponsored Research Agreements (SRA):

1. Dr. Cy Stein's lab at Albert Einstein College of Medicine is using
Cytogenix's proprietary gene silencing DNA technology against a gene
found in melanoma cells that produces a protein known to counteract the
effect of several chemotherapeutic agents in difficult to treat
cancers.

2. Dr. Frank Orson's lab at Baylor College of Medicine is conducting
animal trials to determine the effect of CytoGenix's gene silencing
technology on cancer in the lungs of mice using aerosol gene delivery
system.

3. Dr. Jeffrey Actor's lab at University of Texas Health Science Center in
Houston is conducting animal trials to determine efficacies of
CytoGenix's antimicrobial ODN compounds.

4. Dr. David Weiner's lab at University of Pennsylvania is conducting
animal trials to determine efficacies of CytoGenix's synthetic DNA
vaccines against Smallpox and other targets.

Other research is contemplated to explore various plasmid delivery systems.

The Company and its cooperating university scientists have published a number of
scientific papers and presented at scientific meetings. These publications
include:


1. Tan, X. & Chen, Y., A novel genomic approach identifies bacterial
DNA-dependent RNA polymerase as the target of an antibacterial
oligodeoxynucleotide, RBL-1 Biochemistry, 2005 (in press).
2. Tan, X., Actor, J.K., & Chen, Y. PNA antisense oligomer as a
therapeutic strategy against bacterial infection: proof of principle
using mouse peritonitis model, Antimicrobial Agent and Chemotherapy,
(submitted), 2005.
3. Tan, X, & Chen, Y. Discovery of novel antibiotics using cell-based
screening (Review), Current Drug Discovery, pp. 21-23, April, 2004.
4. Tan, X., Knesha, R., Margolin, W. and Chen, Y. DNA enzyme generated by
a novel single-stranded DNA expression vector inhibits expression of
the essential bacterial cell division gene ftsZ, Biochemistry, 43:
1111-1117, 2004.
5. McMicken, H., Bates, P. and Chen, Y. Antiproliferative activity of
G-quartet-containing oligonucleotides generated by a novel
single-stranded DNA expression system, Cancer Gene Therapy,
10(12):867-869, 2003.
6. Chen, Y. and McMicken, H. Intracellular production of DNA enzyme by a
novel single-stranded DNA expression vector, Gene Therapy,
10:1776-1780, 2003.
7. Chen, Y. , Ji, Y., and Conrad, C. Expression of single-stranded DNA in
mammalian cells, Biotechniques, 34:167-171, 2003.
8. Chen, Y., Novel Technologies for target validation, Genetic Engineering
News, 23(11):7-9, 2003.
9. Chen, Y. A novel single-stranded DNA (ssDNA) expression vector
(Review), Expert Opinion on Biological Therapy, 2:735-740, 2002.
10. Chen, Y. Meeting highlights, 10th International conference on gene
therapy of cancer, Expert Opinion on Biological Therapy, 2:443-445,
2002.
11. Chen, Y., Growth of oligo-based drugs, Genomics & Proteomics, October,
2002.


9




12. Datta, H., and Glazer, P. Intracelullar generation of single-stranded
DNA for chromosomal triplex formation and induced recombination,
Nucleic Acid Research, 29:5140-5147, 2001. A marvel of biochemical
engineering means cells can produce DNA enzyme to attach cancer, New
Scientist, January, 2001.
13. Chen, Y. , Ji, Y., Roxby, R., and Conrad, C. In vivo expression of
single-stranded DNA in mammalian cells with DNA enzyme sequences
targeted to c-raf, Antisense & Nucleic Acid Drug Development, 10:
415-422, 2000.

OUR BUSINESS STRATEGY

The goal and the focus of the Company are to leverage its proprietary technology
to maximize investor value. The Company is developing skin creams that should be
safer and more effective than systemic drugs (pills) for these diseases. Upon
successful completion of Phase I/II clinical trials, the Company intends to seek
distribution agreements with domestic and foreign pharmaceutical companies.

o We intend to independently develop oligonucleotide mediated therapeutic
applications in several disease areas.

o We will pursue partnerships with other pharmaceutical or biotechnology
companies to develop DNA expression-based therapeutics.

o We will seek to maintain and expand our patent portfolio and proprietary
technology. We aggressively o pursue patent protection to maintain
worldwide rights relating to the development, manufacture and sale of
oligodeoxynucleotide mediated therapeutics and gene target validation.

o We intend to leverage our oligonucleotide expertise through licensing,
process development and pilot manufacturing. We believe that we have
established one of the leading nucleic acid chemistry groups that can
provide medicinal chemistry, process development and manufacturing to
others in need of this expertise. We believe that we will be able to
capitalize on our continuing investment in oligonucleotide and nucleic
acid technology by entering into licensing, process development and pilot
manufacturing arrangements with collaborators to generate revenues, while
retaining this capability for our own drug development.

COLLABORATIVE AGREEMENTS

PARTNERSHIPS


The Company currently has several industry and government agency partnerships
and is actively seeking out-licensing opportunities in the application of our
core technologies to promote the development of new therapeutic products in the
fields of infectious diseases, inflammation and cancer. CytoGenix is also
seeking partnerships in the development of products in the areas of animal
health and agriculture. Our cell-free method for the cGMP production of
therapeutic-grade DNA is also available for licensing. Our currents partners
include:


GE HEALTHCARE, FAST TRAK BIODEFENSE GROUP


CytoGenix has entered into an agreement with the Fast Trak BioDefense Group of
GE Healthcare to collaborate in seeking, securing and executing bio-defense
related Federal contracts. GE Healthcare will provide highly qualified technical
and regulatory affairs expertise and will coordinate the application process to
various departments within the U.S. government.


ALDEVRON, LLC.


CytoGenix has teamed up with Aldevron LLC, a leader in the field of DNA
vaccines, to evaluate a synthetic DNA vaccine derived from a plasmid provided by
Aldevron. The synDNA(TM) vaccine was designed to produce a Hepatitis


10




B viral surface antigen and was evaluated in a rabbit model using Aldevron's
proprietary Genetic Immunization and Antibody (GIA(TM)) technology. The pilot
study was successful and further testing is ongoing.


COLLABORATIONS


The Company currently has several academic and government agency collaborations
to promote the research and development of new therapeutic products. Our current
collaborators include:


NATIONAL INSTITUTES OF HEALTH


CytoGenix was given a non-exclusive license to a HIV DNA vaccine construct to be
used as a proof of principle for the synDNA production method. The HIV DNA
vaccine construct was prepared using CytoGenix' proprietary process and the
product was tested in an animal model. The results of this pilot study showed
bioactivity indicating that the synthetic DNA vaccine was able to induce an
immune response. Further investigations are currently being explored to expand
this collaboration.


BAYLOR COLLEGE OF MEDICINE


Several collaborative projects are ongoing with investigators at Baylor College
of Medicine in the Texas Medical Center. A long standing collaboration is
ongoing with Drs. Sheldon Kaplan, Ed Mason and Jesus Vallejo in the Infectious
Disease Group of the Department of Pediatrics. The focus of the project has been
to identify clinical candidates for the treatment of methicillin-resistant
staphylococcus aureus (MRSA).


Another collaboration is ongoing with Dr. Frank Orson to evaluate the effects of
several DNA vaccines in preclinical models. The goal of these studies is to
identify a novel DNA vaccine for the treatment of influenza in human beings.
Preliminary studies have shown that a synDNA(TM) influenza vaccine was of
greater potency than a standard plasmid in generating an immunologic response.
Research continues to apply the information learned from the pilot studies to
design and produce a synDNA(TM) vaccine to be used in the event of a pandemic
outbreak of influenza.


UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON


CytoGenix has several ongoing collaborations with the University of Texas Health
Science Center at Houston. The Company has entered into an agreement to provide
access to animal care facilities to allow CytoGenix scientists to conduct
exploratory studies for product leads. CytoGenix has also worked extensively
with Dr. Jeffrey Actor to identify novel product candidates for use in
infectious disease applications.


UNIVERSITY OF PENNSYLVANIA


Recently CytoGenix added a University of Pennsylvania scientist, Dr. David
Weiner, to the Scientific Advisory Board. Dr. Weiner is a pioneer and is world
recognized in the field of DNA vaccines and several collaborative projects are
ongoing in the areas of smallpox and influenza. A pilot study conducted in a
murine model demonstrated that a synDNA vaccine targeting smallpox was highly
immunogenic.

Technology - Sponsored Research

It is the policy of the Company to seek outstanding scientific leaders and
independent investigators as collaborators in mutually beneficial projects. The
following projects are sponsored in part by the company:

o DR. JEFFERY ACTOR, ASSOCIATE PROFESSOR AT THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER Houston, Texas is conducting a study entitled, "In vivo
proof of concept experiment for anti-bacterial DNA preparation".



11





o DR. FRANK ORSON, PROFESSOR AT BAYLOR COLLEGE OF MEDICINE, Houston, Texas
is conducting a study entitled, "PEI aerosol delivery of ssDNA expression
vector".


o DRS. LYUBA BENIMETSKAYA AND CY STEIN AT ALBERT EINSTEIN COLLEGE OF
MEDICINE, New York are conducting a study entitled, "Down Regulate Gene
Expression in Melanoma Cells using Antisense ODNs generated by CYGX ssDNA
Expression Vectors".

o DR. DAVID WEINER AT UNIVERSITY OF PENNSYLVANIA is conducting studies to
evaluate the safety and efficacy of DNA vaccines using several animal
models.

MARKETING STRATEGY

We plan to market initial products, when developed, and for which we obtain
regulatory approval, through marketing arrangements or other licensing
arrangements with pharmaceutical companies. Implementation of this strategy will
depend on many factors, including the market potential of any products we
develop, and our financial resources. We do not expect to establish a direct
sales capability for therapeutic compounds for at least the next several years.
To market products that will serve a large, geographically diverse patient
population, we expect to enter into licensing, distribution, or partnering
agreements with pharmaceutical companies that have large, established sales
organizations. The timing of our entry into marketing arrangements or other
licensing arrangements with large pharmaceutical companies will depend on
successful product development and regulatory approval within the regulatory
framework established by the Federal Food, Drug and Cosmetics Act, as amended,
and regulations promulgated thereunder. Although the implementation of initial
aspects of our marketing strategy may be undertaken before this process is
completed, the development and approval process typically is not completed in
less than three to five years after the filing of an IND application and our
marketing strategy therefore may not be implemented for several years. See "Drug
Approval Process and Other Governmental Regulation."

PATENTS AND PROPRIETARY RIGHTS

We have developed or acquired a comprehensive body of intellectual rights. The
proprietary nature of, and protection for, our product candidates, processes and
know-how are important to our business. We plan to prosecute and aggressively
defend our patents and proprietary technology. Our policy is to patent the
technology, inventions, and improvements that are considered important to the
development of our business and that are patentable. We also depend upon trade
secrets, know-how, and continuing technological innovation to develop and
maintain our competitive position.

A patent portfolio including 46 domestic and foreign issued or pending patent
applications protects our technologies. We intend to protect our proprietary
technology with additional filings as appropriate.


DRUG APPROVAL PROCESS AND OTHER GOVERNMENT REGULATION

The system of reviewing and approving drugs in the United States is considered
the most rigorous in the world. Costs to bring a single product from research
through market approval and launch into commerce range from $800 million
(Pharmaceutical Research and Manufacturers Association) to $1.7 billion in 2000
through 2002 (FDA), with the timing to do so typically ranging between 10 and 15
years. The Pharmaceutical Research and Manufacturers Association estimates that
of every 5,000 medicines tested, on average, only five are tested in clinical
trials, and only one of those is approved for human use.



12



Drug Discovery

In the initial stages of drug discovery before a compound reaches the
laboratory, tens of thousands of potential compounds are randomly screened for
activity against an assay assumed to be predictive for particular disease
targets. This drug discovery process can take several years. Once a company
locates a screening lead, or starting point for drug development, isolation and
structural determination may begin. The development process results in numerous
chemical modifications to the screening lead in an attempt to improve its drug
properties. After a compound emerges from the above process, the next steps are
to conduct further preliminary studies on the mechanism of action, further in
vitro (test tube) screening against particular disease targets and, finally,
some in vivo (animal) screening. If the compound passes these barriers, the
toxic effects of the compound are analyzed by performing preliminary exploratory
animal toxicology. If the results are positive, the compound emerges from the
basic research mode and moves into the pre-clinical phase.

Preclinical Testing

During the pre-clinical testing stage, laboratory and animal studies are
conducted to show biological activity of the compound against the targeted
disease, and the compound is evaluated for safety. These tests typically take
approximately three and one-half years to complete.

Investigational New Drug Application

During the pre-clinical testing, an IND is filed with the FDA to begin human
testing of the drug. The IND becomes effective if not rejected by the FDA within
30 days. The IND must indicate the results of previous experiments, how, where
and by whom the new studies will be conducted, the chemical structure of the
compound, the method by which it is believed to work in the human body, any
toxic effects of the compound found in the animal studies and how the compound
is manufactured. In addition, an Institutional Review Board, comprised of
physicians at the hospital or clinic where the proposed studies will be
conducted, must review and approve the IND. Progress reports detailing the
results of the clinical trials must be submitted at least annually to the FDA.

Phase I Clinical Trials

After an IND becomes effective, Phase I human clinical trials may begin. These
tests, involving usually between 20 and 80 patients or healthy volunteers,
typically take approximately one year to complete and cost between $300,000 and
$500,000 per trial. The Phase I clinical studies also determine how a drug is
absorbed, distributed, metabolized and excreted by the body, and the duration of
its action. Phase I trials are not normally conducted for anticancer product
candidates. A Phase Ib study involves patients with the targeted disease cancer
and is focused on safety.

Phase II Clinical Trials

In Phase II clinical trials, controlled studies are conducted on approximately
100 to 300 volunteer patients with the targeted disease. The preliminary purpose
of these tests is to evaluate the effectiveness of the drug on the volunteer
patients as well as to determine if there are any side effects. These studies
generally take approximately two years and cost between $500,000 and $4 million
per trial, and may be conducted concurrently with Phase I clinical trials. In
addition, Phase I/II clinical trials may be conducted to evaluate not only the
efficacy of the drug on the patient population, but also its safety.

Phase III Clinical Trials

This phase typically lasts about three years, usually involves 1,000 to 3,000
patients and cost between $5 million and $50 million per trial. During the Phase
III clinical trials, physicians monitor the patients to determine efficacy and
to observe and report any reactions that may result from long-term use of the
drug.



13




New Drug Application

After the completion of the requisite three phases of clinical trials, if the
data indicate that the drug has an acceptable benefit to risk assessment and it
is found to be safe and effective, a New Drug Application (NDA) is filed with
the FDA. The requirements for submitting an NDA are defined by and in
conjunction with the FDA. These applications are comprehensive, including all
information obtained throughout all clinical trials as well as all data
pertaining to the manufacturing and testing of the product. In general, these
filings can far exceed 100,000 pages. With the implementation of the
Prescription Drug Users Fee Act (PDUFA), review fees are provided at the time of
NDA filing. In 2005, each NDA with clinical data must be accompanied by a
$672,000 review fee. If the NDA is assessed as unacceptable in the initial 30
day review, it is returned to the submitter, with 50% of the fee. The average
review time for a New Molecular Entity (NME) has remained static at
approximately 16 months, however, new NME can and have been approved in as
little as six months.

Marketing Approval

If the FDA approves the NDA, the drug becomes available for physicians to
prescribe. Periodic reports must be submitted to the FDA, including descriptions
of any adverse reactions reported. The FDA may request additional studies (Phase
IV) to evaluate long-term effects.

Phase IV Clinical Trials and Post Marketing Studies

In addition to studies requested by the FDA after approval, these trials and
studies are conducted to explore new indications. The purpose of these trials
and studies and related publications is to broaden the application and use of
the drug and its acceptance in the medical community.

COMPETITION


The pharmaceutical and biotechnology industries are highly competitive. We face
competition from biotechnology and pharmaceutical companies using more
traditional approaches to treating human diseases. Our competitors may develop
safer, more effective or less costly gene-based therapeutics. In addition, we
face and will continue to face competition from other companies for corporate
collaborations with pharmaceutical and biotechnology companies, for establishing
relationships with academic and research institutions and for licenses to
proprietary technology, including intellectual property.

Many of our competitors and potential competitors have substantially greater
product development capabilities and financial, scientific, manufacturing,
managerial and human resources than the Company. There can be no assurance that
research and development by others will not render our products, or the products
developed by corporate partners using our licensed technologies obsolete, or
non-competitive, or that any product we or our corporate partners develop will
be preferred to any existing or newly developed technologies. In addition, there
can be no assurance that our competitors will not develop safer, more effective
or less costly cardiovascular therapies, gene delivery systems, gene
therapeutics, non-gene therapies, or other therapies, achieve superior patent
protection or obtain regulatory approval or product commercialization earlier
than Company, any of which could have a material adverse effect on our business,
financial condition or results of operations.


RESEARCH AND DEVELOPMENT

The Company expensed $1,731,764, and $831,472 on research and development
activities during the years ended December 31, 2005, and 2004, respectively.
Research and development (R&D) expenses include related salaries, contractor
fees, materials, utilities. R&D expenses consist of independent R&D costs and
costs associated with collaborative development arrangements. In addition, the
Company funded R&D at other companies and research institutions under
agreements. Research and development costs are expensed as incurred.



14




EMPLOYEES

As of December 31, 2005, we had 11employees, 5 of whom hold advanced degrees.
None of our employees are covered by collective bargaining agreements, and we
consider relations with our employees to be good.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We are a reporting company and file annual, quarterly and current reports, proxy
statements and other information with the SEC. For further information with
respect to us, you may read and copy our reports, proxy statements and other
information, at the SEC's public reference rooms at 100 F. Street, N.E.,
Washington, D.C. 20549, as well as at the SEC's regional offices at 500 West
Madison Street, Suite 1400, Chicago, IL 60661 and at 233 Broadway, New York, NY
10279. You can request copies of these documents by writing to the SEC and
paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for
more information about the operation of the public reference rooms. Our SEC
filings are also available at the SEC's web site at "http://www.sec.gov." In
addition, you can read and copy our SEC filings at the office of the National
Association of Securities Dealers, Inc. at 1735 K Street, N.W., Washington, D.C.
20006.

Copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are
all available on our website (www.cytogenix.com) or by sending a request for a
paper copy to: Cytogenix, Inc. 3100 Wilcrest, Suite 140, Houston, TX 77042,
attn. Investor Relations.

ITEM 1A. RISK FACTORS

RISKS AFFECTING FUTURE OPERATING RESULTS

We do not provide forecasts of our future financial performance. While we are
optimistic about our long-term prospects, the following factors should be
considered in evaluating our outlook. If the possibilities described as risks
below actually occur, our operating results and financial condition would likely
suffer and the trading price of our common stock may fall, causing a loss of
some or all of an investment in our common stock.

Our products are in an early stage of development and may not be determined to
be safe or effective.

We are only in the early stages of development with our biopharmaceutical
products. We have devoted almost all of our time to research and development of
our technology and products, protecting our proprietary rights and establishing
strategic alliances. Our proposed products are in the pre-clinical stages of
development and will require significant further research, development, clinical
testing and regulatory clearances. Our proposed products are subject to
development risks. These risks include the possibilities that any of the
products could be found to be ineffective or toxic, or could fail to receive
necessary regulatory clearances. We have not received any significant revenues
from the sale of products and we may not successfully develop marketable
products that will increase sales and, given adequate margins, make us
profitable. Our competitors may develop superior or equivalent, but less
expensive, products.

We have incurred net losses since our inception, and we may not achieve or
sustain profitability.

We incurred a net loss of $3.53 million in 2005 and of $2.36 million in 2004. As
of December 31, 2005, our total shareholder's equity was $407,521. Our losses
have resulted principally from expenses incurred in research and development of
our technology and products, general and administrative expenses that we have
incurred while building our business infrastructure. We expect to continue to
incur significant operating losses in the future as we continue our research and
development efforts and seek to obtain regulatory approval of our products. Our
ability to achieve profitability depends on our ability to raise additional
capital, complete development of our products, obtain regulatory approvals and
market our products. It is uncertain when, if ever, we will become profitable.


If we fail to attract significant additional capital, we may be unable to
continue to successfully develop our products.


15




Since we began operations, we have obtained operating funds primarily by selling
our company common stock. Based on our current plans, we do not believe that
current cash balances will be sufficient to meet our operating needs in 2006.
Furthermore, the actual amount of funds that we will need will be determined by
many factors, some of which are beyond our control. These factors include the
success of our research and development efforts, the status of our pre-clinical
and clinical testing, costs relating to securing regulatory approvals and the
costs and timing of obtaining new patent rights, regulatory changes, competition
and technological developments in the market. We may need funds sooner than
currently anticipated.

If necessary, potential sources of additional funding could include strategic
relationships, public or private sales of shares of our common stock or debt or
other arrangements. We may not obtain additional funding when we need it on
terms that will be acceptable to us or at all. If we raise funds by selling
additional shares of our common stock or securities convertible into our common
stock, the ownership interest of our existing shareholders will be diluted. If
we are unable to obtain financing when needed, our business and future prospects
would be materially adversely affected.

If we fail to receive necessary regulatory approvals, we will be unable to
commercialize our products. All of our products are subject to extensive
regulation by the United States Food and Drug Administration, or FDA, and by
comparable agencies in other countries. The FDA and comparable agencies require
new pharmaceutical products to undergo lengthy and detailed clinical testing
procedures and other costly and time-consuming compliance procedures. We do not
know when or if we will be able to submit our products for regulatory review.
Even if we submit a new drug application, there may be delays in obtaining
regulatory approvals, if we obtain them at all. Sales of our products outside
the United States will also be subject to regulatory requirements governing
clinical trials and product approval. These requirements vary from country to
country and could delay introduction of our
products in those countries. We cannot assure you that any of our products will
receive marketing approval from the FDA or comparable foreign agencies.

We may fail to compete effectively, particularly against larger, more
established pharmaceutical companies, causing our business to suffer.

The biotechnology industry is highly competitive. We compete with companies in
the United States and abroad that are engaged in the development of
pharmaceutical technologies and products. They include: biotechnology,
pharmaceutical, chemical and other companies; academic and scientific
institutions; governmental agencies; and public and private research
organizations.

Many of these companies and many of our other competitors have much greater
financial and technical resources and production and marketing capabilities than
we do. Our industry is characterized by extensive research and development and
rapid technological progress. Competitors may successfully develop and market
superior or less expensive products which render our products less valuable or
unmarketable.

We have limited operating experience.

We have engaged solely in the development of biopharmaceutical technology.
Although some members of our management team have experience in biotechnology
company operations, we have limited experience in manufacturing or selling
biopharmaceutical products. We also have only limited experience in negotiating
and maintaining strategic relationships, and in conducting clinical trials and
other later-stage phases of the regulatory approval process. We may not
successfully engage in some or all of these activities.

We have limited manufacturing capability.

While we believe that we can produce materials for clinical trials and produce
products for human use at our recently completed synDNA production suite, we may
need to expand our commercial manufacturing capabilities for products in the
future if we elect not to or cannot contract with others to manufacture our


16



products. This expansion may occur in stages, each of which would require
regulatory approval, and product demand could at times exceed supply capacity.
We have not selected a site for any expanded facilities and do not know what the
construction cost will be for such facilities and whether we will have the
financing needed for such construction. We do not know if or when the FDA will
determine that such facilities comply with Good Manufacturing Practices. The
projected location and construction of any facilities will depend on regulatory
approvals, product development, pharmaceutical partners and capital resources,
among other factors. We have not obtained regulatory approvals for any
productions facilities for our products, nor can we assure investors that we
will be able to do so.

If we lose key personnel or are unable to attract and retain additional, highly
skilled personnel required for our activities, our business will suffer.

Competition for qualified personnel in our industry is intense, and our success
will depend on our ability to attract and retain highly skilled personnel. To
date, we have been successful in attracting and retaining key personnel. We are
not aware of any key personnel who plan to retire or otherwise leave the Company
in the near future.

Asserting, defending and maintaining our intellectual property rights could be
difficult and costly, and our failure to do so will harm our ability to compete
and the results of our operations.

Our success will depend on our existing patents and licenses, and our ability to
obtain additional patents in the future. A patent portfolio including 46
domestic and foreign patents issued or pending patent applications protects our
technologies.

We cannot assure investors that our pending patent applications will result in
patents being issued in the United States or foreign countries. In addition, the
patents which have been or will be issu

[Mambo6]

die Amis scheinen ja nicht sonderlich begeistert...

[crashpoet]

Antwort auf Beitrag Nr.: 21.228.965 von Mambo6 am 18.04.06 18:55:52

manche dinge benötigen zeit, um richtig eingeordnet zu werden.

[ketsie]

Antwort auf Beitrag Nr.: 21.241.513 von crashpoet am 19.04.06 16:39:36

na geht ja aufwärts - offensichtlich hatten die amis es jetzt in der post.

[seppel]

Antwort auf Beitrag Nr.: 21.251.999 von ketsie am 20.04.06 11:45:01

Na, sieht doch aktuell ganz gut aus. Tipp mal auf 1,40US$ Schlußkurs.

[Mambo6]

na so hoch muß es ja nicht gleich raufgehen... wäre schon froh wenn wir überhaupt im Plus schließen...

[Boerse24]

Hallo,

wisst ihr vielleicht warum Cytogenix in den letzten Tagen nicht so gut läuft?
Danke schon einmal für die Antwort!
Boerse24

[ketsie]

Antwort auf Beitrag Nr.: 21.438.901 von Boerse24 am 05.05.06 06:56:52

null ahnung, warum so schlecht ... wollten doch ab april produzieren

[crashpoet]

Antwort auf Beitrag Nr.: 21.438.901 von Boerse24 am 05.05.06 06:56:52

ich glaube nicht, daß das einen wirklichen grund hat ausser dem, daß es schon länger keine news gab. da werden manche leute ungeduldig.

[ketsie]

Antwort auf Beitrag Nr.: 21.443.475 von crashpoet am 05.05.06 12:51:53

ich bleibe drin, obwohl ich schon wieder im roten bereich bin ... ich glaube aber, dass der wonnemonat mai mir wieder grünes bringt.

[Boerse24]

Vielen Dank für eure schnelle Antwort!
Ich glaube auch, dass man jetzt nicht vorschnell verkaufen sollte, nur weil ein paar Tage keine neuen News gekommen sind.
Es werden schon noch welche kommen und da Cytogenix eigentlich immer sehr sprunghaft ansteigt, werde ich die Aktie auch erst einmal behalten und abwarten...

[crashpoet]

NEWS:

CytoGenix and USDA to Collaborate in Developing a synDNA(TM) Vaccine Against Costly Livestock Disease
CytoGenix, Inc. (OTCBB:CYGX) announced that it has entered into a formal Cooperative Research and Development Agreement (CRADA) with the USDA Agricultural Research Service.

CytoGenix scientists will work with a team of USDA scientists led by Dr. Steven Olsen to develop synDNA(TM) vaccines against existing and emerging strains of the bacteria that causes brucellosis, a costly disease for ranchers and game managers. Brucellosis causes miscarriages in domestic sheep, goats, cattle, pigs, and in wildlife such as deer, elk and bison. State and Federal governments have spent $11 billion over the last 45 years in an attempt to eradicate this disease.

Dr. Olsen, Director of Vaccine Research for the Agricultural Research Service, USDA commented, "There remain reservoirs of brucella in wildlife within Yellowstone Park, and the potential for brucellosis infection is a serious threat to cattle ranchers in the region. For this reason, ARS has been conducting research to develop DNA vaccines for brucella infections for several years."

Dr. Malcolm Skolnick, CytoGenix Chief Executive Officer, commented, "We are pleased to be working with Dr. Olsen and his team of scientists at USDA. ARS is a leader within the Federal government in the transferal and marketing of new technologies developed from its research laboratories. This CRADA is another example of our commitment to exploring the utility of synDNA(TM) technology in cooperation with governmental agencies."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CytoGenix, Inc.
Kurt L. Berens, 713-789-0070



Source: Business Wire (May 8, 2006 - 9:15 AM EDT)

[Mambo6]

was war das denn jetzt?????

[amk912]

.. keine Ahnung, sieht aber aus als o jemand im groeeseren still abgeladen hat

[ketsie]

Antwort auf Beitrag Nr.: 21.498.855 von amk912 am 10.05.06 08:23:31

warum geht der kurs bei einer solchen meldung in die knie ... ist doch ne gute personalinfo. börse ist einfach nicht zu verstehen.

ketsie

[Mambo6]

vielleicht weiß ja jemand, wer und weshalb jemand solch einen Posten zu diesen Preisen verkauft hat... fundamental denke ich allerdings wird der Kurs wieder anziehen... da darf man sich einfach nicht verrückt machen lassen

[crashpoet]

Antwort auf Beitrag Nr.: 21.504.418 von Mambo6 am 10.05.06 13:34:07

Das Problem dürfte sein, daß CYGX -mangels Cash- alles mögliche mit Aktien bezahlt. Die werden dann wenig kursschonend auf den Markt geworfen. Außerdem ist gestern wohl eine SL-Welle losgetreten worden, der initiale Kursrutsch auf 1.20 $ wurde mit gerade mal 6200 Aktien losgetreten.

[Boerse24]

Ich bin auch der Meinung, man sollte jetzt Ruhe bewahren.
Bisher habe ich noch keine neue Unternehmensmeldung gefunden, die
diesen Kursrückgang verursacht haben könnte.

[ketsie]

Antwort auf Beitrag Nr.: 21.505.948 von Boerse24 am 10.05.06 15:13:22

noch jemand da ... mein depot nun wieder tiefrot ...

[crashpoet]

mir wäre zwar lieber gewesen, die hätten in paar einnahmen gemeldet, aber die nachricht ist trotzdem ziemlich gut.

was wichtig ist: cygx erhält zugriff auf äußerst beschränkte ressourcen (hochsicherheits-labore) - die werden bestimmt nicht vergeben, um ein aussichtsloses verfahren zu testen.

CytoGenix and the University of Texas Medical Branch at Galveston Sign Agreement for Preclinical Testing of synDNA(TM) H5N1 Avian Flu Vaccine Candidates
HOUSTON--(BUSINESS WIRE)--May 16, 2006--CytoGenix, Inc. (OTCBB:CYGX) has entered into a research agreement with the University of Texas Medical Branch at Galveston for preclinical animal studies of synDNA(TM) H5N1 vaccine. Dr. Slobodan Paessler, scientific director of the Animal Biosafety Laboratory and the Galveston National Laboratory Advanced Veterinary Services (GAVS) Core will be supervising the research.


CytoGenix scientists have developed a synthetic DNA vaccine against a known strain of H5N1 as a test bed for efficacy and safety studies. In preparation for a possible pandemic, the synDNA(TM) technology is designed to produce millions of doses of a DNA vaccine in a period of a few months.

The work will be performed in the Robert E. Shope, M.D., laboratory at the University of Texas Medical Branch (UTMB), the only full-sized, maximum containment laboratory on a university campus in the United States and one of just four such Biosafety Level 4 (BSL4) "space suit" laboratories currently operating in the U.S. The Galveston National Laboratory at UTMB is one of two National Biocontainment Laboratories now being constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH). It will provide research space to develop therapies, vaccines and diagnostic tests for naturally occurring emerging diseases such as SARS and West Nile encephalitis, as well as for viral and bacterial agents that might be employed by terrorists.

Dr. Yin Chen, CytoGenix vice president and chief scientific officer, states, "Dr. Paessler is an expert in infectious diseases animal models and has direct access to one of the few high containment laboratories in the country. One of the studies in this plan calls for a challenge with live virus to determine the degree of efficacy of the synDNA(TM) vaccine in conferring protection against H5N1 avian influenza."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.



ich hoffe, das gibt dem kurs wieder auftrieb.

[crashpoet]

Es geht aufwärts!

Detailed Quote Snapshot 05/17/2006 09:35 AM
Last:

1.1 CYGX - CYTOGENIX INC
Change:

+0.08 % Change:

+7.84% High:

1.1 Low:

1.1 Volume:

41,405

Price Data Table
Open 1.1
Previous Close 1.1
Exchange of Last Sale OTCBB
Time of Last Sale 09:30:26
Tick Up
Bid 1.06
Ask
Size Bid/Ask 5x12
Symbol Type Equity

[crashpoet]

Detailed Quote Snapshot 05/17/2006 09:48 AM
Last:

1.14 CYGX - CYTOGENIX INC
Change:

+0.12 % Change:

+11.76% High:

1.14 Low:

1.07 Volume:

52,055

Price Data Table
Open 1.1
Previous Close 1.14
Exchange of Last Sale OTCBB
Time of Last Sale 09:44:46
Tick Up
Bid 1.14
Ask
Size Bid/Ask 5x5
Symbol Type Equity

[crashpoet]

Avian flu contract gives CytoGenix wings
Biochemical company will work with UTMB in animal studies using DNA vaccine against bird flu strain
By Jenna Colley
Houston Business Journal
Updated: 8:00 p.m. ET May 28, 2006
Houston-based CytoGenix Inc. is flying high after landing a contract for its synthetic DNA-based vaccine to be used in testing against the avian flu.

The biochemical company will work with The University of Texas Medical Branch at Galveston on preclinical animal studies of its synDNA H5N1 vaccine against a known strain of H5N1. In preparation of a possible bird flu pandemic, the synDNA technology is designed to produce millions of doses of a DNA vaccine over a period of a few months.

Meanwhile, publicly traded CytoGenix has also signed a federal research agreement with the U.S. Department of Agriculture to jointly develop synDNA vaccines to fight brucellosis, a disease that causes miscarriages in livestock and wildlife.

As part of the UTMB deal, CytoGenix will sponsor research undertaken by university scientists to test its DNA vaccines against their strains of avian flu. The work will be performed in UTMB's new Biosafety Level 4 lab, which is one of only four of its kind currently operating in the United States.

"We are blessed because of all the large academic resources here in Houston," says Frank Vazquez, CytoGenix executive vice president and chief operating officer. "For small companies like ours, sometimes it's better -- either for economical or for scientific reasons -- to use an investigator in a university."

CytoGenix -- which is headed by CEO Malcolm Skolnick -- claims it can make DNA vaccines quicker and in higher volume than anyone else, which was a selling point for UTMB research scientist Dr. Slobodan Paessler. Paessler is one of few researchers in the world intimately involved in testing the effects of vaccines on animals infected with the avian influenza A virus ,or H5N1.

"If their technology works, then they can basically adapt a vaccine within hours or days," Paessler says.

The value of the contract with UTMB was not disclosed.

Animal instincts
Under a separate deal with the Department of Agriculture, CytoGenix will work with a team of government scientists at the organization's Agricultural Research Service to develop vaccines against emerging strains of the bacteria that causes an animal disease called brucellosis.

According to CytoGenix, state and federal governments have spent $11 billion over the last 45 years in an attempt to eradicate the disease -- which continues to affect wildlife within Yellowstone Park and threaten cattle ranchers in the surrounding region.

Vazquez says although no money will change hands as part of the partnership agreement with the USDA, the deal could provide CytoGenix an inroad into government contracts, a position the company is hoping to advance.

Earlier this year, CytoGenix's stock simmered when it joined forces with United Kingdom-based GE Healthcare's Fast Track BioDefense group in an effort to win biodefense-related federal contracts. (See: "CytoGenix stock rises on news of deal with GE Healthcare," March 23.)

News of the deal boosted the company's stock to $1.28 per share, up from about 86 cents near the end of 2005. CytoGenix's stock has dropped somewhat from that perch in March, closing at $1.07 per share on May 22.

But these two new agreements may help bolster the company, especially given the high-profile nature of the avian flu and the measures being taken to fight it should an outbreak occur.

While not as flashy as the avian flu project, the deal with the USDA also holds promise for CytoGenix, which was founded several years ago and currently holds one U.S. patent and has 41 international and U.S. pending patent applications.

Dr. Steven Olsen, a veterinary medical officer with the USDA Agricultural Research Service, says the arrangement between CytoGenix and the USDA will essentially work as a pilot project to see how well the two parties work together and how CytoGenix's technology performs in fighting brucellosis.

"If the initiative works and looks promising, then we will likely be developing a more extensive agreement," Olsen says. "This is the first go-around. They are providing the costs on their side and we are providing the costs on our sides. We'll see how this goes ..."

Either way, Vazquez says, the deals with UTMB and the USDA put CytoGenix in a good position to advance the ultimate goal of commercially producing DNA vaccines. The company's primary goal is to develop DNA-based pharmaceuticals.

But the process is slow-moving.

Although the company, which now has about 14 employees, announced plans a year ago to build a $3 million DNA manufacturing facility in Houston, CytoGenix has yet to break ground or even select a site for the facility.

Vazquez says the company had chosen a parcel of land in west Houston but was outbid by another buyer. Now, CytoGenix is evaluating several other sites in the area.

Still, Vazquez says, the company continues its progression toward commercialization on several fronts.

"For the past six or seven years, the company has been focused on developing DNA technology," he says. "Now we are getting closer every day to commercializing it."

[ketsie]

nun - da sollte ja morgen bei otc was abgehen ... ist ja wieder ne news, die bestätigt, dass ich richtig investiert habe. leider reagiert der kurs in D nicht. aber das kennen wir ja - der kurs wird übersee gemacht.

ketsie

[ketsie]

Antwort auf Beitrag Nr.: 21.861.547 von ketsie am 29.05.06 16:45:36

totale ruhe ... wie kam ich nur auf die idee, hier einzusteigen ...

[crashpoet]

CytoGenix Receives Re-Supply Order for synDNA(TM)
CytoGenix, Inc. (OTCBB:CYGX) announced a follow-on order for the production of synDNA(TM) from a client referred by Aldevron, LLC (Fargo, ND).

The current order for synDNA(TM) was placed after the initial batch of synDNA(TM) proved to be the preferred material for use in the manufacture of innovative products by the client. While the details of the order were not disclosed, success in the next, final series of tests could result in future orders for gram quantities of custom synDNA(TM) material to satisfy the client's anticipated demand.

"The CytoGenix synDNA(TM) technology is ideally suited for many of our clients when conventional plasmid DNA is too costly or difficult to produce," stated Michael Chambers, President and CEO of Aldevron. "The first order of synDNA(TM) met and exceeded our expectations in terms of quality, cost, and turn-around time."

"The relationship between CytoGenix and Aldevron continues to be mutually beneficial," said Malcolm Skolnick, President and CEO of CytoGenix. "We are delighted to service clients by utilizing our excess production capacity thereby generating revenue to fund our internal product development programs."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.

About Aldevron: Aldevron provides contract services to accelerate gene and protein based research. These include plasmid and protein manufacturing for preclinical and clinical applications. For instance, Aldevron manufactures a west-Nile vaccine that has been recognized as the world's first DNA vaccine to be used outside of a trial setting. Aldevron's GIA(TM) technology can be used to rapidly screen new vaccines and to develop antibodies to any gene-specific antigens. Aldevron has facilities in Fargo, ND and Freiburg, Germany. For more information, please visit http://www.aldevron.com

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.


CytoGenix, Inc.
Kurt L. Berens, 713-789-0070
or
Aldevron, LLC
Michael Chambers, 701-297-9256

[Boerse24]

Ich glaube Cytogenix hat eine gute Perspektive und wird sich dieses Jahr auch wieder positiv entwickeln.
Das was dem Markt momentan noch fehlt sind neue Nachrichten und die werden bald schon noch kommen.
Wie man allerdings an dem Kursverlauf des letzten Jahres gut erkennen kann, steigt die Aktie sehr sprunghaft, was beduetet, dass man am besten investiert bleibt, um nicht das Beste zu verpassen...
Mein Kursziel für dieses Jahr sind mindestens 2 Euro...!
Man muss also nur noch ein bisschen Geduld haben.

[crashpoet]

Frost & Sullivan Acknowledges CytoGenix's Revolutionary Approach to Large- Scale Production of Clinical-grade DNA



PALO ALTO, Calif., June 28, 2006 /PRNewswire/ -- Frost & Sullivan has selected CytoGenix, Inc. as the recipient of the 2006 Frost & Sullivan Award for Technology Innovation in biotechnology processing for introducing a fundamental improvement to the large-scale production of DNA. This technology is especially useful in the rapid production of DNA vaccines for pandemic and bioterror applications.



CytoGenix has developed a cell-free production process that enables generation of large quantities of high-purity DNA in small, highly automated production modules at a fraction of the time and cost of traditional bioprocess methods. This breakthrough technology can enhance drug development, and in turn, help protect the lives of millions of people from pandemic disease.

CytoGenix' method is likely to be safer than standard methods (for example, there is a lower risk of allergy). In addition, it takes less than three months to produce a market-ready vaccine from start to finish. The final product does not require refrigeration as standard vaccines do, and this could make a significant difference in vaccination rates in countries where electricity is often not available.

From a regulatory and compliance perspective, the benefits provided by cell-free synthesis are significant and similar to processes for small- molecule drug production.

The CytoGenix technology does not require methods for cell collection, processing, and culture maintenance, which will significantly reduce quality- assurance, quality control, and compliance overhead costs compared to traditional methods. The entire process is bench-scale and requires less equipment, less space and less human intervention compared to bioprocess manufacturing facilities.

"Moreover, the total absence of bacteria and growth media means that there is no need to employ mechanical or chemical purification methods to extract cell or animal proteins, RNA, genomic DNA, and backbone molecules," says Frost & Sullivan Research Analyst Katherine Austin. "This feature provides the designer more control over coding for non-specific and specific immune responses."

CytoGenix has completed the design and construction of a prototype production module for high-quality, cell-free DNA. The company is now implementing standard operating procedures to comply with current good manufacturing practice (cGMP) to enable the production of clinical-grade material.

"As the list of therapeutic antisense molecules continues to grow and more disease states are targeted, the need for dependable delivery and expression systems will increase accordingly," notes Austin. "The CytoGenix technology will speed development and production of these as well."

Each year Frost & Sullivan presents this Award to a company that has carried out new research that has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This Award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About CytoGenix, Inc.

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.awards.frost.com or http://www.healthcare.frost.com .

[ketsie]

Antwort auf Beitrag Nr.: 22.321.103 von crashpoet am 28.06.06 18:05:33

Wollte mal wieder hier posten ... also, wir sind jetzt bei 0,80, wenn es weiter so geht, könnte mein einstiegskurs von 1,20 bald wieder erreicht werden ... wieder einmal.

[ketsie]

Antwort auf Beitrag Nr.: 22.390.260 von ketsie am 03.07.06 10:13:10

geht aber nicht weiter so ...

[amk912]

Antwort auf Beitrag Nr.: 22.537.193 von ketsie am 12.07.06 09:38:19

CYTOGENIX INC ("CYGX-L")
- Patent Application Allowed in People's Republic of China


CytoGenix, Inc. has received allowance for the patent application
No. 00815856.8 entitled "Altering Gene Expression with ssDNA Produced
In Vivo" from the Chinese Patent Office.


Filed in 2000, this patent covers the company's single strand DNA
expression system which is covered by a US patent and by other
applications in major world markets. The patented technology is used
in several of the company's products including Simplivir(TM) (CY301)
and CY303 and has recently been shown to be active in reducing
melanoma tumors in an experimental animal model.


Dr. Yin Chen, CytoGenix, Inc. Vice President and Chief Scientific
Officer and a co-inventor of the single strand DNA expression
technology, states, "This is the first foreign patent allowed for this
technology and it covers an important market. China offers significant
opportunities and we are seeking appropriate Chinese licensees and
partners."


About CytoGenix, Inc.: CytoGenix, Inc. is a Houston-based
biopharmaceutical company that develops and markets innovative
products and services based on its proprietary ssDNA expression
technology. The company has developed a breakthrough synthetic process
for large-scale production of high purity DNA at a fraction of the
cost of traditional fermentation methods. CytoGenix currently has one
issued US patent and 47 international or US pending patent
applications claiming methods and materials in connection with this
platform technology.


SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company's filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology is found on the website at
www.cytogenix.com.


TEL: [phone] CytoGenix Inc., Frank Vazquez
______________________________________

[ketsie]

Antwort auf Beitrag Nr.: 23.061.578 von amk912 am 26.07.06 12:13:35

vielleicht geht nun mal was ... china ist der riesen markt, also professoren macht nun mal los ... ich will ganz schnell die 1,20 wieder sehenketsie

[ketsie]

Antwort auf Beitrag Nr.: 23.061.578 von amk912 am 26.07.06 12:13:35

amk - von wann war denn die meldung ... sehe kein datum. ketsie

[ketsie]

Antwort auf Beitrag Nr.: 23.062.732 von ketsie am 26.07.06 13:23:45

haaaaaaaaaaaaaaalllllllllllllllllopooooooooooooooooooooo - ist hier wer?

[ketsie]

Antwort auf Beitrag Nr.: 23.258.484 von ketsie am 31.07.06 18:52:44

nööö, ketsie, keiner mehr da ...

[ketsie]

Antwort auf Beitrag Nr.: 23.315.543 von ketsie am 04.08.06 12:31:36

keiner mehr da, es wendet doch gerade mal wieder ...

[crashpoet]

CytoGenix’ Gene Silencing ssDNA Technology Patent Allowed in Europe and India
Oct 30 2006, 2:26 PM EST
GEN News Highlights


CytoGenix received notices of allowances for grant of patent applications covering the technology for expressing ssDNA in vivo from the Indian and European Community Patent Offices. These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.


Filed in 1999 and 2000, these patents cover the company's single-strand DNA expression system covered by a U.S. patent. It is used in the company's Simplivir™ antiherpes and CY303 anti-inflammation products.


http://www.genengnews.com/news/bnitem.aspx?name=7826801

[ketsie]

Antwort auf Beitrag Nr.: 25.032.564 von crashpoet am 31.10.06 11:55:41

ups - dann warten wir mal was der us-markt daraus macht. in D gehts ja schon up. allerdings mit mauen umsätzen.

[ketsie]

Antwort auf Beitrag Nr.: 25.033.850 von ketsie am 31.10.06 13:06:44

poet hast du gekauft

[ketsie]

heute noch 100 prozent ... dann bin ich wieder im grünen bereich. müsste kurzfristig so kommen, da ja offensichtlich nun geld verdient wird.ketsie

[crashpoet]

Antwort auf Beitrag Nr.: 25.034.130 von ketsie am 31.10.06 13:19:49

Nein, ich warte erstmal ab.
Hab meine Position in der Zwischenzeit auch schon mal reduziert, hab aber immer noch genug davon.

[ketsie]

Antwort auf Beitrag Nr.: 25.034.438 von crashpoet am 31.10.06 13:34:25

warten wir ab, was die amis machen ... aber hier kann es schnell wieder bis 1,30 gehen. ob ich dann allerdings noch drin bleibe, ist vom newsflow abhängig.ketsie

[crashpoet]

Antwort auf Beitrag Nr.: 25.034.664 von ketsie am 31.10.06 13:45:17

die vergütung des vorstandes hängt wesentlich von den kursen zum jahresende ab. deshalb ist damit zu rechnen, daß in den nächsten 2 monaten ein entsprechender newsflow generiert wird.
man sollte allerdings die news sehr genau lesen und zum jahresende überlegen, ob man aussteigt. ich bin nach wie vor vom potential der syndna-technologie überzeugt, allerdings habe ich in den letzten monaten zunehmend zweifel an den fähigkeiten des managements bekommen.
so long - einstweilen

[Fortschritt]

Freitag 3. November 2006
"CytoGenix Signs Contract for Design/Build Development of New Plant and Office Facility
CytoGenix, Inc. (OTCBB:CYGX) announces the conclusion of negotiations with GSL Constructors, Ltd for the design/build development of a $3.8 million, 20,000 sq. ft. facility in Houston's Westchase District. The building will be located on a two and one-third acre site in the Oak Park at Westchase office park and constructed by GSL's affiliate, Kingham Dalton Wilson whose experience spans over 110 years and 1,000 projects. CytoGenix plans to occupy the building in the fourth quarter of 2007.

The new facility will be the company's headquarters and provide the space for growth and expansion of DNA manufacturing capacity. The building will contain approximately 8,000 sq. ft. of state-of-the-art, GMP-qualified clean-room space for production of clinical-grade synDNA(TM), the company's proprietary synthesized DNA. This area will house several production suites with capacity to produce 50 grams of high purity DNA daily.

[crashpoet]

Antwort auf Beitrag Nr.: 25.144.885 von Fortschritt am 05.11.06 08:14:49

die news kam am freitag nachbörslich, mal sehen, was die amis heute daraus machen.
es würde mich nicht wundern, wenn es dioesmal eine merkliche reaktion nach oben gäbe. abwarten...

[ketsie]

Antwort auf Beitrag Nr.: 25.171.953 von crashpoet am 06.11.06 11:25:44

es tut sich nichts - zumindest nicht viel

[crashpoet]

kam nachbörslich:

CytoGenix synDNA(TM) HIV Vaccine Shows Robust Cellular Immune Response in Monkeys



HOUSTON--(BUSINESS WIRE)--

CytoGenix (OTCBB:CYGX) has demonstrated that a synDNA(TM) vaccine against human immunodeficiency virus (HIV) has activity in monkeys. The study, conducted by Drs. Yin Chen and Frederic Kendirgi at CytoGenix in collaboration with Lauren Hirao and Dr. David Weiner of the University of Pennsylvania, demonstrated that rhesus monkeys injected with a synDNA(TM) HIV vaccine mounted a significant cellular immune response. The study involved monkeys treated with a synDNA(TM) vaccine targeting two key viral proteins (gag and env) with interleukin-15 as an adjuvant.

"This observation, the first evidence of activity for a synDNA(TM) vaccine in non-human primates, is encouraging in that it shows that the synDNA(TM) vaccine is as effective as the DNA plasmid-based vaccine expressing the same antigen. The advantages of using DNA vaccines can be significantly extended using synDNA(TM) constructs and warrants further study to determine if the response is sufficient to protect against HIV infection," stated David B. Weiner, Ph.D., an expert in DNA vaccination and a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine.

The World Health Organization has estimated that nearly 40 million people worldwide are HIV positive with over one half of those infected residing in sub-Saharan Africa. The incidence of newly diagnosed infections has skyrocketed in parts of Eastern Europe and Central Asia with infection rates increasing by more than 50% in some regions since 2004. In the United States, approximately 1.2 million people were reported to be infected with HIV in 2005 and only seven other countries in the world have a higher number of affected citizens.

"Demonstration of the bioactivity of a synDNA(TM) vaccine for HIV in non-human primates is a tremendous step forward for CytoGenix," commented Dr. Malcolm Skolnick, President & CEO of CytoGenix, Inc. "This experiment highlights the potential of the application of synDNA(TM) to the field of DNA vaccines as well as the use of DNA therapeutic drugs," continued Dr. Skolnick.

Dr. Yin Chen, Chief Scientific Officer at CytoGenix, comments, "The use of enzymatically synthesized, bacteria free DNA to achieve significant biological activity is a significant advance for the field of vaccines and gene therapies. CytoGenix's synDNA(TM) products present a number of advantages over DNA plasmids produced by bacterial fermentation. The synDNA(TM) constructs avoid the use of antibiotic resistance genes and other bacterial sequences, can be rapidly produced and are more cost effective to produce. These are major advantages in developing vaccines for a wide range of applications including pandemic and bioterror threats."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has issued patents on its ssDNA expression technology in the US, China and nine European countries with over 41 additional international or US pending patent applications on variations of this and the synDNA(TM) technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Source: CytoGenix, Inc.